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The marine environment continues to be a prolific source of structurally diverse 
and biologically active natural products. Over the past few decades both macro­
and micro-organisms have been extensively studied for such compounds. Annual 
reviews are dominated by novel compounds isolated from marine sponges, even 
though investigations have more recently been focused on micro-organisms. 
After decades of research into the development of marine natural products as 
potential pharmaceuticals, many marine compounds now feature prominently in 
current pre-clinical and clinical trials. This thesis represents a continuation of 
work in the area of isolation and structural elucidation of novel and/or biologically 
active natural products from both marine macro- and micro-organisms. 
The four novel C31 polyacetylenic compounds 2.23, 2.24, 2.25 and 2.26 were 
isolated as the major components of the cytotoxic extract of the New Zealand 
manne sponge Rhabderemia stelletta, using bioassay-guided separation 
techniques. However, these structures were not unambiguously assigned due to 
the low resolution of the NMR signals associated with the long-chain alkyl 
protons and carbons. Elucidation was also hindered by compound degradation 
during structural analysis. The partial structures were identified via mass 
spectrometry and NMR spectroscopy and comparison of structural data for similar 
compounds reported in the literature. 
ABSTRACT II 
The novel pteridines 3.13 and 3.15 were isolated as the maJor and mmor 
. components, respectively, from the cytotoxic organic extract of an as yet 
unidentified Antarctic marine sponge 02WM01-33. Identification was achieved 
using mass spectrometry and NMR spectroscopy, and comparison of these data to 
those published in the literature for similar structures. Although pteridines are 
distributed widely throughout nature, 3.13 and 3.15 represent a chemically 
interesting group of compounds as they possess a mono-oxygenated methyl side 
chain, which has not been previously reported among any of the naturally 
occurring pteridines. 
The novel hydantoin compound 4.8 was isolated as the major biologically active 
component of the organic extract of the Antarctic marine sponge Suberites sp. 
using microtitre plate P388 assay guided fractionation. The relative 
stereochemistry of 4.8 was determined using lD-NOESY experimental data. This 
work represents the first isolation of the hydantoin 4.8 as a natural product from a 
marine sponge. This compound has been reported previously in the literature, but 
only as a synthetic product. 
The two novel anthraquinone compounds 5.35 and 5.41 were isolated as minor 
components of the cytotoxic organic extract of the Antarctic marine sponge­
derived fungus Aspergillus sp., along with the three known anthraquinones 5.32, 
5.34 and 5.40. This series of work revealed several areas in the literature that 
require revising: these include, (i) the compounds 5.31 and 5.41 were both 
reported as a new metabolites in 1985 and 2003, respectively, however, both 
compounds had been previously isolated and reported in 1966; (ii) the compound 
5.36 requires the correct structural assignment in the literature; and finally, (iii) 
the compound 5.35 has two isomeric structures reported in the AntiMarin 
database, however, neither of these structures match the experimental 1 H NMR 
data supplied by the author of the database. 
The three novel compounds 6.9, 6.13 and 6.15 were isolated from the organic 
extract of an Antarctic marine sponge-derived fungus Ulocladuim sp., along with 
the previously reported compounds 6.6, 6.7 and 6.16. These compounds were 
ABSTRACT iii 
identified using NMR spectroscopy and mass spectrometry. This work highlights 
an inconsistency in the literature regarding the structural assignment of two 
carbons for the known compound 6.16. The structural assignment of these 
carbons was confirmed by the independent isolation of 6.16 by another member of 
the Marine Group. 
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compounds from the Antarctic marine sponge-derived 
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1 . 1 :  Introduction 
Ancient human civilizations relied on nature to provide the resources essential for 
survival. This is still as true now as it was thousands of years ago. Our continued 
existence has undoubtedly hinged on the ability to recognise that extracts from 
surrounding flora could be used to treat ailments that, if left untreated, would 
certainly prove fatal. It is upon this foundation that modern medicine has been 
built, and today we see that natural products still constitute a large portion of the 
drugs currently in use or undergoing clinical trials. Unfortunately, due to the 
stringent testing procedures, toxicity and supply requirements, most biologically 
active natural products do not see the inside of a medicine cabinet. However, 
many of these 'failed' compounds provide useful pharmacological information, 
especially if they have a novel mode of action, often resulting in their use as lead 
structures in the development of alternative compounds that may someday be used 
as medicinal agents. 
1 . 2: What are Natural Products ? 
Naturally occurring compounds can be divided into two major classes: primary 
and secondary metabolites. Primary metabolic production pathways for 
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carbohydrates, proteins and nucleic acids are shared by all organisms. It is at the 
secondary metabolite, or natural product, production level that differences appear 
which are unique to a specific species. One such example is morphine (1.1) ,  
which occurs m just two species of poppy, Papaver somniferum and P. 
• I setzgerumoccurs. 
HO 
H0111 • ·  
1 .1 
Williams et al.2 defined a natural product as an organic compound that has "no 
explicit role in the internal economy of the organism that produces it." However, 
the argument was extended by noting that the existence of natural products in an 
organism serve to increase its survival fitness, and hence gain a competitive edge 
in its environment. 
The biological activity of these natural products can be seen as having a protective 
role in the organism: protection from predation, overgrowth by fouling organisms 
and from infection by micro-organisms. This was supported by the observation 
that many organisms produce natural products under some kind of stress. 3 It was 
also noted by Williams et al. that biologically active natural products are sparse in 
organisms that possess an immune system and are common in those that do not.2 
This would imply that biologically active natural products play an important role 
in the chemical defense of organisms Jacking a fully developed immune system 
(e.g. sponges). It also seems that natural products evolved under the pressure of 
natural selection as some of the biologically active natural products isolated to 
date interact directly with specific receptors unique to the predator/competitor. 
One such example is the family of cone snail venoms the conotoxins, which are 
highly selective peptide antagonists or agonists of ligand- or voltage-gated ion 
channels.4 
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1 . 3: Some Famous Natural Products 
3 
Uses for the bark of the willow tree (Cortex salicis) ,  which was well known for its 
antipyretic and analgesic properties, date back to around 400 BC. It was used for 
thousands of years until the main bioactive principle, salicin (1.2) ,  was identified. 
Degradation studies were undertaken in an effort to reduce the associated side 
effects of salicin (1.2) .  As a result of this research, both salicylic acid (1.3) and its 
acetyl derivative, acetylsalicylic acid (1.4), were discovered. Less than two years 
after its synthesis, acetylsalicylic acid (1.4) was marketed under the name 
Aspirin®, which without a doubt has to be one of the most famous and commonly 















In sharp contrast, the natural product Taxol® (paclitaxel (1.5)), an anti-tumour 
agent currently in clinical use, was isolated from the bark of the yew tree Taxus 
brevifolia in 197 1.5 Unfortunately, its success was dependent upon securing 
enough of the active compound. It took years to develop a semi-synthetic analog 
(docetaxel (1.6)) which was derived from a renewable resource. In this case, this 
was the needles of the related yew tree Taxus baccata, which contained several 
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The antimalarial agent quinine ( 1 .7) is obtained solely from the Cinchona tree, 
and was introduced into medicinal use in Europe in 1640.6 However, it was not 
until 1824 that large-scale production started in Germany, and many more years 
passed before the total synthesis of quinine ( 1 .  7) was achieved by Woodward and 
Doering in 1945. 7 The disease malaria remains rampant in many countries despite 
many decades of research and development of antimalarial drugs. The World 
Health Organisation (WHO) estimates that approximately 40 % of the world's 
population are infected, with 300 to 500 mil lion new cases reported each year.6 
Malaria claims between 1.5 and 2.7 mil lion lives annually, mostly children.6'8 
Currently, the preferred treatment centres around the use of drugs that utilize a 
combined mode of action, in an attempt to inhibit the further emergence and 
spread of parasites resistant to one component of the combination. 8 
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The earliest reported observation indicating that the fungus Penicillium sp. 
displayed antibacterial activity was described by Tyndall in 1896.9 During that 
same year, small amounts of an antibacterial substance were isolated in crystalline 
form by Gosio. 1 0 This compound was subsequently confirmed to be 
mycophenolic acid (1.8) . 1 0 Reports describing antibacterial properties of fungi 
continued to surface throughout the late 1800's and early 1900's, the pinnacle of 
which was the historical work published by Fleming in 1929 describing the effects 
of Penicillium notatum on bacteria. 1 1  It was not until the early 1940's, however, 
when a group of scientists at Oxford began investigating the use of penicillin ( e.g. 
Penicil lin G (1.9)) for human treatment, that the full potential of Sir Alexander 




Fleming's work demonstrated the enormous potential tl1at micro-organisms 
possessed. Their ability to biosynthesize antibacterial compounds that were 
suitable for incorporation into human therapeutics began a new era in drug 
discovery. The focus shifted from terrestrial fungi around 1945 in an effort to 
solve a serious clinical problem, the emergence of benzylpenicillin resistant 
Staphylococci. At this point, investigations into marine microbes began after it 
was observed that sewage outfalls displayed some degree of antibiotic activity as 
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they underwent a process of 'self purification'. As a direct result, a fungal isolate 
was obtained, yielding the penicillin related ,B-lactam antibiotic cephalosporin C 
(1.10). 1 1  Although actinomycetes remained the focus for several years, fungal 
isolates still remained a prolific source of antibiotics. The cyclic peptide 
cyclosporin A (1.11) was isolated from the fungus Tolypocladium inflatum in 
1976.1 ° Cyclosporin A (1.11) was initially isolated on the basis of its ability to 
inhibit fungal growth. However, it was also shown to have marked 
immunomodulatory properties, and is currently used as an immunosuppressant to 









Today, the ,B-lactam antibiotics account for over 65 % of the world's antibiotic 
market and represent a $US 15 billion industry per annum. 1 3 The need for new ,B­
lactam antibiotics remains set to continue, due to the ongoing emergence of 
resistant bacterial pathogens. 
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1 . 4: Why Search the Marine Environment? 
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The marine environment represents an enormously diverse ecosystem, covering 
more that 70 % of the planet's surface. Life has its origins in the oceans, and it is 
estimated that some of these ecosystems (coral reefs) have a biological diversity 
higher than that of a tropical rain forest. Current estimations predict the existence 
of 30 marine phyla, constituting 5,000,000 species of marine organisms. 1 4  Due to 
variations in environmental factors such as temperature, turbidity and nutrient 
flow, all marine animals, plants and micro-organisms are expected to produce 
entirely different metabolites to those observed in a terrestrial environment. The 
biomedical potential of the ocean has been known for thousands of years. Ancient 
civilizations from China, India and Japan have made use of seaweed, seashells 
and often parts of marine organisms for medicinal preparations. We are perhaps 
more aware of terrestrial plants and animals that have provided medicinally useful 
natural products, as this is the environment that mankind has evolved in, rather 
than those with marine origin. However, we must consider that the molecular 
physiology of eukaryotic cells evolved in our early marine ancestors.4 Most of the 
marine natural products described to date possess unique chemical structures that 
have no terrestrial counterparts, and frequently exhibit interesting biological 
activity. 1 5  
The survival of an individual organism within this marine ecosystem is dependent 
upon the organism's ability to defend a unique niche in which they can thrive. 
This, combined with the fact that many of these marine organisms are soft bodied, 
slow moving or sessile, has most likely contributed to the organism's evolution 
towards the exceptional ability to either synthesize potent and structurally 
complex secondary metabolites, or form symbiotic relationships with bacteria or 
fungi that produce these toxic compounds, as a direct means of defense against 
spatial competition and predation.4 The high potency of these compounds may be 
a direct consequence of the need to overcome rapid dilution on release into the 
water, in order to exert the desired effect, or be potent enough to deter pretators 
with minimum structural damage.4 
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Since the birth of marine chemistry in the mid-sixties, the number of reported 
metabolites isolated from the marine environment has steadily increased (Figure 
1 . 1 ). This increase can be attributed to both improvements in technologies 
associated with sample collection and compound isolation/elucidation, and 
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Figure 1 . 1 :  The total number of marine natural products isolated from 1 965 
onwards. 1 6 
Data presented by Dr Peter Murphy at the National Cancer Institute (NCI) 
revealed that, when the incidence of biological activity of all the known marine 
natural products isolated were compared across phyla, sponges were the most 
prevalent source. 1 7 
Data reviewing marine natural product isolations from 2000 to the present day 
indicates that this trend seems set to continue, as sponges still remain one of the 
most dominant sources of biologically active natural products (Figure 1.2), 
followed by coelenterates, when activity was compared across Phyla. 1 6• 1 8-2 1 
Sponge statistics may have been biased however, because of their prevalence, 
ease of collection, and ability to biosynthesize a variety of natural product 
structural classes. More recently, a greater interest in micro-organisms has seen 
an associated increase in the number of compounds isolated, and this phylum is 
proving to be a rich source of novel/biologically active natural products. This 
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phenomenon could also possibly be attributed to the accelerating advances m 
marine biotechnology.2 1 
Sponge biodiversity is known to be at its highest in the tropical regions, 
concentrated in the region of Papua New Guinea and radiating concentrically 
outwards.22 Generally, it has been accepted that species diversity differs with 
latitude. The polar regions are typically characterised by high abundance and low 
diversity, while tropical zones are characterised by low abundance but high 
diversity.22 Tropical regions have predominantly been the focus of collection 
efforts, possibly due to high species diversity. It is widely accepted that species 
diversity infers chemical diversity. 
400 
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Figure 1.2: Distribution of novel active and non-active marine natural products 
by £hylum for 2000 - 2003. Adapted from Faulkner et a/.
20·2 1  and Blunt et 
al. '  , 1 8, 1 9  
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1 . 5: Recent Advances in the Discovery of Biologically 
Active Natural Products 
The main chal lenge for the natural product prospector is to be able to identify 
particular compounds containing desirable biological activity characteristics. This 
is necessary if a compound is to be considered as a potential candidate for 
pharmaceutical development. Historical ly, the biological activities of compounds 
from terrestrial sources were evaluated by a process of trial and error by native 
peoples. Compounds that possessed undesirable side effects or no longer 
displayed biological activity were discontinued from use in traditional medicines. 
More recently, during the 70's, compounds that were not antimicrobial were tested 
using animal models and cel l-based assays. Today, elaborate high throughput 
screening programs have allowed tens of thousands of extracts to be routinely 
assessed for biological activity with the use of highly automated robotics. In 
industry, new assays are developed at a rate of one every six months, utilizing 
different target enzymes or receptors. When these assays are developed, all of the 
pure compounds held in the current library are evaluated. This process continues 
as new assays are developed. The high throughput assay is a mechanism-based 
assay system targeting drug candidates that display specific and selective activity. 
The need for excessive processing of the crude extract (solvent partitioning, semi­
purification) is not necessary as the mechanism-based assay is more robust than 
the cell-based assays.23 Ecological impacts are also reduced due to the need for a 
minimal quantity of extract as a result of increased sensitivity of the mechanism­
based assay.23 Although the high throughput assay system has its place in drug 
discovery, it is highly specific and restricts the selection of activity that a normal 
cel l-based assay would identify. It is up to the natural product chemist to not only 
identify compounds that are structural ly novel, but those that are mechanistically 
novel as well. 
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1 .  6: Why Continue Prospecting for Biologically 
Active Natural Products ? 
The need for new therapeutics is always expanding. Many diseases are becoming 
a growing health concern, as classical treatments are no longer effective with the 
development of multi-drug resistance.24 This, combined with the emergence of 
new diseases, has resulted in an immense financial burden for both the individual 
and society. For the pharmaceutical and biotechnology industry, it represents a 
major market opportunity; for chemists it represents an enormous challenge. 
Therefore, the need for new drug leads that can be developed into new 
therapeutics is paramount. 
Since the discovery of antibiotics in the first half of the twentieth century, the 
emergence of antibiotic resistant bacteria has left the scientific community ill 
prepared. This acquired resistance has spread rapidly, and treatment of infections 
caused by Staphylococcus aureus and other strains of resistant bacteria has 
become challenging. Vancomycin (1.12), the antibiotic of last resort for the 
treatment of S. aureus infections, has with increasing frequency also been 
rendered ineffective in recent years. Clearly, the continuing development of new 
and effective classes of antibiotic pharmaceuticals must keep pace with the ever­
evolving antibiotic resistant bacteria. Daptomycin (1.13), a cyclic lipopeptide, is 
one such example, isolated from the fermentation broth of Streptomyces 
roseosporus.24 The precise mechanism of action is not entirely understood, 
however calcium-dependent insertion of the 'lipid tail' into the cytoplasmic 
membrane plays an important role. Daptomycin (1.13) displays a wide spectrum 
of in vitro activity against a variety of Gram-positive organisms, including multi­
drug resistant strains of Staphylococcus, Streptococcus and Enterococcus, and 
was released onto the market in mid 2004 after approval from the United States 
Food and Drug Administration (FDA). Daptomycin (1.13) represents the first 
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Cancer is a growing health concern for the worldwide population, with estimated 
new incidences reported to be 10 million cases per year (six million deaths), and 
is considered the second highest cause of mortality behind heart disease (16.7 
million).26'27 The World Health Organisation (WHO) predicts a rise in worldwide 
incidence to rise to 20 million cases per year (10 million deaths) by the year 
2020.27 Cancer develops after a cell accumulates mutations in several genes that 
control cell growth and survival. When a mutation seems irreparable, the affected 
cell usually enters apoptosis (cycle of cell death) rather than accumulate mutations 
that make it possible for the cell to divide uncontrollably and to metastasize 
CHAPTER 1 INTRODUCTION 1 3  
(break away from the original tumour) and establish tumours at different sites. 
Patients with many types of cancer may experience little or no significant 
response to even the best available combinations of surgery, radiation and drug 
therapy. These treatments possess a small degree of specificity for fast-growing 
cells, although damage stil l occurs to both normal and cancerous cells. When 
responses are obtained, the cancer cells can develop a level of resistance that often 
sees the subsequent treatments fail. To beat cancer, we need smarter therapies. 
Once a tumour is diagnosed, a variety of treatment options are considered, 
depending on the tumour type, extent and location. Radiation and chemotherapy 
are the most commonly used therapies. Although these therapies have proven 
successful for some tumours, they are stil l highly toxic and nonspecific, since the 
primary mode of action is to damage deoxyribonucleic acid (DNA). Conventional 
chemotherapy is associated with drug resistance (both single and multi-drug) and 
systemic toxicity, thereby limiting therapeutic effectiveness. In order to reduce 
these effects, alternative therapies are being developed that are a combination of 
currently available treatments. These include chemotherapy combined with 
radiotherapy, immunotherapy, differentiation and . . angiogenes1s inhibition 
therapy.28 •29 The objective of these approaches is to eliminate the problems 
associated with cancer cell resistance to a particular drug or class of drugs, and to 
diminish toxicity associated with high-dose chemotherapy. Unfortunately, the 
drugs currently used are not tumour specific, and are often associated with severe 
side effects. 
The isolation of C-nucleosides from the Caribbean sponge Cryptotheca crypta
30 
more than 50 years ago, led to the synthetic development of cytarabin ( 1 .1 4, Ara­
C)), the first marine-derived anti-cancer agent to be developed for clinical use. It 
is currently used for the treatment of patients with leukaemia and lymphoma.3 1 
Gemcitabine ( 1 . 1 5), one of its fluorinated derivatives, has also gained clinical 
approval for the treatment of pancreatic, breast, bladder and non-small cel l  lung 
cancer. 
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Numerous natural products have been approved for clinical use and are employed 
in anti-cancer therapies. Some examples of these include, doxorubicin 
(Adriamycin® (1.16) and the related compound daunorubicin (1.17)), vincristine 
( 1 .18), vinblastine (1.19) and mitomycin C (1.20). 
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Doxorubicin (1.16) is an anthracycline-based antibiotic that has been of major 
importance in cancer chemotherapy since its clinical introduction in the early 
1970's. Its main mode of action involves DNA strand breakage due to drug­
mediated inhibition of DNA toperisomerase II ,  an essential cellular enzyme of 
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DNA synthesis and repair. However, considerations of toxicity, lack of 
effectiveness against a number of clinically common carcinomatous tumours (e.g. 
large cell lung, colorectal and bladder cancer) and development of drug resistance 
by tumours are among the reasons for the continuing search for compounds with 
improved therapeutic efficacy. 
Since its first reported incidence in the United States in 1981, AIDS (Acquired 
Immunodefficiency Syndrome), like so many other diseases, has now become a 
worldwide problem. Current estimates (2004) suggest that 39.4 million people 
are living with the human immunodeficiency virus (HIV) that causes AIDS.32 
This number represents the highest recorded incidence to date. In New Zealand, 
figures remain relatively constant, with 157 people diagnosed in 2004 and 154 the 
previous year through HIV antibody testing. 33  HIV infection is primarily 
transmitted through blood to blood contact and sexual intercourse. The disease 
acts by killing the immune 'T-helper cells' that are an integral part of the human 
immune system's response to infection. When the level of T-cells has been 
significantly reduced, the patient often experiences secondary infections and the 
formation of cancers. This process is typical of AIDS, the final stages of the HIV 
viral infection. Initial treatment of the disease consisted of a single antiretroviral 
drug of nucleoside origin. This monotherapy improved the clinical status of 
infected patients by reducing the plasmid viral load, but quickly became 
ineffective due to rapid viral mutations. The 'triple cocktail' combination referred 
to as the 'highly active antiretroviral therapy' (HAART) was considered a major 
advancement in currently available treatments, possessing impressive in vitro 
activity against viral replication. 
Currently, 3 7  licensed retroviral drugs are available for the treatment of HIV 
infections, however only 19 have been formally approved. 34 These belong to four 
families: (i) nucleoside reversed transcriptase inhibitors (NRTI), such as 
zidovudine (1.21) and didanosine (1.22); (ii) non-nucleoside reversed 
transcriptase inhibitors (NNRTI), including nevirapine (1.23) and delavirdine 
(1.24); (iii) nucleotide reversed transcriptase inhibitors (NtRTI), for example 
tenofovir disoproxil fumerate (1.25); and (iv) protease inhibitors (PI), such as 
saquinavir (1.26) and ritonavir (1.27). Unfortunately, even 'HAART' therapy, 
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although successful at reducing viral plasmid levels for many years, is not able to 
destroy residual viral populations that are residing within 'reservoir cells' in the 
lymphoid tissues. These are beyond the reach of any antiviral drugs available. 
This, combined with side effects associated with lifelong treatments including 
emergence of resistant mutations, accumulated toxicity and drug intolerance, has 
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Like cancer and AIDS, tropical diseases affect a large proportion of the world's 
population (approximately 500 million people in Brazil, China, India and across 
the African continent) and include malaria, typhoid fever, leishrnaniasis and 
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Chagas' disease.35 Only a few natural and synthetic compounds have been 
effective at treating such diseases, however many of the currently available drugs 
come at a significant price and level of toxicity. 
Typhoid fever is an illness following infection by the bacterium Salmonella 
enterica serovar Typhi. Chloramphenicol (1.28), isolated from the actinomycete 
Streptomyces venezuelae, 36 was introduced for the treatment of typhoid in 1948 
and proved to be very effective both economically and clinically. However, by 
1972 the first report of chloramphenicol-resistant Salmonella enterica serovar 
Typhi was described.37 The transmission of resistance to Escherichia coli was 
also demonstrated in vitro. The focus of Western drug development centres on 
diseases such as cancer and those of the heart, and of the 1223 new drugs released 
onto the market between 1975 and 1996 only 11 new compounds ( 1  %), two of 
which were reformulations, were treatments for tropical diseases. 35 It is clear that 
effective funding and development of low-cost drugs is urgently needed if any 








Clearly, the natural products that have been developed to date have played a 
pivotal role in controlling/treating human diseases. However, shortcomings in 
terms of drug toxicity, disease mutation, cost and availability can only be 
overcome if a multidisciplinary approach is employed. With the help of 
molecular biology technology, advances can be made in the identification of new 
molecular targets. This could not only revive 'old drugs', but may also provide 
targets for rational drug design. 
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What about the diseases that have yet to emerge? One such recent example is the 
Severe Acute Respiratory Syndrome (SARS) outbreak in Asia. Although 
conventional methods were used to contain further outbreaks of the SARS virus, 
the outbreak highlights the ongoing necessity for new drugs. 
SARS, a previously unidentified disease, emerged from China as an untreatable 
and rapidly spreading respiratory illness. Between late 2002 and the first half of 
2003 SARS outbreaks were reported in 32 countries. By July 5 2003, 8436 cases 
had been documented, 812 of which resulted in death.38 The WHO responded by 
invoking traditional public health measures along with advanced technologies to 
control the illness and contain the cause. A novel coronavirus (Co V) was 
implicated, and its entire genome was sequenced by mid-April 2003. The major 
transmission mode of SARS-Co V is via close human contact, in particular, 
exposure to droplets of respiratory secretions from an infected person. A cluster 
of outbreaks within a Hong Kong apartment building were attributed to the 
persistence of SARS-Co V nucleic acid in excrements and wastewater, extended 
by lower temperatures. Fortunately, conventional methods proved effective in 
control ling the disease. Large amounts of chlorine-based disinfectants were used 
to treat hospital wastewater, and infected patients were kept in isolation once it 
was discovered that SARS-CoV can only persist as infectious particles for a very 
short period of time in in vitro environments. 
1 .  7: The Phylum Porifera: An Overview 
Sponges are noted in many texts as the simplest multicellular organisms and 
constitute the phylum Porifera of the animal kingdom, which includes about 
10,000 described species. 3 They appeared on Earth over 600 million years ago, 
and have undergone little structural evolution over time. Sponges are sessile, and 
the majority are commonly found in locations where suitable substrates like coral 
and rocks are located. Their bodies contain no specific organs, but rather an 
organised mass of cells that exhibit a high degree of specialisation. Sponges 
obtain their food by filtering a high volume of water that is pumped through a 
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complex system of tissues, pores, canals and chambers. The flow of water is 
conducted from the inhalant surface to the exhalant apertures (pores).3 
Sponges come in many colours, shapes and sizes, from millimeter thin 
encrustations, to branching ropes or to giant barrels more than 1.5 metres in height. 
They are ubiquitous, having been discovered in both fresh and salt water at all 
depths and latitudes.3 
Soft tissue makes up the main mass of the sponge body. This tissue is supported 
by a framework of structures that are found in almost all sponges. These skeletal 
structures are of considerable importance in the classification of sponges, and may 
consist of calcareous spicules, siliceous spicules or spongin fibres ( organic 
material). The classification (taxonomy) of sponges is extremely difficult as 
almost all of the identifying characteristics are variable. This has led to many 
reports in the literature of subsequent reclassifications of previously 
identified/classified specimens. 39 
Sponges contribute significantly to the biomass of marine ecosystems, and are 
distributed worldwide in a variety of habitats. This persistent ecological success 
has been attributed to the adaptive reproductive and physiological strategies, and 
an effective defence mechanism.2 
Representatives from the phylum Porifera have a remarkable ability to synthesize 
a wide variety of secondary metabolites with potent biological activity. However, 
studies on metabolite production by sponge symbionts suggest that many 
compounds originally thought to be of sponge origin may well be of symbiont 
origin. One example that illustrates this particular point is the work by Faulkner 
and Bewley on Lithistid sponges,40 where it was demonstrated that, after 
purification and analysis of the four cell types present in the Theonella swinhoei -
eukaryotic sponge cells, unicellular heterotrophic bacteria, unicellular 
cyanobacteria and filamentous heterotrophic bacteria - the macrolide swinholide 
A ( 1 .29) was limited to the population of unicellular heterotrophic bacteria and 
the ,6-amino acid containing cyclic peptides such as theonegramide (1.30) 
occurred only in the filamentous heterotrophic bacteria. Contrary to prior 
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speculation, no major metabolites were located in the cyanobacteria or sponge 
cells. A second example comes from PhD work being carried out at the 
University of Canterbury by Ms. Sarah Bickford on the origins of metabolites 
found in the sponge Lamellomorpha strongylata. Initial details were reported at 
the NZIC conference in Wellington November, 1999.4 1  It has been established 
that the biologically active compounds swinolide H (isolated as the di-methylene 
acetal (1.31)) and theonellapeptolide Ille (1.32) were localised within unicellular 
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Finally, more recently Hill and Harmann42 demonstrated that the microbe 
Micromonospora sp., isolated from a deep-water Indonesian sponge, produced the 
compounds manzamine A (1.33) and 8-hydroxymanzamine A (1.34) when grown 
under certain laboratory culture conditions with specific media. 
compounds were originally isolated from the sponge itself.43 
These 
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The likelihood that a significant number of sponge-derived cytotoxic metabolites 
are in fact of microbial origin seems to be a real possibility as more literature is 
published confirming what many investigators have previously speculated. 
1 .  8: Marine Fungi: An Overview 
Marine fungi are ubiquitous. They are located in any environment that has a 
saline water source, including the oceans, river mouths and marshes. Even a few 
manne species have been isolated from great depths (>1500 ft).44 The main 
factors that control the distribution of marine fungi are the availability of 
substrates, of hosts, temperature, hydrostatic pressure and oxygen. There is still 
debate as to what the properties are that define a fungi as marine. The most 
obvious is that the fungus requires sodium for survival at a concentration that 
defines it as a macronutrient,45 while others claim that it is the absence or 
presence of certain enzyme activity.46 However, the generally accepted 
definitions that are used to divide marine fungi into two groups are obligate and 
facultative. Obligate marine fungi are those that grow and sporulate exclusively 
in a marine or estuarine habitat, while facultative marine fungi are those that 
originate from the land or freshwater but can grow and possibly sporulate in a 
marine environment.47 Many species of fungi were reclassified according to this 
definition, reducing the number of true marine fungi. To date there is no direct 
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method to identify whether or not an isolate is truly marine, other than to observe 
in viva the ability to grow in the marine environment. Species identification has 
become more rapid with the use of molecular data such as deoxyribonucleic acid 
(DNA), ribosomal DNA (rDNA), random amplified polymorphic DNA (RAPD) 
and restriction fragment length polymorphism (RFLP) fingerprints. These 
techniques combined with searchable databases, have made identification more 
consistent, faster and easier for the non-specialist. 1 0 The processes of 
classification, identification and preservation of fungal isolates are very important 
procedures in natural product research. An inaccurate account of any one of these 
techniques would make experimental reproducibility impossible. Literature 
reports also provide chemical/biological information describing structural types 
and biological activities that mycologists can use to help in the profiling and 
classification process. 
Fungal isolates investigated in this thesis were derived from sponge tissue 
collected from the frigid waters of Antarctica. Studies on fungi in Antarctica have 
been largely concerned with terrestrial specimens involved with the 
decomposition of organic matter.48 It has only been in recent times that 
systematic collections have been made from the marine environment, although 
these have generally been limited to sea borne materials such as drift wood.49 
For more detailed information regarding biologically active/novel compounds 
isolated from marine fungi, see Sections 5.1 and 6.1 .  
1. 9: Antarctic Sponges 
Marine sponges continue to be a rich source of biologically active metabolites 
with a wide range of activity. The main attention, however, has been focused on 
the investigation of specimens that inhabit temperate or tropical areas, due to the 
increased biodiversity and ease of collection. The Antarctic marine environment 
has been considered to be harsh; however, below the line where the bottom is 
scoured by anchor ice, the benthic community is remarkably rich and stable. 
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Although vertebrate predators, predominantly fish, which browse on sessile 
invertebrates (sponges) are rare at these latitudes, there is a high incidence of 
predation by macroinvertebrates such as sea stars. This phenomenon could 
explain why a plethora of novel and/or biologically active secondary metabolites 
have been isolated from sponges of widely distributed genera. Approximately 
twenty-one species of conspicuous Antarctic sponges have been identified, most 
of which have been investigated for novel/biologically interesting compounds.22 
Examples of these include sponges of the genera Artemisina,50•5 1  Cinachyra,52 
D d .11 52-57 u . ll 58 59 l d . 60 61 Ph b 50 p 62 en n a, nomaxme a, ' so tctya, ' or as, sammopemma, 
Leucetta,50•63 Suberites,64-67 Latrunculia,68•69 Negombata68 and 
Kirkpatrickia. 50•52 ,70-72 
The two sponges Latrunculia sp. and Kirkpatrickia varialosa have significant 
importance for the Marine Chemistry Group at the University of Canterbury. 
The genus Latrunculia (Order Hadromerida, Family Latrunculiidae) has had at 
least 2 species described, L. apicalis and L. biformis, in Antarctica. A major 
feature of this genus is the characteristic discorhabd microscleres, from which 
they were originally named. It was from this genus that the first reported marine 
isolation of the 1,3,4,5-tetrahydropyrrolo[ 4,3,2-de]quinoline ring system was 
achieved, with the discovery of the discorhabdins ( 1 .35-1 .55). 73 
Discorhabdin C ( 1 .37) was first described in 1986 by Perry et al. as a highly toxic 
pigment isolated from the New Zealand sponge Latrunculia sp. at the University 
of Canterbury. 73 Between 1986 and 2004, 22 compounds in the discorhabdin 
family were isolated and described in the literature from the genus 
Latrunculia.68'69'73-78 More recently the 23rd example, discorhabdin W ( 1 .56), was 
isolated from a New Zealand species collected from Fiordland.79 Discorhabdin W 
( 1 .56) is the first example of a dimeric compound in this series. However, of 
these isolated compounds, only discorhabdins C ( 1 .37) and G ( 1 .4 1 )69 and 
discorhabdins B ( 1 .36) and R ( 1 .52)68 have been isolated from Antarctic waters. 
The discorhabdin series is characterised by a range of biological activities against 
a variety of assays, but especially note worthy are the high levels of in vitro 
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cytotoxic activity against a variety of cell lines (P388, L 1210, LS l 78, HCT-116 
and KB). In subsequent in viva testing, only discorhabdin D ( 1 .38) showed results 
that could be defined as important. 
In mechanism-based assays, discorhabdin P ( 1 .50) was found to be an inhibitor of 
two key peptides, calicneurin and CPP32 (a member of the caspase family), at 
levels that were considered to be highly significant. Interestingly, discorhabdin P 
( 1 .50) is N-methyldiscorhabdin C ( 1 .37) and in distinct contrast, discorhabdin C 
( 1 .35) showed no activity against either enzyme. 73 
CHAPTER 1 
Br 0 
1 .35 R = H 




1 .39 R = Br X= H 
1 .40 R = Br'. t-. 1 6, t-.4, X = H  
1 .4 1  R = Br, t-.7 , X = H  
1 .43 R =  X = H, 
1 .45* X = a,  R = H 
0 
HN 











1 .36 R = Br 
1 .37 R = Br, t-.4 
1 .5 1  R = Br, t-. 1 6,t-.4 
Br 
1 .46* X = OH 
1 .44 X = a 
0 
Br 
1 .53 t,. 1 6  
1 .54 t,.7, t,. 1 6  





1 .38 X = H 
1 .42 X = a 
26 







*Discorhabdins that have been isolated but are as yet unpublished. 1 7  
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The second of the two genera, Kirkpatrickia varialosa, yielded the variolin (1.57-
1.60) group of compounds. They were isolated in 1994 by Blunt, Munro and 
coworkers,7 1 '72 using P388 bioassay-guided isolation techniques, from sponge 
material collected in the Antarctic. The variolins represented a new class of 
marine alkaloid, possessing a novel fused tricyclic heteroaromatic core structure 
(a pyrido[3',2',4,5]pyrrolo [ l ,2-c]pyrimidine) that was unlike any terrestrial or 
marine natural product that had been isolated previously. 
1 .57 1 .58 
0 HO 
1 .59 1 .60 
Pham1acological evaluations of these compounds involved testing against a 
variety of cell lines and micro-organisms. Activity in the P388 (murine leukaemia) 
cell line assay (in vitro) varied across the compounds. Variolin B (1.58) was 
identified as being the most potent against the P388 cell line (IC50 210 ng/mL), as 
well as having moderate antiviral activity. PharmaMar (Spain) undertook further 
development of these compounds as synthetic targets because of their high 
potential as anti-tumour agents. In structure activity studies oxidation of the 
isolated D ring in the molecule as in variolin A (1.58) or N-3'-methyl-3',4',5',6'­
tetrahydrovariolin B (1.59), was found to reduce activity.80 The activity of these 
compounds seems to be associated with the presence of the aminopyrimidine ring, 
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as variolin D ( 1 .60), which lacks this ring, possesses no appreciable activity. Due 
to insufficient quantities of variolin B ( 1 .58), and the inability to re-collect the 
original sponge, interest was stimulated in the total synthesis. The first total 
synthesis was published by Anderson and Morris81 (Chemistry Department, 
University of Canterbury), followed closely by Alvarez and coworkers,80 in 2003. 
The total synthesis provided access to sufficient material suitable for the 
preparation of analogues. At present, the variolin analogues are undergoing 
preclinical trials at PharmaMar.42 
1 . 1 0: The Current State of Play 
Currently, there are many marine-derived compounds that have just entered, or 
are about to enter, into clinical and pre-clinical trials (Table 1 . 1 )  for the treatment 
of various diseases.42 A brief overview is given below for a few selected 
compounds in an attempt to acquaint the reader with the significance that natural 
products are likely to play in the future of modem medicine for the treatment of 
diseases such as cancer. 
Investigations into potential anti-cancer drugs from the marine environment led to 
the isolation of a plethora of chemical compounds. These include didemnin B 
( 1 .61 ) from the tunicate Trididemnum solidum (Rinehart et al.), 82 dolastatin 10 
( 1 .62) from the Indian Ocean mollusk Dolabella auricularia (Pettit et al.),83 the 
simple compound girolline ( 1 .63) from the sponge Pseudaxinyssa cantharella 
(workers at Rhone-Poulenc Rorer),42 the bengamides A ( 1 .64) and B ( 1 .65) from a 
marine sponge (Crews et al.),84 and finally the cryptophycins (for example 
cryptophycin 52 ( 1 .66)) which was initially reported from a blue-green alga 
(Merck)85 but was subsequently isolated from a non-marine cyanophyte (Moore et 
al.)86 and then from an Okinawan sponge (Kobayashi et al.).87 However, all of 
these compounds have been withdrawn from anti-tumour trials. Didemnin B 
( 1 .61 ) proved too toxic in Phase II trials. Dolastatin 10 ( 1 .62) did not demonstrate 
any significant in viva anti-tumour activity (Phase II), while girolline ( 1 .63) 
administration caused substantial hypertensive side effects in patients (Phase I). 
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Problems with the intrinsic biological properties of the bengamides A (1.64) and 
B (1.65) and cryptophycin 52 (1.66) led to the development of synthetic 
derivatives, however, unfortunately all of the natural and synthetic compounds 
were withdrawn from further clinical trials (Phase I and Phase II respectively).42 
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The marine alkaloid ecteinascidin 743 (1.67, ET-743), isolated from the ascidian 
Ecteinascidia turbinata, along with the shark cartilage-derived compound 
neovastat (which is not a true compound but rather a "defined mixture" of 
>500kDa compounds), are currently the most clinically advanced anticancer 
agents, with both compounds having reached phase III trials in Europe.42 
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1.67 
Additional promising anti-cancer agents (that have been selected for preclinical 
trials) include compounds that possess quite different biological modes of action. 
These include the tubulin interactive agents, enzyme and DNA inhibitory 
compounds and actin-active agents. 
After the mechanism of paclitaxel (1.5) was discovered, a systematic study of 
marine organisms began, using bioassay guided separation (tubulin interactive 
assay), in an attempt to identify other compounds which acted via the same 
mechanism. As a result, a variety of compounds were isolated. 
Compounds that are described as tubulin interactive agents include laulimalide 
(1.68) and isolaulimalide (1.69), isolated by Mooberry et al.,88 and peloruside A 
(1. 70), isolated by Northcote's group, 89 from the marine sponges Cacospongia 
mycofljiensis and Mycale hentscheli , respectively. The compound curacin A (1.71) 
was isolated from the cyanobacterium Lyngbya majuscula (Gerwick et al.),90 
while the compounds vitilevuamide (1.72), and diazonamide ( 1 .73), by Ireland's 
group9 1  and Fenical's group,92 respectively, were isolated from the ascidians 
Didemnum cuculiferum and Diazona angulata, respectively. Fenical's group93 
also isolated, from the Australian octacoral Eleutherobia sp., the compound 
eleutherobin (1.74). Pietra's group94'95 identified sarcodictyin (1.75) from both of 
the Mediterranean corals Sarcodictyon roseum and Eleutherobia aurea. 
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0 
1.74 R 1 = H 
In addition, natural products displaying activity as anti-Alzheimer's, anti­
inflammatory, analgesic, anti-microbial, anti-malarial and anti-HIV agents have 
also been reported as entering preclinical trials.42 
All of these compounds demonstrate the ability that manne natural products 
possess to invoke a variety of pharmacological effects. However, the problem of 
supply is one of the major obstacles for the development of a natural product 
currently undergoing clinical trials. In most cases, the compound of interest is 
only isolated in milligram quantities from large collections, often accounting for 
only 1 0-6 of the wet weight of the organism, especially in the case of 
invertebrates.96 Several tonnes of sponge biomass would be required annually to 
meet market requirements. Therefore careful account must be taken regarding the 
source of the active compounds. Synthetic or semi-synthetic routes will reduce 
the need for large-scale collections of the organism, although these strategies need 
to be economically feasible and the yield optimised. The cellular location of the 
compound is also important. Is it the sponge, tunicate or bryzoan that is 
producing the biologically active compounds, or are they of microbial origin? 
This question, when answered, may have significant consequences, especially if 
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microbes are found to be the source. Entirely new approaches for the production 
of the 'drugs' are then opened up, especially given biotechnological advances in 
the area of gene cloning.97'98 
The biologically active compounds discussed in this section are only a small 
representation of the drug candidates currently undergoing trials. A more 
exhaustive list of compounds derived from the marine environment currently in 
preclinical, phase I, I I  or I I I  trials is shown in Table 1.1. These examples also 
illustrate the structural diversity that marine natural products possess. 
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Table 1.1: Marine Natural Products and their synthetic derivatives m vanous 
stages of clinical development.42 
Name Source Status (disease) Status 
didemnin B Tridide11111u111 solidu111 (Tunicate) Phase I I ( cancer) * 
apl idine dehydrodidemnin B (total synthesis) Phase I I ( cancer) 
dolostatin I 0 Dolabella auricularia (cyanophyte) Phase 1/11 ( cancer) * 
TZT- 1 027 synthetic dolastatin Phase I I  ( cancer) 
cematodin synthetic derivative of dolastatin 1 5  Phase 1/1 I ( cancer) 
I LX 65 1 ,  synthatodin synthetic derivative of dolastatin 1 6  Phase 1/11 (cancer) 
giro l l ine Pseudaxinyssa cantharella (sponge) Phase I ( cancer) * 
bengamide derivative Jaspis sp. (sponge) Phase I ( cancer) * 
cryptophycins Nostoc sp. and Dysidea arenaria Phase I ( cancer) 
(terrestrial cyanophyte and sponge) * 
bryostatin I Bugula neritina (bryozoan) Phase II (cancer) 
ecteinascidin 743 Ecteinascidia turbinata (ascidian) Phase 1 1/1 I I ( cancer) 
E7389 Lissodendoryx sp. (sponge) Phase I ( cancer) 
discodermalide Discodermia dissoluta (sponge) Phase I ( cancer) 
kahalalide F Eylsia rufescens/Bryopsis sp. Phase I I ( cancer) 
(mollusk/green microalga) 
ES-285 (spisulosine) Spisula polynyma (clam) Phase I ( cancer) 
HTI-286 (derivative) Hemiasterella minor (sponge) Phase I I ( cancer) 
KRN-7000 Age/as mauritianus (sponge) Phase I ( cancer) 
squalamine Squalus acanthias (dogfish shark) Phase I I ( cancer) 
!E-94 1 (defined mixture) Phase I I/I I I  ( cancer) 
NVP-LAQ824 Synthetic Phase I ( cancer) 
laul imalide Cacospongia mycofijiensis (sponge) precl in ical (cancer) 
curacin A Lyngbya majuscula (cyanobacterium) precl inical (cancer) 
vitilevuamide Dide11111u111 cucliferwn precl in ical (cancer) 
and Polysyncraton lithostrotw11 
(ascidians) 
diazonamide Diazona angulata (ascidian) precl in ical (cancer) 
eleutherobin Eleutherobia sp. (octacoral) precl in ical ( cancer) 
sarcod i ctyi n Sarcodictyo11 roseum (coral) precl inical (cancer) 
peloruside A Mycale hentscheli (sponge) precl inical (cancer) 
sal icylihalimides A Haliclona sp. (sponge) precl inical (cancer) 
thiocoraline Micromonospora marina precl inical (cancer) 
(actinomycete) 
variolins Kirkpalrickia variolosa (sponge) precl inical (cancer) 
dictodendrins Dictyode11drilla verongiformis precl inical (cancer) 
(sponge) 
GTS-2 1 (DMBX) synthetic Phase I (Alzheimer's) 
manoalide lulfariella variabilis (sponge) Phase I I  (antipsoriatic) * 
IPL-576,092 Petrosia co11/ignata (sponge) Phase I I  (antiasthmatic) 
IPL-5 1 2,602 derivative of 576,092 Phase I (antiasthmatic) 
I PL-550,260 derivative of 576,093 Phase II (antiasthmatic) 
ziconotide (Prialt) Conus magnus (cone snai l )  Phase I I I  (pain) 
CGX- 1 1 60 Conus geographus (cone snail) Phase I (pain) 
CGX- 1 007 Conus geographus (cone snail) Phase I (pain and 
epilepsy) * 
AMM336 Conus ea/us (cone snai l )  precl inical (pain) 
x-conotoxin Conus sp. (cone snai l )  precl inical (pain) 
CGX- 1 063 Synthetic precl inical (pain) 
ACV I Conus victoriae (cone snail) 12recl inical (12ain) 
"Denotes compounds that have been reported as discontinued from clinical and preclinical trials. 
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It is clear that marine invertebrates and micro-organisms represent a source of 
biologically active marine natural products that are as structurally diverse as they 
are biologically active. Although investigation into the marine environment 
began many decades ago, few biologically active compounds have made it 
through the drug development process into commercial use, due to their potency 
and lack of target specificity. However, synthetic chemical derivatives hold new 
hope for those compounds that do not possess favorable pharmacological 
properties. In order to increase the number of natural products potentially useful 
as pharmaceuticals, a multidisciplinary approach is needed especially in the areas 
of microbiology and synthetic chemistry. Technology has also allowed for rapid 
advances in drug discovery research, by allowing collections in habitats 
previously inaccessible to humans, genetic fingerprinting of sponges and micro­
organisms, the culturing of previously "unculturable" bacteria and fungi that are 
host specific, rapid throughput screening that is mechanism-based, and finally, the 
development of techniques used in the isolation and structural elucidation of 
potential drug candidates. We can only wonder at what prospects the next few 
decades will hold. 
1 . 1 1 : The A im of this Thesis 
To investigate the biological activity of the chemical constituents of New Zealand 
and Antarctic marine invertebrates, combined with micro-organisms cultured 
from the tissues of Antarctic sponges (fungi), using the assays available in-house 
at the University of Canterbury. 
Isolation and characterization of the active compounds will be achieved using 
combinations of chromatographic techniques, while structural elucidation will 
utilize mass spectrometry, 1 H, 1 3C and 2D NMR spectroscopic techniques. 
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CHAPTER 2 
ISOLATION OF COMPOUNDS FROM THE 
NEW ZEALAND MARINE SPONGE 
Rhabderemia stelletta (0 1 MNP0729) 
2. 1 :  General Introduction 
37 
Long-chain acetylenic compounds are unsaturated fatty acid derivatives that are 
commonly characterised by unbranched long alkyl chains. They are structurally 
simple yet display a high degree of diversity in relation to their chain length and 
functionalities. The most abundant naturally occurring saturated fatty acids have 
the general formula CH3(CH2)11C02H (n=l 2, 14, 16 and 18) and are vital 
components of natural waxes, seed oils and glycerides. Glycerides typically have 
polar head groups and lipophilic tails and are commonly encountered as 
constituents of cell membranes, playing an important role in the structural 
integrity and selective permeability of the cell membrane structure. 
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In addition to their structural role, (poly)unsaturated fatty acids act as precursors 
for biologically active metabolites. Oleic acid (2.1) is the biosynthetic precursor 
for polyacetylenes like crepenynic acid (2.2), a compound produced by many 
species of Compositae ( daisy) which has anti-microbial activity, and wyerone (2.3) 
produced by the broad bean under stress which displays anti-fungal activity.99 
Fatty acid synthases are enzymes that control the biosynthesis of fatty acids. 
Bacterial synthases comprise six or seven discrete enzymes, whilst plants and 
mammals contain more sophisticated synthases comprising two identical 
multifunctional proteins that posses seven different catalytic activities. Each 
protein reacts with the acyl carrier protein (ACP), which acts as a cofactor 
carrying the growing fatty acid on phosphopantetheine attached to its thiol group 












H H 2.3 
Historically the isolation of polyacetylenic compounds from plants has been 
prevalent, and terrestrial sources still provide an abundant source of novel 
polyacetylenic compounds. Recently the novel polyacetylenic compound 
dendrotrifidic acid (2.4) (9Z, l 6S)-l 6-hydroxy-9, 17-octadecadiene- l 2, 14-diynoic 
acid was isolated from the leaves of the Dendropanax morbifera, a plant whose 
extract was reported to display anti- fungal activity.99 Extracts from the 
Dendropanax genus display cytotoxic activity and have been used extensively in 
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traditional medicine for the treatment of migraines and other ailments. Although 
dendrotrifidic acid (2.4) possesses no significant in vitro anti-fungal activities, it 
does display a high degree of anti-complement activity when tested in vitro. '
00 
Aciphyall (2.5), a novel C34 polyacetylene, was identified from the methanolic 
extract of the subalpine giant spear grass Aciphylla scott-thomsonii, representing 
the first instance of a chain length exceeding C 1 8  from a higher plant. 10 1  
Aciphyall (2.5) exhibited both weak cytotoxic activity in the P388 assay (IC50 > 


















It has only been within the last 30 years that biologically active acetylenes have 
been reported from the marine environment, with over 100 compounds currently 
described. Distribution seems ubiquitous, with acetylenes isolated from algae, 1 02 
sea hares, ' 03 stony corals, 1 04 nudibranchs 1 05 and sponges. 1 05- 1 29 
The nonterpenoid Cwhalogenated compounds (Z)-maneonene A (2.6) and B (2.7), 
(E)-maneonene B (2.8) along with iso-maneonene A (2.9) iso-maneonene B (2.10) 
and (Z)-maneonene C (2.11) were isolated from the red marine alga Laurencia 
'difi 1
02 nz l tea . 
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2.6 







Two halogenated acetylenic ethers, dactylyne (2.12) and its isomeric analogue 
isodactylyne (2.13), were reported from the sea hare Aplysia dactylomela. ' 03 
These two compounds are members of a group of similar nonterpenoid C1 5  ethers 
isolated from red algae. 1 02 
2.12 3(Z) 
2.13 3(£) 
C46 to C49 (2.14-2.18) straight chain polyacetylenes have been isolated from both 
the nudibranch Peltodoris atromaculata 1 05 and the marine sponge Petrosia 
ficiformis. ' os, , o9, 1 1 2 , 1 1 4- I I 6, I I 9, 1 20 
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Polyacetylenes isolated from three species of hermatypic corals Montipora sp, M. 
mollis, and Pectinia lactuca inhibited the growth of some bacteria and fungi. 1 04 
Hard corals consist mainly of calcareous skeleton and it was assumed that these 
animals would not produce any significant secondary metabolites, thus they had 
been previously overlooked as a source of novel biologically active compounds. 
However, the polyacetylenic alcohols 2.19 and 2.20 along with the associated 
esters 2.21, 2.22 were isolated from all three species of hard corals. All of the 
compounds displayed ichthyotoxicity against guppies at concentration levels of 1-
5 ppm. Compounds 2.19 and 2.20 were active at 10 µg/disc against Bacillus 
subtilis, Staphylococcus aureus, Aspergillus sp., and Cladosporium sp., while 2.21 
and 2.22 displayed no antimicrobial activity at a concentration of 10-100 µg/disc. 












Despite the fact that polyacetylenes continue to be isolated from various terrestrial 
and marine flora and fauna, marine sponges, in particular sponges from the order 
Haplosclerida, dominate as a source of novel biologically active 
acetylenes/polyacteylenes. 1 1 7 
Haplosclerida have proven a rich source of straight chain polyacetylenic 
compounds that exhibit a variety of different chain lengths and oxygenation 
patterns. From this order, 88 compounds have been reported, with the bulk of 
these originating from five families, consisting of eight genera; specifically 
Adocia, Callyspongia, Cribrochalina, 
S . h h 1 ·  d X. . 1 09 1 1 2  zp onoc a ma an estospongza. · 
Haliclona, Pallina, Petrosia, 
However, a series of C32-C35 
hydroxylated polyacetylenes have also been isolated recently from the marine 
sponge Theonella sp. (order Astrophoridae). 1 1 7 
The genera Petrosia and Xestospongia are characterised by the presence of 
hydroxylated C30 and C46 polyacetylenes as well as brominated C1 8  acetylenic 
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acids, while the Haliclona and Adocia are represented by the highly hydroxylated 
C47 acetylenic acids and hydroxylated C30 polyacetylenes. Hydroxylated C23-C4 1 
and C32-C33 polyacetylenic acids were reported from the genus Pellina. 
Hydroxylated C20-C22 polyacetylenes were found in the genus Cribrochalina. The 
polyacetylenic hydrocarbons C2 1-C22 are also characteristic of the genera 
Callyspongia along with C23 sulfonated and C22-C23 hydroxylated polyacetylenes 
in addition to a C25 polyacetylenic amide. 1 23 
These secondary metabolites exhibit a variety of biological activities including 
antifungal, antimicrobial, HIV protease inhibitory, H IV reversed transcriptase 
inhibitory, antifouling, immunosuppressant and anti-tumour activity. 1 1 7 
In order to rationalize the distribution of these compounds throughout the marine 
environment, and explain their diverse biological activity, the ecological 
chemistry of the predator-prey and symbiotic relationships must be considered. 
There is little doubt that the plethora of secondary metabolites that have been 
identified have arisen in direct response to the continually changing interactions 
between species. The nudibranch P. atromaculata 105 is able to find its prey, the 
sponge P. ficiformis, 1 08 • 1 09• 1 1 2 • 1 1 4- 1 1 6• 1 1 9• 1 20 by chemotaxis and store metabolites 
taken up during predation while the sea hare A. dactylomela 1 03 feeds upon the red 
alga L. nidifica. 1 02 Isolation of biologically active compounds from three of the 
chemically "ordinary" species of hard coral would be highly suggestive that these 
are metabolites from a common symbiotic organism, the activity of which implies 
that they play a significant role in the coral's defensive mechanism. 
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2. 2: Introduction 
The marine sponge Rhabderemia stelletta was collected and identified by the 
National Institute of Water and Atmosphere (NIWA) at an unknown depth, Spirits 
Bay, North Island, New Zealand. A voucher sample of 01MNP0729 is held at 
NIWA Wellington, New Zealand. The material was kept frozen until 
chemical/biological assessment could be performed at the University of 
Canterbury. Subsequent analysis of the organic extract in-house utilizing the 
P388 assay revealed that the extract displayed signi ficant anti-tumour activity 
with an IC50 < 975 ng/mL. An extensive literature search revealed that chemical 
studies on the marine sponge genus Rhabderemia are limited; with no literature 
reported for this genus. 1 30• 1 3 1  For this reason, the biologically active R .  stelleta 
species was selected for further chemical investigation. 
2. 3: Extraction of Marine Sponge Rhabderemia 
stelletta (OJMNP0729) 
The frozen sponge material was thawed in MeOH and homogenised until the 
specimen was completely macerated. After filtering through celite under vacuum, 
the residue was re-suspended and re-extracted using combinations of MeOH and 
DCM. All filtrates were combined and the solvent was removed under vacuum. 
The crude organic extract was partitioned between EtOAc and H20, the organic 
layer was collected and the solvent was removed under reduced pressure to yield a 
thick yellow/brown gum. Both the organic and aqueous fractions were analysed 
to locate the biological activity observed in the initial extract. P388 activity was 
present in the organic fraction only (IC50 < 975 ng/mL, 2.45 g). The aqueous 
layer contained no significant cytotoxic activity (IC50 > 12500 ng/mL). 
The orgaruc extract was subjected to analytical reversed phase (C1 8) HPLC 
microtitre plate chromatography (see Experimental, Section 7.1.6.2) and P388 
assay to locate the compounds responsible for the observed activity (Figure 2.1). 
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Well 88, corresponding to compounds eluting between 26-32.5 minutes, was 
found to contain the compounds responsible for the observed activity. The two 
major components eluting at 28.5 and 29.5 minutes displayed similar ultra violet 
(UV) profiles (Amax (CH3CN/H20) 230 nm, Figure 2.2), which suggested that the 
molecule contained conjugated bonds that were not aromatic in nature. 
Electrospray mass spectrometric analysis by direct injection of the active well was 
inconclusive as an abundance of mass peaks observed in both positive and 
negative modes made the identification any parent ions or any patterns 
corresponding to sodium or potassium adducts impossible. Due to the lack of 
structural information it was unlikely that a positive identification of these 
compounds would be achieved by interpretation of the UV spectra and retention 
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Figure 2.1: HPLC trace of DCM/MeOH crude extract (blue). Region of 
biological activity indicated between 26-32.5 minutes (black) as obtained from 
microtitre plate analysis. 
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200 220 240 260 280 300 
nm 
Figure 2.2: UV profiles of the two major compounds observed in the region of 
biological activity (26-32.5 minutes) as determined by microtitre plate assay 
(P388). 
2. 4: Chromatography of the Organic Extract 
2. 4.1: Reversed Phase (C18) Flash Chromatography of the 
Organic Extract 
The organic extract was dissolved in a minimum volume of solvent (MeOH and 
DCM) and adsorbed onto C 18 • The solvent was removed under reduced pressure 
and the dry pellet was loaded on the top of a reversed phase C 18 flash 
chromatography column equilibrated to 100 % H20. The column was eluted 
using stepped solvent gradient concentrations of H20, MeOH and DCM. Any 
remaining material was washed from the column with MeOH and DCM (0.1 % 
TF A). Seventeen fractions were collected and all fractions were submitted for 
biological assay in the P388 assay. The biological activity was found to be 
localised in fraction 12, which eluted with 2:1 DCM/MeOH (wjm12-312, IC50 
2001 ng/mL, 79.4 mg). This fraction was analysed by reversed phase (C 18) 
analytical HPLC, using the standard gradient elution method (see Experimental, 
Section 7.1.3.2), and it was confirmed that this fraction contained the peaks 
responsible for the activity observed in the initial microtitre plate analysis m 
Figure 2.1. 
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2. 4. 2: Normal Phase (DIOL) Flash Chromatography of 
Fraction wjm l2-312 
47 
The next stage of purification consisted of a normal phase (DIOL) flash 
chromatography column as the compounds contained within fraction wjm12-312 
were very non-polar. Fraction wjm12-312 was dissolved in a minimum volume 
of pet. ether, and loaded onto the DIOL column. Fractions were eluted from the 
column using a stepped solvent gradient from 100 % pet. ether through DCM to 
EtOAc and finally MeOH, with 12 fractions collected in total. Odd numbered 
fractions were submitted for biological assay with fractions wjm12-701 and 
wjm12-703 containing all of the biological activity (IC50 938 and 1205 ng/mL 
respectively). On the basis of these results, it was assumed that fraction wjm12-
702 would also be suitably active in the P388 assay; therefore these three fractions 
were combined. 
At this point of the isolation it was observed that fraction wjm 12-704 had begun 
to crystallize. Closer inspection of the 'crystal' like material using a polarized 
filter microscope showed that no polarization of light was observed. Further 
inspection revealed that a gelatinous gum-like substance that would not dissolve 
had formed. This lack of solubility prevented any further investigation into the 
type of compounds contained within this fraction. 
2. 4. 3 : Reversed Phase (C18) Semi-preparative HPLC 
Chromatography of Fractions wjm l  2- 701 to 
wjml2- 703 
Fractions wjm12-701 to wjm12-703 were combined and purified via semi­
preparative reversed phase (C1 8) HPLC chromatography, using an isocratic 
method developed for maximum resolution on the analytical reversed phase (C1 8) 
HPLC. Fractions were collected as peaks eluted. Four fractions were collected 
(Figure 2.6); purity was confirmed by re-injection onto the analytical reversed 
phase (C1 8) HPLC column. These fractions were subsequently examined by one 
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dimensional ( 1 D) and two dimensional (2D) NMR spectroscopy. Structural 
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Figure 2 .3 :  H P LC trace of the combined fractions wjml2-70 1 to 1 2-703 
indicating the four compounds (peaks) of interest (2.23, 2 .24, 2.25 and 2.26). 
2. 5: Structural Elucidation of Compounds Isolated 
from Rhabderemia stelletta 
2. 5. 1 :  Structural Elucidation of 2.23 
The first compound (2.23) was isolated as a pale yellow oil (6.5 mg). High 
resolution electrospray mass spectrometry (HRESIMS) identified a [M+Cst ion 
at m/z 583.2549 (calc 583.2552) which led to the molecular formula C3 1 H4602 . 
The 1 3C nuclear magnetic resonance (NMR) spectrum (Figure 2.4) combined 
with the heteronuclear single quantum coherence (HSQC) spectrum identified 1 4  
well-defined carbon signals corresponding to : six olefinic carbons (8c 1 46.2 (8H 
5.99), 1 34.4 (8H 5.86), 1 33.5 (8H 5.86), 1 29.5 (8H 5.57), 1 28.4 (8H 5.58) and 1 07.0 
(8H 5.42)), two oxymethine carbons (8c 63.2 (8H 4.80) and 62.7 (8H 4.82)), and 6 
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acetylenic carbons, two of which were protonated (8c 86.9, 83.3, 81 . 1  (8H 3.05), 
80.1, 79.6 and 73.8 (8H 2.54)). The 10 remaining carbon signals left to satisfy the 
molecular formula were largely unresolved (8c 27.8-29.0). These signals 
corresponded to protons at 8H 1.26-1.39 which dominated the 1 H NMR spectrum 
(Figure 2.5) and were subsequently assigned as methylene units of a long alkyl 
chain. 
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Figure 2.4: The 1 3C NMR spectrum of 2.23 (CDCl3) .  
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Figure 2.5 : The 1H NMR spectrum of 2.23 (CDCh). 
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olefinic carbons 1 09• 1 32 of similar compounds, and the coupling constant between 
the H-28/H-29 (J2s,29= 1 0.5 Hz) protons extracted from the 1 H NMR spectrum. 
B 
Figure 2.7: Partial structure B with key COSY (blue) and CIGAR (black) NMR 
correlations. 
The partial structure C (Figure 2.8) was tentatively determined to be similar to 
that of partial structure A (Figure 2.6) on the basis of the I H NMR chemical shift 
comparisons. However, the triple bond contained within this partial structure was 
found to be internal based on the fact that both the C- 1 5  and C- 1 6  carbons were sp 
quaternary. The orientation of the C- 1 5  and C- 1 6  carbons was determined by the 
CIGAR correlation from the H- 1 8  (8H 5.57) olefinic proton to the C- 1 6  (8H 79.6) 
acetylenic carbon. The connectivity from C- 1 2  to C-2 1 was achieved via a 
combination of both COSY and CIGAR NMR data. COSY correlations from the 
H- 1 3  (8H 1.50) methylene protons to the H- 1 4  and H- 1 2  (8H 2.22 and 1 .26- 1 .39, 
respectively) methylene protons secured C- 1 2  to C- 1 4, while the CIGAR 
correlations from the H- 1 4  (8H 2.22) methylene protons to the C- 1 3 , C- 1 5  and C-
1 6  (8c 28.9, 86.9 and 79.2 respectively) carbons established C- 1 3  to C- 1 6  
connectivity. The CIGAR correlation from the 8H 4.80 (H- 1 7) oxymethine proton 
signal to both C- 1 5  and C-16 (8c 86.9 and 79.2, respectively) acetylenic carbons 
established that the oxymethine proton was located on the C- 1 7  carbon position. 
The COSY cross peak correlations from the H- 1 8  (8H 5.57) olefinic proton to both 
H- 1 7  and H-19 (8H 4.80 and 5 .89, respectively) protons, defined C- 1 7  to C- 1 9, 
while COSY correlations from the H-20 (8H 2.05) methylene protons to the H- 1 9  
(8H 5 .89) olefinic proton and the H-2 1 (8H 1.26- 1 .29) methylene protons 
completed connectivity from C- 1 9  to C-2 1 ,  as shown in partial structure C 
(Figure 2.8). The configuration of the double bond C- 1 8/C- l 9 was assigned as (£) 
based on the coupling constant between the H- 1 8  and H- 1 9  (8H 5.57 and 5.89, 
respectively, J1 8 , 1 9= 1 6.5 Hz) olefinic protons and comparison of their 1 3C NMR 
chemical shifts with similar compounds previously isolated. 1 09 
----
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Figure 2.8: Partial structure C with key CbSY (blue) and CIGAR (black) NMR 
correlations. 
The remaining atoms (C 10H20) satisfying the molecular formula were designated 
as long-chain methylene units connecting the partial structures A to C and B to C. 
Elucidation of the long-chain methylene units was perf01med by careful 
examination of the COSY, HSQC and CIGAR data. Due to the nature of the 
overlapping signals, no conclusive assignment could be made. The total 
correlation spectroscopy (TOCSY) experiment was utilized. In the TOCSY 
experiment, magnetization is propagated along a spin system by successive scalar 
coupling and all protons that sit within the same spin-system are correlated, 
regardless of whether they are directly coupled to one another. It is well known 
that in a linear molecule the deshielding effect of a substituent diminishes as the 
distance between it and the proton increases.133 The H-28 (3tt 5.99) proton was 
selected for irradiation based upon the fact that it possessed a well defined 
chemical shift. Various mixing times were selected to enhance relayed coherence 
transfer through the upfield protons, in an attempt to observe the long-range 1H-
1H correlations through the alkyl chain to either the H-14 (3tt 2.22) or H-19 (3tt 
5.89) protons, depending upon the orientation of the central unit. Correlations 
from the H-28 (3tt 5.99) proton would determine the number of methylene groups 
connecting partial structures B and C and the orientation of the central unit C. 
This would also allow the remaining methylene units linking A to C to be 
assigned by default. No TOCSY correlations to either H-14 or H-19 (3tt 2.22 and 
5.86, respectively) protons were observed when H-28 (3tt 5.99) was irradiated, as 
displayed in Figure 2.9. 
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Figure 2.9 : TOCSY correlations observed for irradiated proton H-28 (8H 5.99) 
(mixing time=0.08 ms). 
Therefore, the overall gross structure could not be unambiguously determined by 
TOCSY NMR experiments. Both alkyl subunits (X and Y, Figure 2.10) contain 
protons and carbons with similar chemical shifts and it would not be unreasonable 
to suggest that the alkyl chains have similar lengths, however, this data would also 
support a variety of lengths assigned to each linking 'section' between subunits A 
to C and C to B where X+Y= l O  (C 1 0H20), for the methylene subunits. 
OH 31 
OH -�� -




3 1  
Figure 2.10: Diagnostic TOCSY correlations (black) for 2.23, two possible 
orientations of substructure C.  Confirmed portions of structure are in blue, while 
unconfirmed in red. 
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EI mass spectrometry was employed as an indirect method to fix the location of 
the double bonds by the identification of conspicuous mass fragments. 
Unfortunately no significant fragments were observed to aid in the assignment of 
the overall structure. 
The absolute configuration of compound 2.23 could not be determined by any 
chemical method due to the compound's subsequent degradation while undergoing 
NMR experimental analysis. 
Experimental 1 H, 1 3C and 2D NMR data for 2.23 are shown in Table 2.1. 
Table 2.1: The 1 H, 1 3C, COSY and CIGAR NMR data for 2.23 (CDC!J). 
positiont 
73 . 8  (CH) 
2 83 .3  (C) 
3 62.7 (CH) 
4 1 28.4 (CH) 
5 1 34.4 (CH) 
6 3 1 .8 (CH2) 
7 29.0 (CH2) 
8- 1 2t 27.8-29.0 (CH2) 
1 3  28 .9 (CH2) 
1 4  1 8 .7 (CH2) 
1 5  86.9 (C) 
1 6  79.2 (C) 
1 7  63 .2 (CH) 
1 8  1 29 .5 (CH) 
1 9  1 33 . 5  (CH) 
20 3 1 .8 (CH2) 
2 1 -25t 27.8-29.0 (CH2) 
26 28.7 
27 30.2 (CH2) 
28  1 46.2 (CH) 
29 1 07.9 (CH) 
30 80. 1 (C) 
2.54 ( d, 2.0) 
4 .82 (br d, 5 . 5 )  
5 .58 (dd, 1 6.5,  6.0) 
5 .86 (dt, 1 6.5,  6 .5) 
2.05 (m) 
1 .40 (m) 
1 .26- 1 .39 (m) 
1 .50 (q, 7.0) 
2 .22 (td, 6.5, 2.0) 
4 .80 (br d, 6.0) 
5 .57 (dd, 1 6.5,  6.0) 
5.86 (dt, 1 6.5,  6.5) 
2.05 (m) 
1 .26- 1 .39 (m) 
1 .39 (m) 
2 .32 ( q, 6 .5)  
5 .99 (dt, 1 0.5,  7.0) 
5 .42 (br d, 1 0.5)  
COSY 
H-3 




H- 14 ,  H- 1 2  
H- 1 3  
H- 1 9  
H-20, H- 1 9  
H-20, H- 1 8  




H-3 1 ,  H-28 
CIGAR 
C-3 , C-2 
C-5, C-4, C-2 
C-6, C-3, C-2 
C-6, C-3 
C-7, C-5, C-4 
C-6, C-5 
C- 1 5 ,  C- 1 4  
C- 1 7, C- 1 6, C- 1 5 , C- 1 3  
C- 1 9, C- 1 8, C- 1 6, C- 1 5  
C-20, C- 1 9, C- 1 7, C- 1 6  
C-2 1 ,  C-20, C- 1 8, C- 1 7  
C-22, C-2 1 ,  C- 1 9  
C-29, C-28, C-26 
C-30, C-29, C-26 
C-30, C-28 
3 1  8 1 . 1  (CH) 3 .05 (d, 2.0) H-29 C-30, C-29 
t Numbering defined as the two primary alcohols in (2.23) at C-3 and C- 1 7  and the terminal 
acetylenes at C- 1 and C-3 1 .  § 1 3C NMR chemical shift values (8 ppm from CDC13 at 77.0) 
obtained on Unity 300 (75 MHz). i 1H NMR spectrum recorded at 500 MHz in CDC13 (8 ppm 
from CDC13 at 7 .25) followed by multiplicity and coupling constant(s) (J/Hz) . t1nconclusive 
chemical shift assignment and coupling constants VH-H), due to signals being overlapped. 
-----
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Figure 2.11: The COSY NMR spectrum indicating H- 1 (black) and H-31 (blue) 
correlations from the terminal acetylene protons of 2.23. 
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2. 5. 2: Structural Elucidation of 2.24 
The second compound to elute was 2.24, which was isolated as a pale yellow oil 
(4.5 mg). HRESIMS identified a [M+Cst ion at m/z 581.2396 (calc. 581.2396) 
which led to a molecular formula of C31 H4402, two mass units less than the 
previously isolated compond 2.23. Both the 1 H and 1 3C NMR spectra (Figures 
2.12 and 2.13 respectively) were reminiscent of 2.23, with some significant 
differences. The loss of a proton signal at 81 1  4.80 (H-3 or H-17), the downfield 
shift of the two olefinic protons at 8H 5.57 (H-18) and 5.89 (H-19) to 8H 7.10 and 
6.14 respectively, and the appearance of a new signal at 8H 2.28 were noted. 
These changes strongly suggest that this compound may be the oxidation product 
of 2.23, thus satisfying the requirements of the mass spectral data. 
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Figure 2.12 :  The 1 H NMR spectrum of 2.24 (CDC13) .  
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Figure 2.13: The 1 3C NMR spectrum of 2.24 indicating the addition of a 
carbonyl peak at 8c 179.0 (CDCh). 
--
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The 13C NMR spectrum revealed an additional signal at 8c 179.0 suggesting the 
presence of a carbonyl group at C-17 as a downfield shift of the C-18 (from 8c 
I 
129.5 (2.23) to 8c 153.9) olefinic carbon was observed. The COSY (see Figure 
2.17, page 65) cross peak correlation from the H-18 (8H 7.10) olefinic proton to 
the H-19 (8H 6.14) olefinic proton, combined with the CIGAR correlations from 
theH-18 (8H 7.10) olefinic proton to the C-15, C-16 and C-17 (8c 94.6, 79.2 and 
179.0, respectively) carbons indicated that the carbonyl group was conjugated 
with both the alkyne and the olefin groups, suggesting an a, ,8-unsaturated ketone 
with the carbonyl a to the acetylene moiety. Consecutive COSY correlations 
from the H-11 (8H 1.27) alkyl methylene protons to H-12, H-13 and H-14 at (8H 
1.41 , 1.60 and 2.22, respectively), combined with the H-18 (8H 7.10) olefinic 
proton to H-19, H-20, H-21 and H-22 (8H 6.14, 2.28, 1.50 and l.32, respectively), 
defined the partial structure D (Figure 2.14) from carbons C-11 to C-22. Due to 
the deshielding effect of the carbonyl functionality, a greater number of methylene 
units could be defined. The geometry of the double bond was determined to be (E) 
based on the H-18/H-19 proton coupling constants extracted from the 1H NMR 
spectrum (J18,19 = 15.5 Hz) and chemical shift comparison with those from partial 













Figure 2.14: Proposed partial structure D with key COSY (blue) and CIGAR 
(black) NMR correlations. 
Analysis of the NMR data, including 1H, 13C, COSY, HSQC and CIGAR NMR 
spectra also led to the conclusion that 2.24 contained the same partial structures A 
and B (Figure 2.15) as dete1mined for compound 2.23. The geometry of the 
double bonds was confirmed by 13C NMR chemical shift data and coupling 
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constants and assigned as (E) for the C-4/C-5 (J4,5 = 16.5 Hz) carbons and (Z) for 
the C-28/C-29 (J28 ,29 = 10.5 ) carbons. 
A 




Figure 2.15: Partial structures A and B with key COSY (blue) and CIGAR (black) 
NMR correlations. 
No TOCSY NMR data was obtained for 2.24, due to subsequent compound 
degradation. Although a greater number of methylene units could be defined for 
partial structure D, the molecular formula still required C6H12 to be assigned. 
Because of the overlapping nature of the chemical shifts for the remaining carbons 
(oc 28.0-29.0) and protons (oH 1.26-1.39), it was concluded that the number of 
methylenes linking partial structures A to D and D to B would be similar. 
However, to satisfy the mass requirements X + Y had to equal six methylene units. 
No information regarding the orientation of the central partial structure D was 
available; therefore, no unambiguous assignment of 2.24 could be made. Figure 
2.16 is a representation of the possible orientations and connectivities of the 
proposed subunits. 
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Figure 2.16: Proposed connectivity for subunits A, B and D where X+Y=6, 
confirmed partial structures in blue, unassigned methylene portions in red. 
The subsequent degradation of compound 2.24 meant that no further mass 
spectrometric, NMR or chemical experiments could be carried out to obtain 
additional structural information for the unambiguous assignment of 2.24. 
The NMR data for compound 2.24 is shown in Table 2.2. 
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Table 2.2: The 1 H, 1 3C, COSY and CIGAR NMR data for 2.24 (CDCh). 
Positiont 
1 74.2 (CH) 
2 83 .6  (C) 
3 62 .7 (CH) 
4 1 28 .3  (CH) 
5 1 34 . 1  (CH) 
6 32 .0(CH2) 
7 27 .8 (CH2) 
8 - !0t 28 .0-29.0 (CH2) 
1 1  28 .9 (CH2) 
1 2  29.0 (CH2) 
1 3  28 .0 (CH2) 
1 4  1 9 .2 (CH2) 
1 5  94.6 (C) 
1 6  79.2 (C) 
1 7  1 79.0 (CO) 
1 8  1 53 .9  (CH) 
1 9  1 32.4 (CH) 
20 32 .4 (CH2) 
2 1  29.0 (CH) 
22 1 .32  (CH2) 
23-25t 28 .0-29.0 (CH2) 
26 28 .9 (CH2) 
27 30.0 (CH2) 
28 1 46 . 1 (CH) 
29 1 08.0 (CH) 
30 80. 1 (C) 
1 H o  r 
2.54 ( d, 2.0) 
4 .82 (br d, 5 .5 )  
5 . 58  (dd, 1 6.5,  6.0) 
5 .86 (dt, 1 6.5 ,  6 .5)  
2 .05 (m), 
1 . 39 (m) 
1 .26- 1 .39 
1 .27 (m) 
1 .4 1  (m) 
1 .60 (q, 7 .0) 
2 .22 (td, 6.5, 2.0) 
7. l O (m) 
6 . 1 4  (m) 
2 .28 (m) 
1 .50 (m) 
1 .32 (CH2) 
1 .26- 1 .39 (m) 
1 .39 (m) 
2 .32 ( q, 6 .5) 
5 .98 (dt, 1 0.5,  7.0) 




H-5,  H-3 
H-6, H-4 
H-7, H-5 
H- 1 2, H- 1 0  
H- 1 3 , H-1 1 
H- 1 4, H- 1 2  
H- 1 3  
H - 1 9  
H-20, H- 1 8  
H-2 1 ,  H- 1 9  
H-22, H-20 
H-27, H-25 
H-28,  H-26 
H29, H-27 
H-3 1 , H-28 
CIGAR 
C-3, C-2 
C-5, C-4, C-2, C- 1 
C-6, C-3, C-2 
C-6, C-4, C-3 
C-7, C-5, C-4 
C-8, C-6, C-5 
C- 1 5 ,  C- 1 4, C- 1 2, C- 1 1  
C- 1 6, C- 1 5 , C- 1 3 ,  C- 1 2  
C-20, C- 1 9, C- 17 ,  C- 1 6  
C-2 1 ,  C-20, C- 1 8, C- 1 7  
C-22, C-2 1 ,  C- 1 9  
C-23, C-22, C-20, C- 1 9  
C-29, C-28, C-26 
C-30, C-29, C-27 
C-30, C-28 
3 1  8 1 .0 (CH) 3 .07 (d, 2.0) H-29 C-30, C-29 
t Numbering defined as the primary alcohol in (2 .24) at C-3 and the carbonyl carbon at C- 1 7, 
while the terminal acetylenes are at C-1  and C-3 1 .  § 1 3C MR chemical shift values (8 ppm from 
CDC13 at 77.0) obtained on Unity 300 (75 MHz). 1 1H NMR spectrum recorded at 500 MHz in 
CDC13 (8 ppm from CDC13 at 7 .25) followed by multiplicity and coupling constant(s) (J/Hz). 
trnconclusive chemical shift assignment and coupling constants (JH-H), due to signals being 
overlapped. 
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Figure 2. 17 :  The COSY NMR spectrum of 2.24 indicating the correlations from 
the H-3 (oH 4.85) oxymethine proton (black), and the H- 1 8  (oH 7.10) proton a to 
the C-17 carbonyl (blue) . 
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2. 5. 3 : Structural Elucidation of 2.25 
The third compound to elute was also isolated as a pale yellow oil (2.3 mg). 
HRESIMS identified a [M+Cst ion at m/z 583.2547 (calc. 583.2552) 
corresponding to a molecular formula of C31 H4602 . This compound was therefore 
isobaric with 2.23. Both the 1 H (Figure 2.18) and COSY (Figure 2.19) NMR 
spectra had features in common with those observed for 2.23. These included two 
acetylenic protons (8H 2.56, 3.07) and six olefinic protons (8H 5.45, 5.61 5.68, 5.91 
6.00 and 6.03). However, an obvious difference was that although compound 
2.25 contained two oxymethine protons, one had shifted upfield from 8H 4.80 to 
4.14 (8c 63.2 to 72.7, respectively) and was no longer a broad doublet, but a 
quartet (integrating for one proton), indicating that it was now located in a more 
electron rich environment. 

























Figure 2.18 : The 1 H NMR spectrum of 2.25 (CDCl3), new quartet peak indicated. 
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Figure 2.19: The COSY NMR spectrum of 2.25, with key cross peak correlations 
from the H-1 and H-31 (8H 2.57 (blue) and 3.06 (red), respectively) terminal 
alkyne protons, the H-14 (8H 4.41, yellow) oxyrnethine proton and the H-16 (8H 
5.68, black) olefinic proton (CDCh). 
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Due to the paucity of compound 2.25, a minimal amount of carbon chemical shift 
data could be acquired and the little that was obtained was done so via the HSQC 
and CIGAR NMR experiments. Therefore it was necessary to elucidate the 
structure of 2.25 by careful comparison of the proton ch~mical shifts observed for 
the previously described compounds 2.23 and 2.24 (see Sections 2.5.1 and 2.5.2). 
Partial structure A (Figure 2.20) was assembled by the sequential COSY cross 
peak correlations. The H-1 (8H 2.57) terminal acetylenic proton was coupled by 
long-range COSY correlations to the H-3 (8H 4.86) oxymethine proton. 
Consecutive correlations from the H-3 (8H 4.86) oxymethine proton to the H-4 
and H-5 (8H 5.61 and 5.91 , respectively) olefinic protons and the H-6 and H-7 (8H 
2.08 and 1.39, respectively) methylene protons, terminated this section of the 
molecule and completed the assignment of carbons C-1 to C-7. Overlapping 
proton signals made the assignment of the protons on the long-alkyl chain past the 
C-7 (8H 1.39) position impossible. The configuration of the double bond at the C-
4 and C-5 carbons was assigned as (E) based upon the coupling constants 
extracted from the 1H NMR spectrum for the H-4 and H-5 (8H 5.61 and 5.91, 




Figure 2.20: Key COSY correlations (blue) and the long-range correlation (black) 
observed in the elucidation of partial structure A for 2.25. 
Using the same methodology, substructure B (Figure 2.21) was constructed via 
correlations from the second terminal acetylenic proton at DH 3.06. Successive 
COSY cross peak correlations were observed from H-31 (8H 3.06) to the H-29, H-
28, H-27 and H-26 (8H 5.45, 6.00, 2.35 and 1.43, respectively) protons. The poor 
resolution of the overlapping alkyl chain signals made any further assignment of 
the methylene groups beyond H-26 impossible, therefore substructure B, carbons 
C-31 to C-26, was assigned. The double bond geometry at the C-28 and C-29 
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carbons was defined as (Z) based on the proton coupling constants extracted from 
the 1 H NMR spectrum for the H-28 and H-29 (8H 6.00 and 5.45, respectively, 
Jz8,29= 1 0.5 Hz) protons, and the carbon chemical shifts observed in the CIGAR 
experiment for C-28 and C-29 (8c 1 46.5 and 108.2, respectively) as compared to 
compounds 2.23 and 2.24. 
B 
Figure 2.21: Observed COSY correlations (blue) for substructure B. Long-range 
correlation (black). 
Substructure E (Figure 2.22) was elucidated using a combination of COSY and 
limited HSQC and CIGAR NMR correlations. The key COSY cross correlation 
was observed from the H-14 (8H 4.14) oxymethine proton to H- 1 3  and H-15 (8H 
l .49 and 6.03, respectively) protons. This indicated that the H- 1 4  oxymethine 
proton was no longer a to an acetylenic carbon as in compound 2.24. The 
location of the triple bond was determined by the observation of the CIGAR 
correlations from the H-16 (8H 5.68) olefinic proton to the C-17 and C-18 (8c 91.0 
and 78.5, respectively) alkyne carbons. A long range COSY correlation was 
observed between the H- 1 6  (8H 5.68) proton and the methylene protons at 8H 2.28 
which suggested that these alkyl protons were directly on the other side of the 
triple bond. This was confirmed by the CIGAR correlations from the H-19 (8H 
2.28) methylene protons to both C-17 and C-18 (8c 9 1 .0 and 78.5, respectively) 
alkyne carbons. Sequential COSY correlations from the H-19 (8H 2.28) protons to 
the H-20 and H-21 (8H l .51 and l .26-1.39, respectively) protons, established C-19 
to C-21. The geometry of the C-15/C-16 double bond was assigned as (£) 
according to the coupling constant extracted from the 1 H NMR spectrum between 
the H-15 and H-16 (8H 6.03, 5.68, respectively, J1 5 ,1 6 = 17.5 Hz) protons, 
combined with a 1 3C NMR chemical shift comparison with similar compounds 
previously published. 1 22 This data confirmed connectivity from carbons C-13 to 
C-21 and allowed for the proposed partial structure E as shown in Figure 2.22. 
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13 l~o / 
OH 
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Figure 2.22: Partial structure E with key COSY (blue) and long-range COSY 
(black). 
Connectivity between the confirmed fragments or orientation of the central partial 
structure E could not be achieved with the limited NMR experimental data. In 
order to satisfy the requirements of the mass spectrum, the alkyl chain fragment 
C10H20 (10 methylene units) required assignment. Due to the overlapped nature of 
the chemical shifts in this region of both the HSQC (8H 1.26-1.39) and 13C (8c 
28.0-29.0) NMR spectra, the exact number of carbons (X and Y) linking partial 
structures A to E and E to B could not be determined, however, X + Y has to equal 
10. The overall structure for 2.25 is represented in Figure 2.23 with the two 




~(CH2)x 1 3 




~(CH2)x ~17 5 29 
~ (CH2)~
OH 31 
Figure 2.23: Proposed structure of compound 2.25, where X+Y = 10. 
As with the previously isolated compounds, degradation prevented any further 
structural information being gained; this included the stereochemistry at carbons 
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C-3 and C-14 and the unambiguous assignment of the central subunit by mass 
spectrometry or chemical modification. 
Table 2.3: The 1 H, 1 3C, COSY and CIGAR NMR data for 2.25 (CDC13) .  
Positiont 
1 74.2 (CH) 
2 83 .5  (C) 
3 63.0 (CH) 
4 1 28 .7 (CH) 
5 1 34 .8  (CH) 
6 32.0 (CH2) 
7 28 .9 (CH2) 
8- 1 2t 28 .0-29.0 (CH2) 
1 3  36.9 (CH2) 
1 4  72.7(CH) 
1 5  1 44 .2 (CH) 
1 6  1 1 1 .0 (CH) 
1 7  9 1 .0 (C) 
1 8  78 .5 (C) 
1 9  1 9.5  (CH2) 
20 29.7 (CH2) 
2 l -25t 28 .0-29.0 (CH2) 
26 29. 1 (CH2) 
27 30.0 (CH2) 
28 1 46 .5  (CH) 
29 1 08 .2 (CH) 
30 80. 1 (C) 
2 .57 ( d, 2.0) 
4 .86 (br d, 5 . 5 )  
5 . 6 1  (dd, 1 6.5 ,  6.0) 
5 . 9 1  (dt, 1 6.5 ,  6.5) 
2 .08 (m) 
1 .39 (m) 
1 .26- 1 .39 (m) 
1 .49 (m) 
4 . 1 4  (q, 6 .5)  
6 .03 (dd, 1 7.5 ,  6 .5)) 
5 .68 (d, 1 7.5)  
2 .28 (m) 
1 . 5 1  (m) 
1 .26- 1 .39 (m) 
1 .43 (m) 
2 .35  ( q, 6 .5)  
6.00 (dt, 1 0.5 ,  7 .0) 
5 .45 (br d, 10 .5 )  
COSY 
H-3 





H- 1 2, H- 14  
H- 1 5, H- 1 3  
H- 1 6, H- 14  
H- 1 9, H- 1 5  
H-20, H - 16  




H-3 1 ,  H-28 




C-5 ,  C-4 
C-2 1 ,  C- 1 7  
C-20, C- 1 8, C- 1 7  
C-2 1 ,  
C-29, C-28,  C-26 
C-29, C-27 
C-30, C-28 
t Numbering defined as the two primary alcohols in (2.25) at C-3 and C- 1 7  and the temlinal 
acetylenes at C- 1 and C-3 1 .  § 1 3C NMR chenlical shift values (8 ppm from CDCl3 at 77 .0) 
obtained from both HSQC and CIGAR experiments. 1 1H NMR spectrum recorded at 500 MHz in 
CDC13 (8 ppm from CDCl3 at 7 .25) followed by multiplicity and coupling constant(s) (J/Hz). 
trnconclusive chenlical shift assignment and coupling constants (JH-H) ,  due to signals being 
overlapped. 
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2. 5. 4: Structural Elucidation of 2.26 
The final compound to elute was 2.26; it was also isolated as a pale yellow oil (2.5 
mg). HRESIMS identified a [M+Kt ion at m/z 503.3264 (calc. 503.3291) 
indicating a molecular formula of C32ILi802 , 14 mass units more than 2.25, the 
previously described compound. Both the 1 H and COSY NMR spectra (Figures 
2.24 and 2.25, respectively) were reminiscent of the compound 2.25 (Figures 2.18 
and 2.19 respectively); however two significant differences were observed. 
Firstly the appearance of a singlet proton signal at 8H 3.26 (Figure 2.24), assigned 
as methyl ether protons on the basis of the HSQC correlation from 8H 3.26 to a 
carbon at 8c 56.7 (14-0CH3) ,  and secondly, the upfield shift of the H-14 (8H 4.14) 
quartet signal previously assigned as an oxymethine, to 8H 3.51. The addition of a 
methyl ether at position C-14 would satisfy the additional mass requirement of 14 
Da, and explain the chemical shift change observed for the H-14 oxymethine 
proton. 
Due to the paucity of compound 2.26, structural elucidation was performed by 
careful examination of the COSY (Figure 2.25) NMR data and limited HSQC and 
CIGAR NMR data. Partial structures A and B were easily deduced by direct 
comparison with data obtained from compounds 2.23 and 2.24 (Tables 2.1 and 
2.3) .  
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Figure 2.25: The COSY NMR spectrum of compound 2.26, with key cross peak 
correlations from the H-1 and H-31 (black and red, respectively) terminal alkyne 
protons and the H-14 (yellow) oxymethine proton. 
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Partial structure A was assigned on the basis of COSY correlations from the H-1 
(8H 2.56) terminal acetylenic proton to the H-3 (8H 4.83) oxymethine followed by 
sequential COSY correlations from the H-3 (8H 4.83) oxymethine proton to the H-
4 and H-5 (8H 5.60 and 5.90, respectively) olefinic protons and from the H-6 (8H 
2.06) methylene protons to both the H-5 (8H 5.90) olefinic proton and the H-7 (8H 
1.40) methylene protons. This confirmed the connectivity from C-1 to C-7. As 
with the previous substructures, resonances for C-8 and H-8 and beyond were too 
heavily overlapped for individual chemical shift assignment. Therefore partial 




Figure 2.26 : Key COSY (blue) and long-range COSY (black) correlations for the 
construction of partial structure A. 
Partial structure B was elucidated using the cross peak correlation from H-31 (8H 
3.06) the second terminal alkyl proton, to the H-29 (8H 5.45) olefinic proton, 
followed by the sequential correlations from H-29 (8H 5.45) to H-28 (8H 6.00) the 
second olefinic proton, and then from the H-27 (8H 2.32) methylene protons to 
both the methylene protons at 1.43 (H-26) and the olefinic proton at 8H 6.00 (H-
28). These correlations confirm the connectivity from C-26 to C-31. As before, 
the resonance H-25 (8H 1.26-1 .39) was too overlapped for individual chemical 
shift assignment. Therefore, partial structure B proposed in Figure 2.27, was 
found to be identical to those elucidated for the previous compounds (see Figures 
2.9, 2.15 and 2.21). 
B 
Figure 2.27 : Key COSY (blue) and long-range COSY (black) correlations for 
partial structure B. 
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The geometry of the double bond for partial structure A (C-4/C-5) was determined 
as (E) on the basis of the direct comparison of the 1 3C NMR chemical shift data 
obtained from the HSQC and CIGAR experiments, with those previously reported 
(Tables 2.1, 2.2 and 2.3) and the coupling coupling constant extracted from the 
1H NMR spectrum (J4,5 = 16.5 Hz). The double bond geometry assignment for 
partial structure B was determined as (Z) for the C-28 and C-29 carbons, and was 
achieved by direct comparison of the 1 3C NMR chemical shift data obtained from 
the HSQC and CIGAR experiments with those previously reported (Tables 2.1, 
2.2 and 2.3), combined with the coupling constant extracted from the 1 H NMR 
spectrum between the H-28 and H-29 olefinic protons (bH 6.00 and 5.45, 
respectively, J2s,29= l l.O Hz). 
Partial structure F (Figure 2.28) was elucidated using COSY (Figure 2.25) and 
limited HSQC and CIGAR NMR correlations. The key COSY cross peak 
correlations were observed from the H-14 (bH 3.51) oxymethine proton to both the 
H-13 alkyl and H-15 olefinic (bH 1.49 and 5.85, respectively) protons, confirming 
that this proton was in the same configuration as partial structure E for compound 
2.25 (Figure 2.22). The location of the triple bond was determined by the 
observation of CIGAR correlations from the H-16 (bH 5.63) olefinic proton to the 
C-17 and C-18 (be 91.6 and 78.6, respectively) carbons. A long range COSY 
correlation between the H- 16 (bH 5.63) olefinic proton and the H-19 (bH 2.30) 
methylene protons placed the H-19 methylene proton directly on the other side of 
the triple bond, confirming that the ene-yne configuration as seen in 2.25 was stil l  
present. The geometry of the C-15/C-16 double bond was assigned as (E) due to 
the 1 3C NMR chemical shifts comparison of C-16 and C- 15 (CIGAR correlation 
from H-14 (bH 3.53) to carbons C-16 and C-15 (be 1 11.0 and be 144.2, 
respectively)) with those reported for 2.25, combined with previously published 
data for similar compounds (see Table 2.4). 
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Figure 2.28: Key COSY (blue), long-range COSY (black) and CIGAR (green) 
NMR correlations used in determining partial structure F. 
Connectivity between the confirmed fragments or orientation of the central partial 
structure F could not be achieved with the limited NMR experimental data. In 
order to satisfy the requirements of the mass spectrum, the alkyl chain fragment 
C 10H20 (10 methylene units) required assignment. Due to the overlapped nature of 
the chemical shifts in this region of both the HSQC (DH 1.26-1.39) and CIGAR 
(&c 28.0-29.0) NMR spectra, the exact number of carbons (X and Y) linking 
partial structures A to F and F to B could not be determined, however, X + Y has to 
equal 10. The overall structure for 2.26 is represented in Figure 2.29 with the two 
possible orientations for partial structure F. 
OH 







Figure 2.29: Overall proposed structure of 2.26, where X+Y = 10. 
As with the previously isolated compounds, degradation prevented the acquisition 
of any further structural information; this included the stereochemistry at carbons 
C-3 and C-14 and the unambiguous assignment of the central subunit by mass 
spectrometry or chemical modification. 
The full NMR data for 2.26 is shown in Table 2.4. 
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Table 2.4: The 1 H, 1 3C, COSY and CIGAR NMR data for 2.26 (CDCh). 
Positiont 1 3C o § 1 H o I COSY CIGAR 
74.2 (CH) 2 .56 (d, 2.0) H-3 
2 83 .5  (C) 
3 63.0 (CH) 
4 1 28 . 5  (CH) 
5 1 34 .8  (CH) 
6 32 .0 (CH2) 
7 28 .9 (CH2) 
8- 1 2t 28 .0-29.0 (CH2) 
1 3  28 .7  (CH2) 
1 4  82.3 (CH) 
1 4-0CH3 56.7 (CH3 
1 5  1 44.2 (CH) 
1 6  1 1 1 .0 (CH) 
1 7  9 1 .6 (C) 
1 8  78 .6 (C) 
1 9  1 9.5  (CH2) 
20 29.7 (CH2) 
2 l -25 t 28 .0-29.0 (CH2) 
26 29. 1 (CH2) 
27 30.0 (CH2) 
28 1 46.5 (CH) 
29 1 08.0 (CH) 
30 80. 1 (C) 
4.83 (br d, 5 .5 )  
5 .60 (m) 
5 .90 ( dt, 1 6.5 ,  6.0) 
2.06 (q, 7 .5 )  
1 .40 (m) 
1 .26- 1 .39 (m) 
1 .49 (m) 
3 . 5 1  (q, 6.5) 
3 .26 (s) 
5 .85 (m) 
5 .63 (m) 
2 .30 (m) 
1 .5 1  (m) 
1 .26- 1 .39 (m) 
1 .43 (m) 
2 .32 ( q, 6 .5 )  
6.00 (dt, 1 1 .0, 7 .5 )  
5 .45 (brd, 1 1 .0) 
H-4, H-1  




H- 12 ,  H- 1 4  
H- 1 5 , H- 1 3  
H- 1 6, H- 1 4  
H- 1 9, H- 1 5  
H-20, H- 1 6  




H-3 1 ,  H-28 
3 1  8 1 . l (CH) 3 .06 (d, 2.0) H-29 
C-2 
C-6, C-3 
C-5 ,  C-4 
C- 1 4  
C-2 1 ,  C- 1 7  
C- 1 8, C- 1 7  
C- 1 9  




t Numbering defined as the primary alcohol in (2.26) at C-3 and the methyoxy at C- 1 4  while the 
terminal acetylenes at C-1  and C-3 1 .  § 1 3C NMR chemical shift values (8 ppm from CDCh at 77.0) 
obtained from both HSQC and CIGAR experiments. 1 1H NMR spectrum recorded at 500 MHz 
in CDC13 (8 ppm from CDCl3 at 7 .25) followed by multiplicity and coupling constant (J/Hz). 
t rnconclusive chemical shift assignment and coupling constants (JH-H), due to signals being 
overlapped 
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2. 6: Biological Activity 
Due to subsequent degradation, the purified compounds could not be individually 
tested for P388 activity. However, all of the purified compounds were isolated 
from fractions that displayed cytotoxic activity (IC50 < 975 ng/mL). 
It has been recently reported that polyacetylenes possessing the l -yn-3-ol terminal 
moiety (2.27) possess cytotoxic activity while those containing the alternate 1-yn-
3-one moiety (2.28) display negligible activity when tested in vitro in the HCT-
166 assay. Structure activity relationship measurements concluded that it is the 1-
3 1 . l . h · · · h "  1 f d I 9 20 I 25 yn- -o termma moiety t at imparts activity to t 1s c ass o compoun s. · · 
Therefore it would not be unreasonable to assume that compounds 2.23, 2.24, 






2. 7: Concluding Remarks 
The aim of this section of work was to isolate and identify the compounds 
responsible for the observed biological activity (P388) in the crude extract of the 
marine sponge Rhabderemia stelletta (01MNP0729). 
Initial bioassay guided fractionation (HPLC microtitre plate collection) located 
the region of activity in the HPLC chromatogram which corresponded to several 
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non-polar compounds. With limited structural information (UV, retention time 
and inconclusive mass spectra), no positive identification for the compounds 
eluting in the region of activity could be made. Therefore further purification was 
deemed necessary. Several steps of chromatography, C 1 8  and DIOL flash 
chromatography followed by semi-preparative reversed phase (C 1 8) HPLC 
chromatography yielded four novel, C3 1  long-chain unsaturated triacetylenes 2.23, 
2.24, 2.25 and 2.26. This work represents the first reported isolation of 
polyacetylenic compounds from the marine sponge Rhabderemia stelletta and 
also represents the first reported isolation of polyacetylenes from the marine 
sponge Order, Microcionina. 
Subsequent biological activity assessment (P388 assay) on the purified 
compounds could not be achieved due to compound degradation. However, these 
four compounds were isolated from the region of activity as located by microtitre 
plate analysis of the crude extract and they contained the active l-yne-3-ol moiety 
reported in the literature, 1 1 8 • 1 25• 1 34 Therefore, on the basis of these two factors, all 
of these compounds should exhibit some degree of activity in the P388 assay. 
Structural elucidation of these four compounds was achieved with the use of 1 H, 
1 3C, COSY, lD-TOCSY, HSQC and CIGAR NMR spectroscopy, high resolution 
ESI mass spectrometry and subsequent comparisons of chemical shift data 
published for similar compounds. 1 22 
The absolute stereochemistry of all four compounds could not be determined 
using Masher's or modified Masher's method, as the compounds degraded before 
this analysis could be carried out. The most obvious pathway would be the light 
activated free radical polymerization as samples became more concentrated 
throughout the purification process, although samples were stored in the dark at 4 
�C. The remaining frozen sponge material of Rhabderemia stelletta was extracted 
in an attempt to re-isolate 2.23, 2.24, 2.25 and 2.26 for further structural analysis, 
however after several steps of chromatography no significant biological activity 
was detected in any of the semi-purified fractions. Further work on these 
fractions was abandoned (see Section 7.2.5). 
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No optical rotation data was obtained nor was any IR or UV ( except HPLC photo 
diode array (PDA)). Unambiguous positional assignment of the central 
substructure containing the double bond could not be achieved by EI or ESI 
(variable cone voltage) mass spectrometry at the University of Canterbury, 
although it is well reported that F AB-CID tandem mass spectrometry, is an 
effective tool for such an application.1 1 9  
I t  i s  unlikely that long-chain polyacetylenic compounds will find clinical use as 
anticancer drugs due to their hydrophobic nature and tendency to degrade. 
However, derivatives that display a high degree of stability/solubility are more 
likely to succeed. One such compound (tazarotene 2.27) containing an internal 
acetylene functionality is currently in phase I clinical trials for the treatment of 
basal cell carcinoma, the most common cancer in humans. 1 35 
Polyacetylenic compounds have a broad range of biological activities and their 
widespread occurrence and chemical simplicity warrant continued investigation 
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2. 8: Summary of Isolation 
Rhabderemia stelletta (01MNP0729) 
MeOH/DCM Extraction (330 mg) 
C 1 8  Column Chromatography 
H20 
I 
MeOH DCM DCM/MeOH I I I I I I I I I I I I I I I I 
Fraction # I 2 3 4 5 6 7 8 9 1 0  I I  1 2* 1 3  1 4  1 5  1 6  1 7  
Mass (mg) 98.3 7.0 1 .0 33.2 22 1 .5 3.2 0.8 1 .6 6.6 1 5 25 .7 79.4 34.9 88.3 1 82.7 72.5 1 20 
I 











Fraction # 1 * 2 * 3 * 4 5 6 7 8 9 1 0  1 1  1 2  
Mass (mg) 4.4 3.6 1 5.9 6. 1 5 .3 26.4 1 0.6 4.3 1 . 8  2.6 1 . 8  2.2 
Semi-preparative (C 1 8) 
Chromatography 




(4. 1  mg) 
I 




Scheme 2.1 : Chromatographic purification summary for the New Zealand marine 
sponge Rhabderemia stelletta (01MNP0729). *Fraction contains biologically 
active compound( s) of interest. 
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CHAPTER 3 
ISOLATION OF COMPOUNDS FROM 
AN UNIDENTIFIED ANTARCTIC 
MARINE SPONGE (02WM0 1 -33)  
3. 1 :  General Introduction 
84 
Pteridines are widely distributed throughout the animal kingdom, having been 
isolated from both terrestrial and marine organisms. They have long been known 
as yellow pigments from insects, serving as a growth factor in some cases, while 
their function in marine organisms is not entirely clear. 1 36 There seems little in 
the way of information relating to the biological activity of these compounds, and 
it can only be assumed that they provide some degree of chemical defense for the 
marine animal or in fact are representative of evolutionary convergence by 
unrelated species. 1 3 7 
In the marine environment, simple pteridines known from terrestrial sources have 
been isolated from sponges, ascidians, diatoms and copepods, 1 36• 1 38 while 
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pteridines previously unknown from terrestrial sources have been isolated from 
the following marine organisms: dendrophylliid coral, sponges and a free 
polychaete. 1 36,1 39 ,1 40 
Leucettidine (3.1), was isolated as a minor metabolite from the calcareous sponge 
Leucetta microraphis in 1981 by Cardellina and Meinwald, 1 37 however, in 1984 
Pfleiderer revised the structure of leucettidine (3.1) to that of 6-(1-
hydroxypropyl)- l -methyllumazine (3.2) by direct comparison of the NMR data 
for the natural product with an authentic sample prepared by unambiguous 
h · 1 40 synt es1s. 
The structure of the lumazine 3.2 represented a departure from the usual 
substitution patterns of previously isolated pteridines, such as biopterin (3.3) from 
insects and 3-methylbiopterin (3.4) from the Mediterranean dendrophylliid coral 
Astroides calycularis, in that it did not possess an amino group at the C-2 
position. 1 37 The lumazine 3.2, along with the three l '-keto analogues, 3-methyl-6-
propionyllumazine (3.5), 1,3-dimethyl-6-propionyllumazine (3.6) and 6-
propionyllumazine (3.7) isolated from the marine polychaete Odontosyllis 
undecindonta and isosepiapterin (3.8) and 6-(1-hydroxypropyl)-8-
methylisoxanthopterin (3.9) isolated from the firefly Photinus pyralis, appear to 
be among the few naturally occurring pteridines that have a mono-oxygenated 
side chain. 1 36, 1 37 , 1 39 
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The pseudoanchynazines A-C (3.10-3.12) 1 4 1  isolated from the manne sponge 
Clathria sp. collected off the coast of Rio Negro, Argentina, represent a family of 
novel pteridines alkaloids. These compounds possess two pteridine moieties, a 
three carbon side chain, an unusual tryptophan unit that has its a-amino group 
blocked by a methyl carbamate and different pteridine substitution patterns. 
Pseudoanchynazine A (3.10) has pteridine substitution at C-2, pseudoanchynazine 
B (3.11) at N-1, and pseudoanchynazine C (3.12) at C-4 of the indole moiety. In 
all cases the tryptophan carboxyl forms an ester with the second pteridine unit.1 4 1  
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2-amino-04-benzylpteridine derivatives are known to be potent inactivators of the 
human DNA repair protein 06-alkylguanine-DNA alkyltransferase. This repair 
protein is the primary source of resistance many tumour cells exhibit to 
chemotherapeutic agents that modify the 06-position of guanine residues. Their 
in vitro activity has been shown to be as potent as the prototype alkyltransferase 
inactivator currently in clinical trials. 1 42 
Pteridines have been reported from several sources within the manne 
environment. 1 36 Since sponges are filter feeders they may obtain these 
compounds directly from their environment, by metabolizing substrates obtained 
in their diet or they may be synthesised de novo by the sponge as a secondary 
metabolite. 
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In this chapter, the isolation and structural elucidation of two previously 
undescribed pteridines, 6-hydroxymethyl- lH-pteridine-2,4-dione (3. 1 3) and 6-
hydroxymethyl-3-methyl- lH-pteridine-2,4-dione (3. 1 5) (numbering assignment 
consistent with that proposed in the literature for similar compounds 1 36), 1s 
described from the unidentified Antarctic marine sponge 02WM01-33. 
3. 2: Introduction 
As part of our continuing effort to isolate novel biologically active compounds 
with pharmaceutical application, sponge specimens of various genera were 
collected at different sites in Antarctica for further chemical investigation. These 
samples were collected in collaboration with the Australian Institute of Marine 
Science (AIMS) as an ongoing investigation into the biological activity of benthic 
Antarctic organisms. In an effort to increase the probability of finding novel 
biologically active compounds, the collection team was instructed to collect 
samples they did not immediately recognize at a depth of 40 m, the limits of open 
circuit self contained underwater breathing apparatus (SCUBA). This depth is 
unprecedented at our collection sites. Due to the nature of the extreme conditions 
diving time at a depth of 40 m is very restricted (8 minutes); therefore only 58 
samples were collected across multiple dives. Extracts from the collected samples 
were analyzed for in vitro anti-tumour activity (P388 assay), and of these, 
02WM01-33 and 02WM01-46 were considered to have collected weight and 
activity sufficient for further investigation. 
The first of the two active species of Antarctic sponges to be investigated was 
02WM0 1 -33 (Extraction of the active sponge specimen 02WM0 1 -46 is discussed 
in Chapter 4). This unidentified sponge specimen was collected in October 2002 
along the shoreline at Cape Armitage, Ross Island, Antarctica. The sample was 
immediately frozen and stored at -20 °C until it could be transported to the 
laboratory for biological activity assessment. The sponge was targeted for further 
analysis on the basis that the crude organic extract possessed activity in the in­
house P388 assay (IC50 11.8 µg/mL). 
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The exploitation of Antarctic sponges as a source of novel/biologically active 
compounds is discussed in detail in Chapter 1, Section 1.9. 
3. 3: Extraction of the Unidentified Antarctic Marine 
Sponge (02 WMOJ-33) 
The frozen specimen 02WM01-33 was thawed and extracted with combinations 
of MeOH and DCM (1: 1, 500 mL). The extract was filtered through a bed of 
celite after homogenization; the solid material was re-suspended and extracted a 
further two more times with a mixture of MeOH and DCM. All filtrates were 
combined and the solvent was removed under vacuum. The organic extract was 
subjected to analysis via high performance liguid chromatography (HPLC) 
microtitre plate assay. Wells A4 to A9 were found to contain the biological 
activity (P388) observed in the crude organic extract. This region of activity 
corresponded to the compounds eluting between 2.8 and 4.2 minutes (Figure 3.1). 
These major peaks encompassed the bulk of the compounds observed in the entire 
extract as determined by Evaporative Light Scattering Detector (ELSD). UV 
spectra were obtained via HPLC PDA (CH3CN/H20, 0.05 % TF A). The two 
major compounds eluting at 2.8 and 3.8 minutes displayed identical chromophores 
(Amax 330 and 240 nm), suggesting the presence of a bicyclic heteroaromatic ring 
system. The component eluting at 4.2 minutes displayed a chromophore (Amax 260, 
210 nm) which suggested that an aromatic moiety was present in the molecule 
(Figure 3.2). 1 43 Liquid chromatography electrospray ionisation mass 
spectrometry (LCESIMS) was inconclusive as no direct correlations could be 
made relating the ions observed in the total ion current (TIC) trace and the 
compounds eluting in the chromatogram (PDA). With only UV and retention 
time data, it was unlikely that a search profile 1 30• 1 3 1 based upon these two 
parameters would afford a positive identification of the compounds observed in 
the extract. It was on this basis that further purification was required. 
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Figure 3.1: HPLC trace of DCM/MeOH crude extract (blue). Region of 
biological activity indicated between 2.8-4.2 minutes (black) as indicated by 
microtitre plate analysis. 
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nm 
Figure 3.2: UV spectra (HPLC PDA) of the major compounds observed in the 
region of biological activity (2.8-4.2 minutes) as determined by the microtitre 
plate assay (P388). Compounds eluting at 2.8 and 3.8 minutes are identified as 
red and blue, respectively. 
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3. 4: Chromatographic Isolation of Bioactives 
3. 4. 1 :  Reversed Phase (C18) Flash Chromatography of the 
Organic Extract of02 WMOJ-33 
9 1  
The organic extract was dissolved in a minimum volume of  solvent (MeOH and 
DCM) and adsorbed onto C1 8  solid phase. The solvent was removed under 
vacuum, and the dry pellet was loaded onto a reversed phase (C1 8) flash 
chromatography column, equilibrated to 1 00 % H20. The column was eluted 
using a steep solvent elution gradient from 100 % H20 to 100 % MeOH. Any 
material remaining on the column was eluted as the final fraction with a mixture 
of MeOH and DCM (1 : 1 ). A total of 1 2  fractions were collected. Odd numbered 
fractions were analysed by reversed phase (C1 8) analytical HPLC column to 
identify the fractions that contained the compounds responsible for the activity as 
located by microtitre plate analysis (Figure 3.1). Fraction wjm20-203 was 
determined to contain the compounds of interest and due to the complexity of the 
chromatogram further purification was deemed necessary. 
3. 4. 2: Reversed Phase (C18) Semi-preparative HPLC 
Chromatography of Fraction wjm20-203 
Fraction wjm20-203 (4 1 .2 mg) was subjected to further purification by reversed 
phase (C1 8) semi-preparative HPLC chromatography using a gradient method 
developed on the analytical HPLC (C1 8) column for maximum resolution. Four 
fractions were collected as peaks eluted, the purity of which were confirmed by 
re-injection on the analytical HPLC column (Figure 3.3). Fraction wjm20-203.3 
was found to be contaminated with wjm20-203.2 and wjm20-203.3, and was 
deemed to contain too little mass for further purification via the same semi­
preparative method. The 1 H NMR spectra of the three remaining fractions 
revealed that fraction wjm20-203. l was not suitable for further structural analysis 
due to mass limitations, although it did display a similar UV chromophore to 
those observed for fractions wjm20-203.2 and wjm20-203.4. Therefore wjm20-
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203.2 and 20-203.4 were subjected to the full range of lD and 2D NMR 
spectroscopy experiments and high resolution ESI mass spectrometry. Structural 
elucidation of these pure compounds is discussed in Sections 3.5.1 and 3.5.2 
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Figure 3.3: Overlaid HPLC chromatograms of isolated compounds from fraction 
wjm20-203. All traces are at spectrum max wavelength. 
3.5: Structural Elucidation of Compounds Isolated 
from 02WMOJ-33 
3.5.1: Structural Elucidation of 3.13 
Compound 3.13 was isolated as a pale brown oil (14.0 mg). HRESI mass 
spectrometry identified a [M+Ht ion at mlz 193.0341 (calc 193.0362) which led 
to the molecular formula of C7H6N40 3 corresponding to 7 double bond 
equivalents (DBE). The 1H NMR spectrum (Figure 3.4) was relatively simple, 
revealing the presence of only four well defined signals; these consisted of two 
broad, possibly exchangeable, N-H protons (cSH 11.92 and 11.86), one proton 
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singlet at 8H 8.69 indicative of a heteroaromatic proton, and finally a 
hydroxymethylene singlet at 8H 4.66. 
The 1 3C NMR (Figure 3.5) and HSQC data disclosed the presence of two 
carbonyl (8c 161.6 and 150.4), three s/ quaternary (8c 152.5, 148.7 and 126.4), 
one s/ methine (8c 147.2) and one s/ methylene (8c 62.7) carbons. 
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Figure 3.5 : The 1 3C NMR spectrum of 3.13 (DMSO-d6) .  
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The chemical shift of the hydroxymethylene proton cSH 4.69 (8c 62. 7) suggested 
that this moiety was most likely attached to the speculated aromatic nucleus. This 
was confirmed by the presence of CIGAR correlations from the H-7 (cSH 4.69) 
methylene protons to the C-5 and C-6 (8c 152.5 and 147.2, respectively) aromatic 
carbons. No further 3 JCH CIGAR correlations from the H-7 methylene protons 
were observed, suggesting that the proposed aromatic ring was substituted at the 4 
position with a heteroatom. However, a very weak 4JcH coupling was observed 
from the H-7 (cSH 4.69) protons to the C-3 (8c 126.4) carbon. The assignment of 
the heteroatom at the 4 position was validated by the presence of only two 3 JCH 
CIGAR correlations from the H-6 (cSH 8.69) aromatic proton to the C-7 and C-2 
(8c 62.7 and 148.7, respectively) aromatic carbons. If position 4 was a carbon 
atom then a correlation would have been observed. The only 2JCH coupling 
observed from the H-6 (cSH 8.69) proton was to the C-5 (8c 152.5) aromatic carbon, 
suggesting that a second heteroatom was located at the 1 position. The proposed 
heteroaromatic ring was tentatively assigned to be a pyrazine ring (i.e. positions 1 
and 4 possessing tertiary nitrogen atoms and positions 2 and 3 quaternary carbons). 
The partial structure ring A is proposed as shown in Figure 3.6 and accounts for 4 
of the 7 required DBE's. 
Figure 3.6: The key CIGAR correlations used to assign partial structure ring A. 
The absence of critical 3 JCH and 2JcH coupling al lowed for the assignment of the 
quaternary nitrogen atoms. 
The two remaining carbonyls, positions C-4' and C-2', and the two NH's (NH-1' 
and NH-3') left to satisfy the molecular formula were assigned as a pyrimidine-
2,4-dione ring system, ring B, entirely on the basis of the chemical shifts of 
carbons C-3 and C-2 as no CIGAR correlations were observed for either NH-1' or 
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NH-3', and comparison of 1 H and 1 3C chemical shift data with published data 1 37 
for compounds containing a similar pyrimidine-2,4-dione ring system. The two 
carbonyls combined with the formation of ring B, satisfied the remaining 3 DBE's. 
The working structure for compound 3.13 (Figure 3.7) with arbitrary numbering 
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Figure 3.7: The proposed structure for 3.13 annotated with arbitrary numbering 
system used for structural elucidation and table ofNMR data (Table 3.1) .  
After a literature search, this compound was deduced to be a novel pteridine with 
no structural matches identified. The compound 3.13 was tentatively named as 
the novel 5-hydroxymethyl- lH-pteridine-2',4'-dione (using the arbitrary 
numbering system assigned for structural elucidation). The 5-dehydroxymethyl­
pteridine-2',4'-dione (lumazine (3.14)) and lumazine derivatives have been 
previously isolated from both terrestrial and marine animals. 1 40• 1 44 The NMR data 
for 3.13 are displayed in Table 3.1 .  
3.14 
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Table 3.1 : The 1 H, 1 3C, and C IGAR NMR data for compound 3.1 3 (DMSO-d6) .  
Position 1 3C O § 1 H O l CIGAR 
1 4 - (NH) 1 1 .92 ( l H, br s, NH) 
2' 1 50.4 (CO) 
3 •t - (NH) 1 1 .68 ( l H, br s, NH) 
4' 1 6 1 .6 (CO) 
2 148 .7 (CH) 
3 1 26.4 (C) 
5 1 52 .5  (C) 
6 147 .2 (CH) 8 .69 ( l H, s) C-7, C-5 , C-2 
7 62 .7 (CH2) 4.69 ( l H, s) C-6, C-5 , C-3 
§ 1 3C NMR spectra recorded at 1 25 MHz in DMS0-d6 . 1 3C chemical shifts 8 ppm from DMS0-d6 
(39.6) .  1 1 H NMR spectra recorded at 500 MHz. 1H chemical shift values 8 ppm from DMS0-d6 
(2 .60) followed by number of protons and multiplicity. t Assigned on the basis of the chemical 
shifts assigned of 3.1 5 (Section 3.5.2). 
3. 5. 2: Structural Elucidation of 3. 15 
The second compound, 3.15, was isolated as a red oil (5.0 mg). High resolution 
ESI mass spectrometry identified a [M+Ht ion at m/z 207.0498 (calc. 207.0518), 
14 mass units greater than 3.13, which led to the molecular formula of C8H8N403 . 
Both the 1 H and 1 3C NMR spectra were representative of a compound structurally 
very similar to that of 3.13, although the purity of this fraction was such that 
signals were observed for both the major compound 3.1 5 and 3.13 as a minor 
contaminant. The 1 H NMR spectrum (Figure 3.8) confirmed the presence of the 
following; a proton signal (8H 8.69) consistent with the heteroaromatic proton 
identified previously, a signal at 8H 4.92 associated with the oxymethylene 
protons and a new signal at 8H 3.23 integrating for three protons, suggesting the 
addition of a methyl group. However, one of the signals associated with the D20 
exchangeable protons at 8H 1 1.68 (NH-1' or NH-3') was absent. The 1 3C NMR 
(Figure 3.9) and HSQC data disclosed the presence of two carbonyls C-2' and C-
2' (8c 161.6 and 150.4, respectively), three sp2 quaternary carbons C-5, C-2 and 
C-3 (8c 152.5, 148.7 and 126.4, respectively), one s/ methine C-6 (8c 147.2), one 
sp3 oxygenated methylene C-7 (8c 62.7) and the additional signal at 8c 28.3 
corresponding to an s/ methyl carbon. 
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Figure 3.8 : The 1 H NMR spectrum of 3.15 (DMSO-d6) .  
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Figure 3.9: The 1 3C NMR spectrum of 3.15 (DMSO-d6) . 
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CIGAR correlations from the H-6 (8H 8.69) aromatic proton to C-2, C-5 and C-7 
(8c 148.7, 152.5 and 62.7, respectively) combined with the CIGAR correlations 
from the H-7 (8H 4.92) hydroxymethylene protons to the C-6 and C-5 (8c 147.2, 
152.5) carbons confirmed the presence of the heteroaromatic pyrazine ring system 
identified in the previous structure 3.1 3 as ring A.(Figure 3 . 1 0) .  
Figure 3 . 10 :  The key CIGAR (black) correlations for the assignment ofring A. 
The remaining atoms were assigned by their 1 3C NMR chemical shifts to be part 
of a pyrimidine-2,4-dione ring system (see Section 3.5. 1 ,  structural elucidation of 
3 . 1 3) .  The placement of the methyl group on the nitrogen at position 3' of the 
pyrimidine-2,4-dione ring system between the carbonyl groups, was based upon 
the CIGAR correlations observed from the H-5' (8H 3.23) methyl protons to both 
of the C-2' and C-4' (8c 150.4 and 161.6, respectively) carbonyl carbons 
completing ring B (Figure 3 . 1 1 ) . This methylation at the N-3' position allows for 
the unambiguous assignment of the NH-1' and NH-3' (8H 11.92 and 11.68, 
respectively) protons in compound 3 . 15 . 
A literature search 1 30• 1 3 1 • 1 45 was performed resulting in no exact structural matches 
for the proposed structure 3. 1 5 . Therefore, 3 . 15  the novel pteridine, was 
tentatively named 5-hydroxymethyl-3'- lH-pteridine-2',4'-dione (using arbitrary 
numbering assigned for structural elucidation), the N3
0
-methyl derivative of 3 . 13 .  
The working structure proposed for compound 3 . 15  is shown in Figure 3 . 1 1 ,  with 
the arbitrary numbering system used for both structural elucidation and the NMR 
data in Table 3.2 .  
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Figure 3.1 1 :  Proposed structure of 3.1 5 with key CIGAR correlations (black) and 
arbitrary numbering system used for structural elucidation and Table 3.2. 
Table 3.2: The 1 H, 1 3C and CIGAR NMR data for 3.15  (DMSO-d6) .  
Position 
1 '  
2' 
4' 






1 50.4 (CO) 
1 6 1 .6 (CO) 
28.3 (NCH3) 
1 48 .7 (C) 
1 26.4 (C) 
1 52 .5 (C) 
1 47.2 (CH) 
CIGAR 
1 1 .92 ( l H, br s,NH) 
3 .23 (3H, s) 
8.69 ( l H, s) C-7, C-5 , C-2 
7 62 .7  (CH2) 4.92 (2H, s) C-6, C-5 , C-3 
§ 1 3C NMR spectra recorded at 1 25 MHz in DMSO-d6 . 1 3C NMR chemical shifts 8 ppm from DMSO-d6 (39.6) . 1 1H NMR spectra recorded at 500 MHz. 1H chemical shift values 8 ppm from DMSO-d6 (2 .60) followed by number of protons, multiplicity and coupling constant (J/Hz). 
3. 6: Biological Activity 
All of the purified fractions were submitted for biological activity assessment. 
The compound 3.1 5  isolated as a major component of the organic extract was 
responsible for the biological activity (P388) observed in the crude organic extract 
of the unidentified Antarctic marine sponge 02WM01-46. The IC50 of the 
purified compound 3.15  was 9.6 µg/mL, and was consistent with the area of 
activity located by the initial microplate P388 assay analysis. It was interesting to 
note that the demethyl derivative of 3.1 5, 3.1 3, displayed no significant activity 
(ICso > 1 2.5 µg/mL). 
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3. 7: Concluding Remarks 
The aim of this project was to isolate and identify the compound(s) responsible 
for the biological activity (P388) observed in the crude extract of the unidentified 
sponge 02WM01-33. 
Two novel pteridines, 5-hydroxymethyl- lH-pteridine-2,4-dione (3.13) and the N­
methyl derivative 5-hydroxymethyl-3'- lH-pteridine-2',4'-dione (3.15) (numbering 
system used is consistent with that used for elucidation of structures) were 
isolated as the major components of the organic extract of the Antarctic marine 
sponge 02WM01-33. 
These two compounds were initially identified by reversed phase (C 1 8) HPLC 
microtitre plate assay (P388). Compounds 3.13 and 3.15 were purified by 
successive chromatography consisting of reversed phase (C 1 8) flash column 
chromatography followed by semi-preparative reversed phase (C 1 8) HPLC. 
Biologically active 'peaks' of interest were located with the help of analytical 
reversed phase (C 1 8) HPLC analysis. Although four compounds were isolated 
only two contained enough material and were suitably pure enough for structural 
elucidation. 
The purified compounds were evaluated for their cytotoxic activity in-house using 
the P388 (murine leukaemia) assay. The compound 3.15 was the only 
biologically active compound identified, with an IC50 of 9.6 µg/mL. The 
cytotoxic activity of 3.15 supported the initial data obtained by the microtitre plate 
(P388) assay performed on the organic extract, as 3.15 eluted within the located 
area of activity. Cytotoxicity against P388 cells from extracts containing 
pteridines has been reported in the literature previously (ID50 < 10 µg/mL). 1 44 
Structural elucidation of 3.13 and 3.15 was achieved with the use of 1 H, 1 3C, 
HSQC and CIGAR NMR spectroscopy and high resolution mass spectrometry, 
assisted by the direct comparison of data obtained from NMR simulated 
predictions 1 46' 1 9 1  and comparisons to the literature. 1 37 These compounds are 
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chemically interesting in that they possess a mono-oxygenated methyl side chain, 
which has not been previously reported among any naturally occurring pteridines. 
Pteridines have found therapeutic use, with their derivatives currently undergoing 
clinical trials for the potent inhibition of the human-DNA repair proteins. This 
methodology is targeted at killing tumour cells by inactivating alkyl transferase in 
cells that over express folic acid receptors. They represent a promising new class 
of alkyl-transferase inhibitors with greater specificity and solubility than their 
predecessors. 1 42 
3. 8: Summary of Isolation 
Unknown Specimen (02WMO 1 -33) 
I 
MeOH/DCM Extraction ( 1 . 1 g) 
C l  8 Column Chromatography H,O 
I 
M,OH DCM 
I I I I I I I I I I I 
Fraction # I 2 3• 4 5 6 7 8 9 I O 1 1  1 2  
Mass (mg) 278 . 1 32.6 4 1 .2 1 2.6 1 9.3 3 1 .2 1 5 .4 29.3 33.4 44.9 85.9 1 42 .6 
I 
Semi-preparative (C 1 8) 
Chromatography 
3 . 1 3  
( 1 4 mg) 3 . 1 5 
(5.0 mg) 
Scheme 3.1: Chromatographic purification summary for the Antarctic marine 
sponge 02WM01-33. ·Fraction contains biologically active compound(s) of 
interest. 
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CHAPTER 4 
ISOLATION OF COMPOUNDS FROM THE 
ANTARCTIC MARINE SPONGE Suberites sp . 
(02WM0 1 -46) 
4. 1 :  General Introduction 
There are approximately eighty described species of the genus Suberites. This 
genus is ubiquitous in distribution, but most commonly found in cold waters.39 
The Suberites spp appear to be specialized at producing a specific class of 
sesterterpenes (isoprenoid skeletal class), known as the suberitanes, which possess 
an unprecedented carbon skeleton. The absence or presence of these compounds 
could be used as taxonomic marker for Antarctic sponges of the genus Suberites.65 
To date four suberitenones, A (4. 1 ), B (4.2), C (4.3) and D (4.4) along with 
caminatal (4.5) and two novel sesterterpenes (4.6) and (4.7), have been isolated 
fr An · S b . · 64 65 66 67 om tarct1c u entes species. ' ' ' Bioactivity assessment of these 
compounds (4. 1 -4.7) revealed that they possess neither cytotoxicity, nor antiviral 
activity, but do contribute towards defense against a major Antarctic spongivore, 
the sea star Perknaster fuscus.65 Suberitenone B (4.2) was shown to inhibit the 
cholesterol ester transferase protein (CETP), which mediates the transfer of 
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cholesterol ester and triglyceride between high-density lipoproteins (HDL) and 
low-density lipoproteins (LDL).67 HDLs have been recognised as 'good 
cholesterol' as they transport surplus cholesterol back to the liver where it can be 
disposed of by bile acids. LDLs however, transport cholesterol to the peripheral 
tissues. Many studies have shown that there is an inverse correlation between 
levels of HDL and the incidence of atherosclerotic cardiovascular diseases.67 
Therefore, CETP has been recognised as a significant target protein, and these 
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Work on this Antarctic marine sponge Suberites sp. to date has focused primarily 
on determining the bioactive compound(s) present in the extract. The 
suberitenones 4.1 and 4.2 were independently isolated, but shown to be 
inactive. 1 47 The bioactive compound was determined to be a previously 
undescribed C-5 substituted hydantoin alkaloid, (Z)-5-(3,4-
dihydroxybenzylidene )-imidazolidine-2,4-dione ( 4.8). 
4.2: Introduction 
A specimen of a Suberites sp. (02WM01-46) was collected by SCUBA, at Scott 
Base, Ross Ice Shelf, Antarctica, at a depth of 40 m in October 2002. The 
specimen was stored frozen at -20 °C in the Scott Base laboratory until it could be 
transported to the University of Canterbury, New Zealand for chemical 
investigation. Taxonomy was performed on a voucher sample held at the 
Australian Institute of Marine Science (AIMS) by Professor Patricia Bergquist. 
Initial screening of the specimen in the University of Canterbury Chemistry 
Department in-house anti-tumour assay (P388) indicated that the organic extract 
possessed cytotoxic activity (IC50 9.5 µg/mL). On the basis that this extract was 
active and the species was unidentified, it was deemed that further chemical 
investigation was required. 
4. 3 :  Extraction of the Antarctic Marine Sponge 
Suberites sp. (02 WMOJ-46) 
The frozen specimen, 02WM01-46 (62 g), was thawed, homogenised and 
successively extracted three times with combinations of MeOH and DCM. The 
solvent was removed under reduced pressure to yield a green extract (248 mg). 
An aliquot of the extract (250 µg) was subjected to reversed phase (C 1 8) analytical 
HPLC chromatographic microtitre plate analysis (see Experimental, Section 
7.1.6.2) in an attempt to locate the compound associated with the observed 
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activity (P388). The biological assay results located the activity at 7.8 minutes, 
corresponding to a single peak, in the HPLC chromatogram (Figure 4. 1 )  
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Figure 4. 1 :  HPLC chromatogram of the organic extract of the marine sponge 
02WMO 1 -46, indicating the region of activity as located by microtitre plate assay. 
Analysis of the UV spectrum, (Figure 4.2, HPLC PDA, CH3CN/H20 0.05 % 
TF A), revealed that this compound displayed a UV chromophore with a Amax at 
348 nm. The absorbance in the long wavelength region of the spectrum would 
suggest the presence of an aromatic ring with extended conjugation, or a bicyclic 
heteroaromatic ring. Low resolution ESI mass spectrometry of the active wells by 
direct injection was inconclusive. Although there were significant ion peaks 
observed in the spectrum, identification of the parent ion, or ion patterns for 
sodium/potassium adducts was difficult. It was at this point that further 
purification of the extract was deemed necessary as it was unlikely that a search 
profile based upon two parameters, UV (PDA) and retention time, would afford a 
positive identification of the active compound present in the extract. 
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Figure 4.2: UV chromatogram of major compound located in region of activity 
(7.8 minutes) as identified by microtitre plate assay. 
4. 4: Chromatographic Isolation of Bioactives 
4. 4. 1 :  Reversed Phase (C18) Vacuum Chromatography of the 
Organic Extract of the Antarctic Marine Sponge 
Suberites sp. 
The organic extract of 02WM0 1-46 was further purified by reversed phase (C 1 8) 
vacuum chromatography. The C 1 8  vacuum chromatography column was 
equilibrated to H20 and eluted with solvents ranging from H20 through to MeOH.  
Any material remaining on  the column was removed in  the final fraction with 
DCM. Twelve fractions were collected, and odd numbered fractions were 
analysed by re-injection onto an analytical reversed phase (C 1 8) HPLC column to 
identify the fractions that contained the compound responsible for the observed 
P388 activity (as located by microtitre plate analysis, Figure 4.1). The compound 
of interest was concentrated into fractions wjm9-3204 to wjm9-3206. Therefore, 
these fractions were combined for further purification. 
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4. 4. 2: Reversed Phase (C18) Semi-preparative HPLC 
Chromatography of Fractions wjm 9-3204 to 
wjm9-3206 
1 1 0 
Due to the required resolution of separation ( compounds eluting between 7 and 8 
minutes), semi-preparative reversed phase (C 1 8) H PLC was chosen for the next 
stage of purification. After a suitable method had been developed on an analytical 
reversed phase (C 1 8) HPLC column, the fraction combination wjm9-3204 to 
wjm9-3206 was processed with consecutive injections. Four fractions were 
collected, and the purity of each fraction was confinned by re-injection onto the 
reversed phase (C 1 8 ) analytical HPLC column. Fraction wjm9-340 1 .3 was 
selected for further analysis on the basis that it was the only fraction to contain the 
compound of interest. This compound now eluted at 1 1 .3 minutes under the semi­
preparative purification gradient conditions (previously 7.8 minutes by P388 
microtitre plate analysis of the initial organic extract) as shown in Figure 4.3. 
This fraction was deemed to contain enough mass for 1 D and 2D NMR 
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Figure 4.3: HPLC trace of purified compound 4.8 using semi-preparative 
gradient elution conditions (see Experimental, Section 7.4.3). 
CHAPTER 4 Suberites sp. 
4. 5: Structural Elucidation of 4. 8 
1 1 1  
Compound 4.8 was collected as a white powder ( 4.5 mg) from the third fraction 
eluting off the semi-preparative HPLC. HREI mass spectrometry indicated an ion 
at m/z 220.0469 1 (calc. 220.0484), which led to a molecular formula of 
C 1 0H8N204, corresponding to 8 DBE. The 1 3C NMR (Figure 4.4) and HSQC data 
confirmed the presence of 1 0  well defined signals, comprising two carbonyl (8c 
1 65.8, 155.7), four sp2 quaternary (8c 146.6, 1 45.5, 1 25.6 and 1 24.4) and four sp2 
methine (8c 1 21.5, 1 1 7.3, 1 1 5.5 and 1 09.9) carbons, which satisfied the 
requirements of the molecular formula. In the 1 H NMR spectrum (Figure 4.5), 
four olefinic protons (8H 7.07, 7 .06, 6.86 and 6.36) and four exchangeable signals 
were observed. Two of these exchangeable signals were very broad at 8H 9.55 
and 9 . 1 0, possibly due to phenolic protons, while the remaining two broad signals 
at 81-1 1 1 . 19  and 1 0.36 were assigned as N-H protons. 
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Figure 4.4: The 1 3C NMR spectrum of 4.8 (DMSO-d6). 
1 1 2 
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Figure 4.5 : The 1 H NMR spectrum of 4.8 (DMSO-d6) . 
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COSY cross correlations (Figure 4.6) from the H-11 (8H 6.86) aromatic proton to 
the H-12 (8H 7.07) aromatic proton suggested that these two protons were adjacent 
to one another on an aromatic ring, while the long-range correlation from the H-8 
(8H 7.06) proton to the H-12 (8H 7.07) aromatic proton implied that these protons 
were arranged on an aromatic ring (i.e. C-8, C-11 and C-12, respectively). 
However, H-6 (8H 6.36) was disqualified as being aromatic based on the 
observation there were no COSY correlations from either H-8 or H-11 (8H 7.06 
and 6.86, respectively) to H-6 (8H 6.36). The H-6 location was confirmed by the 
long-range COSY correlations observed from the H-12 (8H 7.07) aromatic proton 
to the H-6 (8H 6.36) proton, placing H-6 a to the proposed aromatic ring on the 
s/ C-6 (8c 109.9) carbon. 3JcH CIGAR correlations from both H-8 and H-12 (8H 
7.06 and 7 .07, respectively) to C-6 (8c 109.9) validated the H-6 assignment. 
The aromatic ring was constructed by 3JCH CIGAR correlations from the H-12 (8H 
7.07) proton to both of the C- 10 and C-8 (8c 146.6 and 121.5, respectively) 
carbons, the H-8 (8H 7.06) proton to both of the C-10 and C-12 (8c 146.6 and 
117.3, respectively) and the H-11 (8H 6.86) proton to both of the C-7 and C-9 (8c 
124.4 and 145 .5, respectively) carbons. This data was combined with the 2JCH 
correlations from the H-8 (8H 7.06) proton to the C-6, C-10 and C-12 (8c 109.0, 
146.6 and 117.3, respectively) carbons, from the H- 11 (8H 6.86, 8c 115.9) proton 
to the C-10, C-9 and C-7 (8c 146.6, 145.5 and 124.4, respectively) carbons, and 
finally fron the H- 12 (8H 7.07) proton to both of the C-7 and C-9 (8c 124.4 and 
145.5, respectively) carbons completed the assignment of the proposed aromatic 
ring. The chemical shifts for both the C-9 (8c 145 .5) and C-10 (8c 146.6) carbons 
suggested that these s/ quaternary carbons were oxygenated (containing an 
hydroxy group). This observation was supported by the very broad signals 
observed in the 1 H NMR spectrum at 81- 1  9.55 and 9.10. The remaining atoms 
consisted of two carbonyls, one s/ quaternary carbon and two exchangeable 
protons, which were assigned using CIGAR correlations. The proton NH-3 (8H 
11.19) was placed between two carbonyl groups on the basis of the observed 
correlations to the C-4 and C-2 (8c 165 .8 and 155.7, repectively) carbons, while 
the CIGAR correlation from the NH- 1 (8H 10.36) proton to the C-2 (8c 155.7) 
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carbonyl carbon and the sp2 C-5 (8c 125.6) carbon positioned NH-1 adjacent to C-
2. Location of the NH-3 group between both of the carbonyls would account for 
the downfield shift difference between the NH-3 (8H 11.19) and NH-1 (8H 10.36) 















































Figure 4.6 : The long-range COSY correlations for 4.8, with the minor isomer 
and impurities denoted by '*' and 'X', respectively (DMSO-d6) 
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The presence of a hydantoin ring substituted at the C-5 (8c 1 25.6) carbon was 
confirmed by the critical C IGAR correlations from the exchangeable NH-3 (8H 
1 1 . 1 9) proton to the C-5 (8c 1 25.6) carbon, combined with the correlation from 
the H-6 (8H 6.36) proton to the C-4 (8c 1 65.8) carbonyl carbon (Figure 4.7, red 
arrows). 
Figure 4.7: Proposed structure of compound 4.8 showing key COSY and long­
range COSY correlations (blue) and key C IGAR correlations (black). 
Experimental 1 D and 2D NMR data for the proposed compound 4.8 are shown in 
Table 4.1 while the arbitrary numbering system used for both the structural 





Figure 4.8 :  The proposed structure of 4.8 with arbitrary numbering assignment 
used for both structural elucidation and NMR data Table 4.1. 
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2 1 55 .7 (CO) 
3 - (NH) 
4 1 65 . 8 (CO) 
5 1 25 .6  (C) 
1 0.36 ( I H, br s, NH) 
1 1 . 1 9  ( I H, br s, NH) 
6 1 09.9 (CH) 6.36 ( I H, s) 
7 1 24.4 (C) 
8 1 2 1 .5 (CH) 7.06 ( I H, s) 
9 145 .5  (C) 
9-0Ht - (OH) 
1 0  1 46.6 (C) 
9 . 1 0  ( I H,v br s) 
1 0-0Ht - (OH) 9 .55( 1 H, v br s) 
COSY CIGAR 
H-6, NH-3 C-5, C-2 
NH- 1 C-5, C-4, C-2 
H- 1 2, NH- 1 C- 1 2, C-7, C-5, C-4 
H- 1 2  C- 1 2, C- 1 0, C-9, C-6 
1 1  1 1 5 .5  (CH) 6 .86 ( I H, d, 7 .5) H- 1 2  C- 1 2, C- 1 0, C-9, C-7 
1 2  1 1 7 .3 (CH) 7.07 ( 1 H, d, 7 .5) H- 1 1 , H-8, H-6 C- l l , C- 1 0, C-8, C-6 
§ 1 3C NMR spectra recorded at 1 25  MHz in DMSO-d6 • 1 3C chemical shifts 8 ppm from DMSO-d6 
(39.6) . 1 1H NMR spectra recorded at 500 MHz. 1H chemical shift values 8 ppm from DMSO-d6 
(2 .60) followed by number of protons, multiplicity and coupling constant (J/Hz). tvalues may be 
interchanged within column. 
4. 5. 1 :  Stereochemistry of 4.8 
Conformational isomerism of the C-5/C-6 double bond would imply that two 
possible stereoisomers exist for 4.8. Careful analysis of the 1 H NMR spectrum 
(Figure 4.5) of the purified compound 4.8 revealed that the signals for the major 
compound were accompanied by weaker signals of the same multiplicity. This 
suggested that one major isomer is dominant in the isomeric mixture. It was 
noted that during the course of 2D-NMR structural elucidation experiments, the 
signals of the minor component were becoming more obvious. Compounds of 
this type (C-5 substituted hydantoins) that do not possess any substitution at the 
N-3 position are isolated in predominantly the (Z) configuration, but on irradiation 
with 350 nm light or under normal daylight conditions will slowly afford mixtures 
richer in the (E) isomer. 1 48 NMR samples were prepared under normal ambient 
laboratory conditions, and the observed increase in 1 H NMR spectrum peak 
intensity of the minor compound could therefore be explained by the reported 
phenomenon. In order to obtain NMR data for both isomers, the 1 H NMR spectra 
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were recorded after the addition of both two and four equivalents of pyridine-d5, 
in an attempt to enrich the sample with the minor isomer. Comparison of the peak 
area ratios for the major and minor compounds in each 1 H NMR spectrum 
confirmed that the ratio of major (natural) to minor isomer had decreased from 
approximately 6: 1 to 2: 1 (major:minor) after the addition of four equivalents of 
base, as shown in Figure 4.9. 
In addition, reports suggest that the carbonyl located at C-4 is responsible for the 
deshielding of the proton at C-8 (8H 7.06) while in the (E) configuration by up to 
as much as 1 ppm. 1 48 It is worth noting that the chemical shift of the aromatic 
proton H-8 (8H 7.06) in the major isomer is overlapped with that of H-12 (8H 7.07), 
while the H-8* (minor compound) proton in the initial 1 H NMR spectrum is 
clearly resolved. This initial data would suggest that the minor compound could 
be tentatively assigned as being in the (E) configuration based on the resolved 
chemical shift of the H-8* proton in the initial 1 H NMR spectrum. 
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Figure 4.9: 1 H NMR spectra of 4.8. Native isomer (top) after the addition of two 
(middle) and four (bottom) equivalents of pyridine-d5 . The minor isomer and 
solvent peaks (pyridine- d5) are indicated with an '* '  and '• '  respectively. All 
spectra are referenced to DMSO-d6 (oH 2.60). 
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In order to determine the unambiguous configuration of the natural isolated 
isomer, a 3D-structural analysis of 4.8 (MM2 minimized, Chem3D) was carried 
out (Figure 4.10) to determine the distance between the H-6 and NH- 1  protons in 
the (£) and (Z) configurations. These data suggested that the structural geometry 
of /15•6 could be determined via NOE experiments, as the (Z) configuration affords 
a distance through space between H-6 and NH- 1  that would result in no 
observable NOE enhancement (3.9 A). Consequently, irradiation of the H-6 
proton would result in co1Telations to both of the H- 1 2  and H-8 aromatic protons, 
due to the C-6/C-7 carbon bond rotation if the natural isomer (major) is in the (Z) 
configuration. Equally, irradiation of the NH- 1  proton would result in an NOE 
signal enhancement to both of the H- 1 2  and H-8 protons. 
Z isomer 
� �  / \ H-6 NH- 1 
E isomer 
Figure 4. 10 :  Energy minimized Chem3D structures of the two possible isomers, 
(Z) and (£) respectively, for compound 4.8. 
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On the basis of the 3D-structural analysis, the NOESY- 1 D experiment was used 
to determine the geometry of !':,.5•6 by selective irradiation of both H-6 and NH- 1. 
It is important to note that the chemical shifts displayed in the NOESY- 1 D NMR 
spectra (Figure 4.11, and the data reported in Table 4.2), have been affected by 
the addition of d5-pyridine (four equivalents). These chemical shifts were 
obtained from the 1H NMR spectrum (bottom spectrum of Figure 4.9, referenced 
to DMSO-d6 (8H 2.60)). 
Irradiation of the H-6 (now at 8H 6.48) proton (Figure 4.11) resulted in the 
positive enhancement of both the H-8 (now at 8H 7 .21) and the H- 12 (now at 81-1 
7. 17) protons, due to C-6/C-7 bond rotation. No enhancement of the NH-1 (81-1 
10.57) proton was observed. Alternatively, irradiation of the NH- 1 (81-1 10.57) 
proton resulted in the positive NOE enhancement of the H-8 and H- 12 (8H 7.21 
and 7 . 17, respectively) protons, while no enhancement of the H-6 (8H 6.48) proton 
was observed. These results strongly suggested that the major isomer was (Z), 
validating the initial speculation. 
NH-1 (8H 1 0.57) 
I 
UA ... IU tJ .. .. 
H-8 (c\ 7.2 1 ) 
� 
u 
H-12 (8H 7 . 17) 
/ H-6 (B, 6.48) 
/ , · �  
,. -
H-8 (8H 7.� H-12 (8H 7. 17) 
/ H-6 (&H 6.48) 
I ,  
Figure 4.11: l D-NOESY spectra from irradiation of the H-6 (8 1-1 6.48, top) and 
NH- 1 (81-1 10.57, bottom) protons. Spectra are recorded in and referenced to 
DMSO-d6 (8H 2.60) after the addition of four equivalents of pyridine-d5 . 
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The proton chemical shift data, referenced to DMSO-d6, is shown in Table 4.2 for 
the major isolated natural isomer of compound 4.8 before and after the addition of 
pyridine-d5 . 
Table 4.2: 1 H NMR chemical shift comparison for the major isomer of 4.8 before 
and after the addition of four equivalents of pyridine-d5 (in DMSO-d6) .  






1 1  
1 2  
1 0.36 ( I H, br s, NH) 
1 1 . 1 9  ( I H, br s, NH) 
6.36 ( I H, s) 
7.06 ( I H, s) 
6 .86 ( I H, d, 7 .5) 
7.07 ( I H, d, 7 .5) 
1 0.57 ( I H, br s, H) 
1 1 .3 8  ( I H, br s, NH) 
6.48 ( I H, s) 
7 .2 1 ( I H, s) 
6.97 ( I H, d, 7 .5) 
7. 1 7  ( I H, d, 7 .5) 
§ 1H NMR spectra recorded at 500 MHz in DMSO-d6• 1H chemical shift values 8 ppm from 
DMSO-d6 (2 .60) followed by number of protons, multiplic ity and coupling constant (J/Hz). 
The experimental 1 H NMR chemical shift data for both the major (Z) and minor 
(£) isomers of compound 4.8 isolated as natural products from the semi­















(£) 5-(3 ,4-dihydroxybenzylidene)-imidazolidine-2,4-dione 
(E) 4.8 
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Table 4.3: The 1 H NMR data obtained for the major (Z) and minor (£) isomers of 







1 0.36 ( l H, br s, NH) 
1 1 . 1 9  ( 1 H, br s, NH) 
6.36 ( l H, s) 
7 .07 ( l H, s) 
minor (£) 
1 0.34 ( l H, br s, NH) 
1 1 . 1 1  ( lH, br s, NH) 
6.43 ( lH, s) 
6.89 ( l H, s) 
9-0Ht 9.0 ( l H, v br s) 9 .0 ( lH, v br s) 
1 0-0Ht 9.5 ( l H, v br s) 9 .5  ( l H, v br s) 
1 1  6 .86 ( l H, d, 7 .5 )  6.65 ( l H, d ,  7 .5)  
1 2  7.07 ( l H, d, 7 .5)  6 .97 ( l H, d,  7 .5)  
§ IH NMR spectra recorded at 500 MHz in DMS0-d6 . 1 H chemical shift values o ppm from 
DMS0-d6 (2 .60) followed by number of protons, multiplicity and coupling constant (J/Hz). 
tvalues may be interchanged within the column. 
4. 6: The Incidence and Biological Activity of 
Hydantoins 
Hydantoins are a class of compounds containing an imidazolidine ring substituted 
at the C-5 position. The hydantoins are associated with a variety of biological 
· h · l d · l · 1 49 1 50 . d . . l 1 5 1  properties. T ese me u e ant1convu s1ve, ' anti epressant, antiv1ra , 
antimicrobial and herbicidal 1 52 activity. They were introduced into medicine over 
40 years ago as an alternative to barbiturates during chemical studies into the 
treatment of convulsive disorders such as epilepsy. 1 50 Diphenylhydantoin 
(phentoin, 4.9) was synthesised by Wheeler and Hoffmann in 1911 via the 
condensation of benzaldehyde with the hydantoin moiety. Currently, phentoin 
( 4.9) is still the drug of choice for the treatment of many seizure disorders, and 
possesses several attractive pham1acological features. There are, however, a 
number of side effects that limit the use of the drug. 1 49 
Many derivatives of hydantoin have been prepared in an effort to improve its 
pharmacokinetics by minimizing some of the less desirable side effects. The 
generation of hydantoin combinatorial libraries has emerged as a powerful tool for 
drug discovery, providing a wealth of spectroscopic and biological data. 1 53 
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Naturally occurring hydantoins from terrestrial sources also possess biological 
activity. A novel hydantoin, hydantocidin (4.10) displays potent non-selective 
herbicidal activity, and was isolated from a fermentation broth of Streptomyces 
hygroscopics found in Annaka City, Japan. 1 54 This is a unique hydantoin 
compound, as it has a spiro-hydantoin ring fused at the anomeric position of (3-o­
ribofuranose. Herbicidal activity has been demonstrated by hydantocidin (4.10) at 
levels comparable to the commercially available glyphosate and bialaphos 
herbicides and it has been shown to be non-toxic to mammals (LD50 > 1 OOO 
mg/kg). 1 52 Because of the potential commercial utility, hydantocidin (4.10) has 
become a synthetic target. 
There are also a number of reports where hydantoins substituted at the C-5 carbon 
position have been isolated from the marine environment. 
Aplysinopsin (4.11), an indole alkaloid, was first isolated from the sponge 
Aplysinopsis reticulata (Dictyoceratida) collected off the coast of Lizard Island, 
Great Barrier Reef, and was later reported from the taxonomically unrelated 
sponges Verongia spengelii from the Florida Keys, and Dercitus sp. from 
Belize. 1 48 Aplysinopsin has also been isolated from scleractinian corals of the 
family Dendrophylliidae, such as Tubastraea aurea from Japan and Astroides 
calycularis from the bay of Naples. 1 48 
Considerable interest in aplysinopsin (4.11) was provoked as it displayed specific 
cytotoxicity for cancer cells that was not surpassed by any synthetic analogue. 
The N3
0
-methyl derivative (4.12), also isolated from A. recticulata, was most 
effective in affecting neurotransmission by directly inhibiting the biosynthesis of 
nitric oxide, an important secondary messenger that regulates neurotransmission 
h h . l . l 1 4s 1 55 among many ot er p ys10 og1ca processes. 
Aplysinopsin-type alkaloids can be classified into four structural types : 
aplysinposin (4.11), which was isolated from taxonomically unrelated sponges as 
well as from scleratinian corals; 3'-deimino-3'-oxoaplysinopsin (4.13) and 3'­
deimino-2',4'-dedimethyl-3'-oxoaplysinopsin (4.14), which came from the 
dendrophylliid corals Tubastraea sp. and Leptopsammia pruvoti, respectively, and 
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finally 2'-demethylaplysinopsin (4.15) and the 6-bromo analogue (4.16), both 
isolated from the marine sponge Dercitus sp. 1 56 Although compounds 4.11 to 
4.16 are structurally related, only 3'-deimino-3'-oxoaplysinopsin (4.13) and 3'­
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In 1990, Pettit and co-workers 1 57 isolated (E)-axinohydantoin (4.17) from the 
sponge Axinella sp. The structure was determined by X-ray crystallography. 
Subsequently, the isolation of (Z)-axinohydantoin (4.18) and (Z)­
debromoaxinohydantoin (4.19) from Stylotella aurantium and Hymeniacidon sp., 
respectively, has been reported by two groups. 1 58• 1 59 Some of these tricyclic 
compounds have been shown to exhibit inhibitory activity against c-erbB-2 kinase 
and cyclin-dependent kinase 4, while others have shown no inhibitory activity 
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The mukanadins A-C (4.20-4.22), isolated from the extracts of the Okinawan 
sponge Age/as nakamurai collected off le Island, also represent a series of 
bromopyrrole alkolids that possess unique biological activity. 1 60 However, only 
mukanadin B (4.21) contains a hydantoin moiety. The structurally related 
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Ulosantoin ( 4.24), along with the structurally related compound dimethyl N2-
creatininylphosphate (4.25), were isolated from the sponge Ulosa ruetzleri. 
Although ulosantoin ( 4.24) is structurally extremely simple and represents the 
first report of a phosphorylated hydantoin, it exhibits potent insecticidal activity 
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against both the tobacco hornworm and the more persistent cockroach.1 62 Feeding 
assays revealed that dimethyl N2 -creatininylphosphate ( 4.25) was void of activity, 
while ulosantoin ( 4.24) caused 100 % mortality within 24 hours at a dose of 200 
ppm (in agar-based diet) against the tobacco hornworm. Topical applications of 
0.2 and 2.0 µg, respectively, to the Mexican bean beetle and the southern 
armyworm were 100 % lethal. 
4.24 
4. 7: Concluding Remarks 
CH3 
N 0 ( r 'p-c;:: O 
)-- N· I "ocH 
0 I Q 3 CH2 
4.25 
The aim of this section of work was to isolate and identify the compound(s) 
responsible for the biological activity (P388) observed in the crude extract of the 
deep water Antarctic marine sponge Suberites sp. (02WM01-46). 
Analytical reversed phase HPLC chromatography (in conjunction with a 
microtitre plate P388 assay) located the compound responsible for the observed 
activity in the crude extract, eluting at 7. 8 minutes under standard 10 % 
CH3CN/H20 solvent gradient conditions. C1 8  flash column chromatography and 
reversed phase (C1 8) semi-preparative HPLC yielded the purified novel CS­
substituted hydantoin, (Z)-5-(3,4-dihydroxybenzylidene)-imidazolidine-2,4-dione 
(4.8). 
Structural elucidation of 4.8 was achieved with the use of 1 H, 1 3C, COSY (long­
range), HSQC, CIGAR and NOESY NMR spectroscopy, accompanied by high 
resolution ESI mass spectrometry and comparison of 1 3C NMR chemical shift 
data from previously reported synthetic analogues. 1 53 
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The geometry of the C-5/C-6 double bond was determined using the lD-NOESY 
NMR experiment after the addition of four equivalents of pyridine-d5 . The 
addition of base affected the chemical shifts of the protons observed in the 1 H 
NMR spectrum of the isolated compound. Irradiation of the olefinic proton H-6 
(8H 6.48, initially at 8H 6.36) resulted in an NOE enhancement of the aromatic 
protons positioned at H-8 and H-12 (8H 7.21 and 7.17, respectively, initially at 8H 
7.06 and 7.07, respectively) only, suggesting the (Z) configuration for the major 
natural product isolated, as no enhancement of the amide proton NH-1 (8H 10.24) 
was observed. The ratio of major to minor isomer was determined through direct 
comparison of the peak area integrals in the initial 1 H NMR spectrum of the 
purified compound 4.8 (ZIE 6:1). Reports indicate that if the N-2 position is 
methyl substituted, the (E) isomer is thermodynamically more stable, however if 
N-2 bears a proton or a lone pair in place of the methyl group, the (Z) isomer is 
thermodynamically more stable. 1 56 These reports also indicated that isomeric 
ratios for compounds of this type are photochemically and thermally enriched. 1 56 
This phenomenon was observed in the current study, with increased exposure to 
ambient light conditions in the laboratory altering the signal ratios in the 1 H NMR 
spectra during structural elucidation. Isomeric ratios were also altered after the 
addition of base (pyridine-d5), from 6: 1 to 2: 1 (Z/E). Therefore the equilibrium is 
dependant upon exposure to light and pH. The ratio was not restored upon the 
addition of a few drops of acid (TF A). Furthermore, thermal enhancement of 
isomer ratios was not observed in 1 H NMR experiments with a probe temperature 
increase from 23 °C to 43 °C. The photochemical equilibrium represents a useful 
means of obtaining the (E) isomer, provided that chromatographic methods are 
available to separate the stereoisomeric mixture. 
This work represents the first isolation of (Z)-5-(3,4-dihydroxybenzylidene)­
imidazolidine-2,4-dione (4.8) as a natural product from a marine sponge. The (Z)-
5-( 4-hydroxybenzylidene )-imidazolidine-2,4-dione ( 4.9) compound has been 
reported previously in the literature, but only as a synthetic product or as a 
derivative used in the synthesis of potential pharmaceuticals, pesticides and 











Evaluation of the cytotoxicity using the in-house anti-tumour assay system (P388) 
resulted in an IC50 of 4.5 µg/mL. Anti-tumour activity has been reported 
previously, however the 5-substituted hydantoins are more noted for their 
fungicidal and herbicidal activity. 1 48, 1 50, 1 5 1 , 1 63 
The ecological role of the novel hydantoin 4.8 can only be speculated on. 
Compounds of this class display a variety of biological activities, and as sponges 
are susceptible to overgrowth, predation and infection, such compounds may 
afford some level of chemical protection. It has also been suggested that the 
photoisomerisation of these compounds may be a non-destructive process for 
entrapping radiant energy, thus protecting the shallow water sponge from 
damaging UV rays. 1 48 However, it would seem unreasonable that a deep water 
Antarctic sponge, shielded from UV light by a thick layer of surface ice for a high 
percentage of the year, would require such an elaborate UV protection mechanism. 
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4. 8: Summary of Isolation 
Suberites sp. (02WM01-46) 
MeOH/DCM Extraction (248 mg) 
Reverse phase (C 1 8) Vacuum Column Chromatography (35 g) 
H20 I 0% 20% 30% 40% 50% 60% 70% 80% 90% MeOH DCM 
Fraction # 1 
Mass (mg) 74_3 
2 3 
35.6 3 .2  
4* 
3 . 1  








Semi-preparative reverse phase (C 1 8) 
Chromatography 
Hr-r1-r,H3C m,o 
Fraction # 1 2 3* 4 
Mass (mg) 1 .0 2 .2 4.5 0.9 
4.8 (4.5 mg) 
9 10 1 1  12 
1 3 .0 1 4 .3  44.4 35 .2 
1 3 1  
Scheme 4.1: Chromatographic purification summary for the Antarctic marine 
sponge Suberites sp. *Fraction contains biologically active compounds of interest. 
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CHAPTER S 
ISOLATION OF COMPOUNDS FROM THE 
ANTARCTIC MARINE SPONGE-DERIVED 
FUNGUS Aspergillus sp . (WS 76) 
5. 1 :  General Introduction 
Aspergillus is one of the most commonly encountered and well recognised genera 
of terrestrial fungi. 1 64 They occupy a wide spectrum of habitats and rank among 
the most economically important fungi worldwide. 1 65 Although much of their 
impact is detrimental (food spoilage), they possess enormous economic utility in 
industrial applications. These include the production of synthetic chemicals, 
saccharification of rice starch for alcoholic liquors, the production of citric acid 
and other biosynthetic transformations. 1 66 Aspergillus enzymes are used 
extensively in the production/preservation of food stuffs, however, Aspergilli are 
frequently encountered in food products such as corn, rice and peanuts that are 
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stored incorrectly. 1 67 The most important consequence of their presence is 
mycotoxin contamination, which can cause serious toxic effects in humans and 
animals, including cancer (following ingestion) and acute/chronic respiratory 
disease (after inhalation). 1 68 The mycotoxins are secondary fungal metabolites 
produced by the fungi genera Aspergillus, Penicillium and Fusarium. Currently, 
more than 300 secondary metabolites from these filamentous fungi have been 
isolated and classified as mycotoxins. 1 69 Mycotoxins isolated from the genus 
Aspergillus include the aflatoxins (5.1-5.5) (Aspergillus jlavus toxins). These five 
compounds are associated with the contamination of incorrectly stored grains and 
nuts. 1 70-1 74 The biosynthetic pathway leading to the aflatoxins is complex and 
involves many enzymes and genes. Simple anthraquinones are required early in 
the pathway where they are derivatised to xanthones, while the final stages consist 
of oxidative ring cleavage leading from xanthones to aflatoxins. Aflatoxin­
producing species such as A. jlavus only produce aflatoxins B 1 (5.1) and B2 (5.2), 
while A. parasiticus and A. nomius are capable of further oxidative ring expansion 
to produce aflatoxins G l  (5.3) and G2 (5.4). 1 67 • 1 68• 1 7 1 • 1 75 Aflatoxin B1 (5.1), is 
generally the most common metabolite, and is considered the most toxic in terms 
of both acute and chronic toxicity. Despite there being only a small number of 
species of fungi producing aflatoxins, A. jlavus and A. parasiticus are very 
widespread and are associated with a number of important food commodities 
consumed in all parts of the world. 1 68 While aflatoxin M 1 (5.5) is not as toxic or 
carcinogenic as aflatoxin B1 (5.1), 1 73 it does, however, survive the pasteurization 
process and has even been reported in UHT milk. 1 74 The potential for widespread 
food contamination has prompted the world health organization to reclassify 
aflatoxins as Group I carcinogens and subsequently review the accepted 
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Native bioaerosols from compost facilities are a rich source of fungal secondary 
metabolites including mycotoxins.1 76 The Aspergillus species A. fumiagatus, A. 
versicolor and A. nidulans are among the most frequently isolated species of fungi 
from the air space surrounding composting material.1 69' 1 76 Compounds frequently 
occurring in high concentrations from these species include gliotoxin (5.6), 
verruculogen (5.7), fumagillin (5.8) and sterigmatocystin (5.9). Exposure to these 
mycotoxins represents a genuine health hazard for workers at compost bio-waste 
handing facilities as they are attributable to both acute (toxic mould syndrome) 
and chronic (human lung cancer) health effects. 1 77 In order to establish the 
mechanism of toxicity of these compounds, gliotoxin (5.6), verruculogen (5.7), 
fumagillin (5.8) and sterigmatocystin (5.9) were tested in vitro against four 
established cell lines as a surrogate to tissues known or suspected to be targets of 
toxic effects of mycotoxins. These were the human lung cancer cell line (A-549), 
an epithelium-like cell line from human carcinoma (Hep-G2), murine fibroblasts 
from areolar and adipose connective tissue (L-929) and a neuronal cell line from 
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munne neuroblastoma (Neuro-2a). Of the four mycotoxins described, 
sterigmatocystin (5.9) possesses the highest toxicity. It was the most active 
against the A-549 cell line with an IC50 of 1.2 µg/ml. 1 69 No activity was observed 
for verruculogen (5.7) in any of the cell lines. The in viva activity of 
sterigmatocystin (5.9) involves activation in the liver by enzymes where it binds 
covalently to DNA and induces various tumours. Non-cancer effects have also 
been observed following long term exposure to sterigmatocystin (5.9). Rats 
developed granulomatous lesions of the Jung after two years of chronic airborne 














Another mycotoxin commonly isolated from airborne particulate associated with 
the processing of agricultural products infected with Aspergillus ochraceus is 
ochratoxin (5. 1 0) .  This compound has been detected in settled and airborne dust 
at workplaces processing coffee, cocoa beans and spices. Elevated concentrations 
of ochratoxin (5. 1 0) were detected in blood samples taken from exposed 
workers. 1 78 It has been shown to be potentially lethal when inhaled, and has been 
linked with renal failure. 1 79 As with the previously described mycotoxins, 
ochratoxin (5. 1 0) possesses potent nephrotoxic and carcinogenic activity. 








It has been known for many decades that marine-derived fungi are a rich source of 
diverse novel secondary metabolites. 1 1  Most commonly, the novel natural 
products are structural variations of compounds isolated from terrestrial fungi. 
Recently, many compounds have been reported from marine derived fungi of the 
genus Aspergillus isolated from sources that include red1 80-1 82 and green1 83 alga, 
sediment,1 84 anenomes 1 85 and mussels. 1 86' 1 87 Although reports in the literature for 
studies on the sponge-derived fungus Aspergillus are limited, those that have been 
published illustrate that sponge-derived fungi have enormous potential for the 
discovery of novel and/or biologically active natural products. 
Sponges are filter feeders, and so accumulate a large variety of micro-organisms. 
Some of these are a direct representation of the microbes in the surrounding water 
column, while others are indicative of a specialized relationship. It is not clear, 
however, if the fungal cultures isolated from sponge tissue are from spores that 
have been accumulated from the feeding process, or whether they have been 
propagating within the host. 1 88 
A typical example of fungal biodiversity is shown with the isolation of five 
secondary metabolites from a seawater culture of a sponge-derived fungal isolate 
of Aspergillus niger by Crews et al. in 2000. 1 89 The saltwater culture of A. niger 
was obtained from the marine sponge Hyrtios proteus collected in the Dry 
Tortugas National Park in Florida. The organic extract afforded the novel 
compound asperic acid (5.11), along with the known compounds hexylitaconic 
acid (5.12), malformin C (5.13), pyrophen (5.14) and asperazine (5.15). Due to 
compound paucity, the absolute stereochemistry of asperic acid (5.11) was not 
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pursued. Structural assignment of the known compounds was achieved via direct 
comparison of experimental NMR data with that for the previously published 
structures. These compounds are representative of the ability of marine fungi to 
biosynthesize a variety of structural classes, including rearranged terpenes, 
polyketides, pyrones and unusual amino acids. 
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5. 14  
In  2003, seven new compounds were isolated from the fungus Aspergillus 
versicolor, derived from the marine sponge Xestospongia exigua. This sponge 
was collected by SCUBA diving at Mengangan Island, Bali, Indonesia, by Lin 
and co-workers. 1 90 The new compounds (5.15-5.21) represented previously 
undescribed angular chromones belonging to two structural classes. The 
compounds were subsequently named aspergillitine (5.15) and aspergione A-F 
(5.16-5.21). Aspergillitine (5.15) displayed only moderate antibacterial activity 
against Bacillus subtilis, while it was inactive against Escherichia coli and 
Saccharomyces cerevisiae. In the same assay system, aspergione C (5.18) and E 
(5.20) were inactive. 
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5.20 R =  CH3 
5.21 R = H  
More recently, eight metabolites, seven of which were novel, were isolated from 
the sponge-derived fungus Aspergillus niger, cultured from the marine sponge 
Axinella damicornis collected in the Mediterranean in 2004. 1 88 The compounds 
included the known fungal pigment cycloleucomelone (5.22), and the new 
compounds bicownanigrin (5.23), the structurally unusual 4-benzyl- lH-pyridin-6-
one derivatives aspemigrins A and B (5.24 and 5.25, respectively) and 
pyranonigrins A-D (5.26-5.29) which feature the novel pyrano[3,2-b ]pyrrole 
skeleton previously undescribed in nature. All structures were elucidated using 
extensive ID  and 2D NMR techniques, and for the two chiral structures (5.25 and 
5.26, respectively) absolute configurations were established by quantum chemical 
calculations of their circular dichroism spectra. Weak cytotoxicity in vitro against 
human cancer cell lines was reported for bicoumanigrin (5.23), while aspemigrin 





























5.27 R = H  R 1 = CH3 
5.28 R = CH3 R 1 = H 
1 39 
OCH3 
In this chapter, the previously undescribed anthraquinone compounds 6,8-0-
dimethylbipolarin (5.35) and 5,6-dihydroxy-1,3-0-dimethoxy-2,3,4,5-tetrahydro­
l-oxa-cyclohepta[ b ]anthracene (5.41) and the previously described 6,8-0-
dimethylaverufin (5.32), 6,8-0-dimethylaverufanin (5.34), and 8-0-
methylaverufin (5.40) were isolated from the organic extract of the Antarctic 
sponge-derived fungus Aspergillus sp. Structural elucidation was achieved using 
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l D  and 2D NMR spectroscopy and mass spectrometry, and was aided by data 
comparisons with structural information reported in the literature. The biological 
activity of each compound was assessed in-house. 
5. 2: Introduction 
The fungal culture (WS 132) was isolated from the Antarctic sponge 
Kirkpatrickia varialosa collected at Cape Armitage, Ross Island, Antarctica, at a 
depth of 25-30 m by SCUBA in Feburary 2002. The K. varialosa sponge tissue 
was sliced into 5 mm cubes, placed onto fungal-specific media and incubated at 
26 °C until the cultures grew. To obtain enough material for structural elucidation, 
the isolate was re-cultured on rice (500 g) for 3-4 weeks at 26 °C, until all of the 
surface area of the solid rice media had been covered by the fungal growth. 
5. 3 :  Extraction of the Antarctic Marine 
Sponge-derived Fungus Aspergillus sp. (WS 76) 
The entire fungal isolate WS 76 (500 mL) was extracted repeatedly with distilled 
EtOAc. The solvent was removed under vacuum, and the organic extract was 
further purified by partitioning between Et0Ac/H20. The organic layer was 
collected, and the solvent removed under vacuum to yield an orange gum (229 
mg). A small fraction (250 µg) of the extract was dissolved in MeOH, and 
subjected to reversed phase (C 1 8) analytical HPLC microtitre plate collection (see 
Experimental, Section 7.1.6.2). The dilution plates were analysed via the in­
house P388 assay. Two areas of activity were identified. These were attributable 
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Figure 5. 1 :  HPLC trace of EtOAc extract of WS 76, indicating the areas of 
activity determined by P388 assay. 
Analysis of the UV chromophores (Figure 5.2) for the compounds associated 
with these areas of activity revealed that these compounds were all related, with 
Amax at 225, 285 and 445 nm. However, it was also noted that the UV profiles of 
the major non-active compounds eluting at 1 8.6 and 23 minutes were also similar 
to those in the active region of the chromatograph. UV maxima (Amax) at 225 and 
285 nm are characteristic of a quinone moiety (5.30), however, the presence of the 










Positive LCES I mass spectrometry of the organic extract identified [M+Ht ions 
ranging from 369 to 399 Da for the compounds eluting in the region of observed 
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activity. A database search130•145 based on mass and UV structural information 
resulted in 125 hits. The majority of these compounds possessed some level of 
biological activity. Due to the number of possible matches for the compounds 
present in the extract, further isolation was deemed necessary for an unambiguous 
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Figure 5.2: UV profile of peaks in areas of P388 activity as determined by 
microtitre plate assay. This includes the UV profile of the major (non-active) 
compound eluting at 23 minutes. 
5. 4: Chromatographic Isolation of Bioactives 
5.4.1: Normal Phase (DIOL) Flash Chromatography of the 
Organic Extract of the Antarctic Marine Sponge-
derived Fungus Aspergillus sp (WS 7 6) 
The EtOAc-soluble fraction was subjected to further purification by normal phase 
(DIOL) flash chromatography. The column was eluted with a stepped solvent 
gradient from a pet. ether/DCM mixture to EtOAc. The remaining material was 
washed from the column with combinations of EtOAc and MeOH into the 17th 
fraction. All fractions were submitted for reversed phase C 18 HPLC 
chromatographic analysis using the standard 10 % gradient (as described in 
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Experimental, Section 7.1.3.2). Fractions wjml6-703 (100 % DCM, 78.3 mg), 
wjml 6-705 (4: 1 DCM/EtOAc, 15.6 mg), wjml 6-708 (1:1 DCM/EtOAc, 5.2 mg) 
and wjml 6-710 (3:7 DCM/EtOAc, 5.4 mg) contained major components that 
exhibited the characteristic retention times and UV chromophores of the 
compounds responsible for the activity observed in the original organic extract of 
WS 76. None of these fractions were considered pure enough for spectroscopic 
analysis. They were therefore subjected to further purification. 
5. 4. 2: Reversed Phase (C18) Semi-preparative 
HPLC Chromatography of Fraction wjml 6- 703 
Fraction wjm16-703 (78.6 mg) contained two major components eluting at 23 and 
25 minutes, respectively. This fraction was subjected to further purification by 
reversed phase (C 1 8) semi-preparative HPLC chromatography. Two fractions, 
each containing one of the two major components were collected. Purity was 
confirmed by re-injection onto an analytical HPLC column. Both fractions were 
analysed by 1H NMR, and were found to contain sufficient mass for COSY, 
HSQC and CIGAR 2D NMR spectroscopic experiments. Initial inspection of the 
NMR spectra confirmed that these compounds were related. Molecular mass was 
confirmed by HRESI mass spectrometry, which in combination with the NMR 
data led to the identification of the previously reported compounds 6,8-0-
dimethylaverufin (5.32) and 6,8-0-dimethylaverufanin (5.34) (see Sections 5.5.1 
and 5.5.2, respectively). 
5. 4. 3 :  Reversed Phase (C18) Semi-preparative HPLC 
Chromatography of Fraction wjml 6- 705 
The compounds eluting in fraction wjm 16-705 were not responsible for the 
observed biological activity, but did possess the characteristic UV profile of the 
compounds isolated in fraction wjm 16-703. This fraction was further purified by 
semi-preparative reversed phase C 1 8 chromatography. A separation gradient was 
developed on an analytical scale, and then scaled up by an appropriate factor to 
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make large scale injections possible. Fraction wjm 16-705 was processed via 
consecutive injections onto the column, and fractions were collected as peaks 
eluted. The purity of the collected fractions was confirmed by re-injection onto 
the analytical HPLC column. One fraction contained sufficient mass and was 
sufficiently pure for structural elucidation by I D  and 2D NMR analysis. The 
previously unidentified compound 6,8-0-dimethylbipolarin (5.35) was 
subsequently identified (see Sections 5.5.3). 
5. 4. 4: Reversed Phase (C18) Semi-preparative 
HPLC Chromatography of Fraction wjm l  6- 708 
Analytical reversed phase HPLC analysis of fraction wjm 16-708 established that 
this fraction was essentially pure, with only a minor contaminant eluting 1.5 
minutes after the major component. Reversed phase (C 1 8) semi-preparative HPLC 
chromatography was used, and a gradient method was developed to facilitate 
further separation. One major fraction was collected and analysed using ID  and 
2D NMR spectroscopy and mass spectrometry to identify the previously reported 
compound 8-0-methylaverufin (5.40) (see Section 5.5.5). 
5. 4. 5: Reversed Phase (C18) Semi-preparative HPLC 
Chromatography of Fraction wjm l  6- 71 0 
Fraction wjm16-710 was identified in earlier experiments, via microtitre plate 
analysis, to contain additional compounds responsible for the activity of the crude 
extract. This fraction, like fraction wjml 6-708, was essentially one compound 
(C, s-HPLC), and was purified by the same reversed phase (C 1 8) semi-preparative 
HPLC chromatography. One major fraction was collected, and the purity was 
confirmed by re-injection onto the reversed phase (C 1 8) analytical HPLC column. 
Further examination of this fraction by l D  and 2D NMR spectroscopy and mass 
spectrometry resulted in the identification of the previously unreported 
cyclohepta[b Janthracene (5.41) (see Section 5.5.6). 
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5. 5: Structural Elucidation of Compounds Isolated 
from the Antarctic Marine Sponge-derived 
Fungus Aspergillus sp. (WS 76) 
5. 5. 1 :  Structural Elucidation of 5.32 
145 
Compound 5.32 ( 4.4 mg) was isolated as a bright yellow powder from the first 
fraction of wjm16-703. The HRESI mass spectrum indentified a [M+Ht ion at 
m/z 397.1264 (calc. 397.1287), which led to the molecular formula of C22H2007 
corresponding to 13 DBE. Analysis of the UV-VIS spectrum, combined with the 
fact that this compound was highly coloured, suggested that an extended 
conjugated aromatic system was present within the molecule, such as an 
anthraquinone ring system. The 1 H NMR spectrum (Figure 5.3) revealed the 
presence of 11 well-defined signals. These comprised a downfield phenolic 
proton (8H 13 .45) hydrogen bonded to a carbonyl, three methine aromatic protons 
(8H 7.47, 7.22 and 6.79), a methine proton (8H 5.38), two methoxy signals (8H 
4.04 and 3.99), six methylene signals (8H 2.06, 1.86, 1.66, 1.57, 2.02 and 1.86), 
and finally a methyl signal (8H 1.53). These proton signals satisfied the 
requirements of the molecular formula. The 1 3C NMR chemical shift data was 
assigned from close examination of both the HSQC and CIGAR NMR spectra. 
Two carbonyl carbons (8c 205 .4 and 183 .1 ), nine sp2 aromatic quaternary carbons 
(8c 165.2, 162.9, 159.8, 159.7, 137.5, 132.8, 117.2, 1 15.5 and 110.4), three 
protonated sp2 aromatic carbons (8c 107.9, 105.1 and 104.5), one s/ carbon 
bearing oxygen (8c 67.1), three s/ methylene carbons (8c 27.3, 16.2 and 35.8), 
one s/ quaternary carbon bearing two oxygen atoms (8c 101. 1 ), two s/ methyl 
carbons associated with two methoxy groups (8c 56.6 and 56.1) and one s/ 
methyl (8c 28.0) were detected. 
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Examination of the COSY spectrum established a partial structure via 
observations of the consecutive correlations from the H- 1 1  (8H 5.38) oxygenated 
methine proton to the, H-8a,b (8H 2.02, 1 .86), H-9a,b (8H 1 .66, 1 .57) and H- 1 Oa,b 
(8H 2.06, 1 .86) methylene protons. 
The C IGAR correlations from the H- 1 6  (8H 1 .53) methyl protons to the C-7 (8c 
1 0 1 . 1 ) carbon confirmed the position of the methyl group at position C-7, while 
the additional C IGAR correlations to C-6a and C-8 (8c 1 59.8 and 35.8, 
respectively) carbons, combined with the correlations from the H- 1 1  (8H 5.38) 
methine proton to the C-6a, C-7, and C- l l a (8c 1 59.8, 1 0 1 . 1  and 1 1 7.2, 
respectively) carbons, established the connectivity of ring E through ring D to the 
aromatic core (Figure 5.4). 
Figure 5.4: COSY (blue) and CIGAR (black arrows) correlations leading to the 
assignment of rings D and E, and establishing connectivity to the aromatic core. 
The chemical shift of the C- 1 2  (8c 1 59. 7) aromatic carbon suggested phenolic 
substitution at this position. The phenolic proton observed in the I H NMR 
spectrum at 8H 1 3  .35 was hydrogen bonded to a carbonyl moiety forming a 
pseudo 6-membered ring, confirmed by the C IGAR correlation from OH- 1 2  (8H 
1 3.45) proton to the C- 1 3  (8c 205.4) carbonyl carbon. This low field C- 1 3  (8c 
205 .4) carbon established the presence of an aromatic ketone group, one of the 
two required for the anthraquinone moiety suggested by the UV data. The H-6 
(8H 7.22) aromatic proton was correlated by the C IGAR experiment to the C-5, C-
6a, C- l l a and C- 1 2a (8c 1 83. 1 ,  1 59.8, 1 1 7.2 and 1 1 0.4, respectively) carbons, 
identifying the second downfield aromatic ketone positioned at carbon C-5. This 
satisfied the requirements of the partial anthraquinone core structure indicated by 
the initial UV spectral data, and confirmed ring C. However, no 2D NMR 
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correlations were observed for C-5a within ring C. A 1 3C NMR spectrum 
simulation 1 9 1 estimated a chemical shift value of approximately 8c 134. On this 
basis, the assignment of position C-5a (8c 132.8) ortho to the aromatic proton at 
H-6 (81-1 7.22) was tentatively made (Figure 5.5). 
H 
Figure 5.5: The key CIGAR (black arrows) correlations leading to the 
assignment of ring C and the partial structure of ring B, the central ring associated 
with the anthraquinone core structure. 
The remaining connectivity was achieved utilising the signals of the remaining 
aromatic protons H-2 and H-4 (81-1 6.79 and 7.47, respectively). The COSY cross 
peak correlation from H-2 (81-1 6.79) to the H-4 (81-1 7.47, J2,4 = 2.5 Hz) proton, 
combined with the coupling constant extracted from the 1 H NMR spectrum, 
suggested that a meta relationship existed between these protons on the aromatic 
ring, establishing C-2 to C-4 connectivity. CIGAR correlations from the H-2 (81- 1  
6.79) aromatic proton to the C-2, C-3, C-4a and C-5 (8c 105.1, 165.2, 137.5 and 
183.1, respectively) carbons and correlations from the H-4 (81-1 6. 79) aromatic 
proton to the C-1, C-3, C-4 and C-13a (8c 162.9, 165.2, 104.5 and 115.5, 
respectively) carbons established ring A. This data also confirmed the previous 
assignment of C-5a (8c 132.8) to ring C as it had the most reasonable carbon 
chemical shift followed by the signal at 8c 137.7. However C-3 (81-1 137.7) was 
unambiguously assigned as being part of ring A. The two remaining methoxy 
methyl proton signals 81-1 3.99 and 81-1 4.04, were assigned as a result of the 
observed CIGAR correlations from the H-14 and H-15 (81-1 4.04 and 3.99, 
respectively) methyl protons to the C-1 and C-3 (8c 162.9 and 165.2, respectively) 
aromatic carbons, therefore, the two methoxy groups H-14 and H-15 were 
positioned at C-1 and C-3, respectively (Figure 5.6). 
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Figure 5.6: COSY (blue) and CIGAR (black arrows) correlations leading to the 
assignment of rings A and B of the anthraquinone core structure of 5.32. 
On the basis of these findings structure 5.32 was proposed, annotated with an 
arbitrary numbering system used for the structural elucidation process and also 
used in Table 5. 1 .  This structure also satisfies the requirements of the DBE's. 
0 
5.32 
From a literature search, 1 30' 1 45 this compound was identified as 6,8-0-
dimethylaverufin (5.32), a l-hydroxy-6,8-dimethoxy-anthraquinone that contains 
a 1 ,3-benzodioxan system. The numbering system used in the literature is shown 
in Figure 5.7. 
OCH o,,
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Figure 5.7 : Numbering assignment for 5.32, as reported in the literature. 1 92• 1 93 
The demethyl compound averufin (5.33) was first isolated by Pusey et al. in 
1 963. 1 94 However, the structure was reported incorrectly, with the methyl group 
located at C- 1 1 . Three years later Holker et al. 1 93 isolated both 6,8-0-
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dimethylaverufin (5.32) and averufin (5.33) as natural products, and suggested on 
the basis of 1 H NMR analysis that the methyl group should be positioned at C-7 
not C-11 as originally reported. 1 94 The structure of averufin (5.33) was formally 
revised in a paper published by Roffey et al., 1 95 where two benzo-1,3-dioxan ring 
moieties were synthesised with the methyl group positioned at C-11 in one 
compound and at the C-7 position in the other. Their NMR experiments 
confirmed that the methyl positioned at C-7 was consistent with Holker's 
hypothesis. In 1985, Maebayashi et al. 1 96 reported the isolation of 6,8-0-
dimethylaverufin as a novel compound from a rice extract inoculated with 
Emericella foeniculicola. The first full NMR characterisation was published by 
Maebayashi, 1 96 and direct comparison of the current data ( 1 H, 1 3C, MS, IR and 
optical rotation) with that of the known compound confirmed that the isolated 




5. 5. 1 . 1 :  Stereochemistry of 5.32 
The optical rotation for 6,8-0-dimethylaverufin (5.32), [a] 020 = -20° (c=0.22, 
CHCb)), was consistent, within experimental error, with the data reported 1 96 
([a]020 = -18° (c=0.22, CHCl3))  suggesting the stereochemistry for 5.32, was 
identical to that reported. However, no stereochemistry was indicated on the 
structure described in this paper. A later publication reported that atoms C-1' and 
C-5 '  of 6,8-0-dimethylaverufin (5.32) were assumed to have the S-configuration 
based upon direct comparisons of NMR data for structurally similar compounds 
produced by the same organism, although the published structure is graphically 
depicted as having incorrectly assigned stereochemistry at C-1' and C-5 '.
1 97 
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Based on the available NMR and optical rotation data no relative stereochemistry 
was assigned for 5.32, as the S-isomer could not be unambiguously assigned over 
the R-isomer. 
The full experimental NMR data for 6,8-0-dimethylaverufin (5.32) is shown in 
Table 5.1. Note that the arbitrary numbering system used for structural 






14  H 
OCH3 o" 'o 
1 3  I 
5.32 




1 6  
Table 5.1: The 1 H, COSY, HSQC and CIGAR NMR data for 5.32 (CDCh). 
Position 'Jc o § 1 H o r  COSY CIGAR 
1 1 62.9 (C) 
2 1 05 . 1 (CH) 6.79 (1 H, d, 2 .5) H-4 C-1 3a, C-4, C-3, C-1 
3 1 65.2 (C) 
4 1 04.5 (CH) 7.47 (1 H, d, 2.5) H-2 C-5, C-4a, C-3, C-2 
4a 1 37.5 (C) 
5 1 83. l (CO) 
5a 1 32 .8 (C) 
6 1 07.9 (CH) 7.22 (1 H, s) C- l 2a, C-1 1 a, C-6a, C-5 
6a 1 59 8 (C) 
7 1 01 1  (C) 
8 35.8 (CH2) 8a: 2.02 (1 H,  m) H-9a, H-9b, H-8b, 
8b: 1 .86 (I H, m) H-9a, H-9b, H-8a, 
9 1 6.2 (CH2) 9a: 1 .66 (1 H, m) H- IOa, H- lOb, H-9b, H-8a, H-8b 
9b: 1 .57 (I H, m) H- IOa, H- lOb, H-9a, H-8a, H-8b C-1 1 ,  C-8, C-7 
10  27 .3  (CH2) 
1 Oa: 2.06 ( 1  H, m) H-1 1 ,  H-I Ob, H-9a, H-9b, , C-1 1 , C-8 
I Ob: 1 .86 (I H,  m) H- 1 1 ,  H- I Oa, H-9a, H-9b, C-1 1 
1 52 
I I  67.1 (CH) 5.38 (I H, dd, 2.5, 9) H- I Oa, H- I Ob C-1 2,  C-1 l a, C-9, C-7, C-6a 
I l a 1 1 7.2 (C) 
1 2  1 59.7 (C) 
OH- 1 2  1 3.45 (OH, s) C- 1 3  
1 2a 1 1 0.4 (C) 
1 3  205.4 (CO) 
1 3a 1 1 5 .5 (C) 
56.6 
1 4  (OCH3) 4.04 (3H, s) C-1 
56. 1 
1 5  (OCH3) 3.99 (311, s) C-3 
1 6  28.0 (CH3) 1 .53 (3H, s) C-8, C-7 
§ 1 3C NMR chemical shift values (8 ppm from CDCl3 at 77.0) obtained from both HSQC and 
CIGAR experiments. t 1H NMR spectra recorded at 500 MHz in CHCl3 (8 ppm from CHCl3 at 
7.25), followed by number of protons, multiplicity and coupling constants (J/Hz). 
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5. 5. 2: Structural Elucidation of 5.34 
Compound 5.34 (3.4 mg) was isolated as an orange powder, and was the second 
compound to elute from fraction 16-703. HRESIMS identified the [M +Ht ion at 
m/z 399.1450 (calc. 399.1444), which led to the molecular formula of C22H2207, 
which is 2 Da more than 6,8-0-dimethylaverufin (5.32) and equated to 12 DBE. 
Analysis of both the UV chromophore and the 1 H NMR spectrum (Figure 5.8) 
revealed that this compound was structurally related to 6,8-0-dimethylaverufin 
(5.32). However, several differences in the 1 H NMR spectrum were noted. These 
consisted of the addition of a second hydrogen bonded phenolic proton (8H 9.80), 
a variation in the splitting pattern for the oxymethine at 8H 5.38 now at 8H 5.16 
(previously a doublet, but now a doublet of doublets, J = 2.5, 9.0 Hz), the 
appearance of a new signal at 8H 3.72 (m) and the singlet methyl previously 
identified at 8H 1.53 was now a doublet positioned up field at 8H 1.29 (J = 2.5 Hz). 
Overall, this suggested a change in the cyclic ketal functionality, ring D of 6,8-0-
dimethylaverufin (5.32) . 
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Figure 5.8 : The 1 H NMR spectrum for 5.34 in CDCh. 
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The 1 3C NMR data was obtained by careful examination of both the HSQC and 
the C IGAR spectra, due to the paucity of the compound. Comparison of the data 
with 6,8-0-dimethylaverufin (5.32) confirmed the presence of an anthraquinone 
core structure within compound 5.34. The substitution pattern of the aromatic 
ring A was deduced by both the coupling constants for the H-4 and H-2 (8H 7.45 
and 6.78, respectively, Jz,4 = 2.5 Hz) aromatic protons combined with the CIGAR 
correlations from the H-4 (8H 7.45) aromatic proton to the C-3, C-4a, C-5 and C­
l 3a (8c 1 65. 1 , 1 37.6, 1 82.8 and 1 1 5.5 ,  respectively) carbons and the correlations 
from H-2 (8H 6.78) the second aromatic proton to the C- 1 ,  C-3, C-4 and C- 1 3a (8c 
1 63.0, 1 65. 1 ,  1 04.0 and 1 1 5.5 ,  respectively) carbons. The two methyl signals 
associated with the methoxy groups were assigned via CIGAR correlations from 
the H- 1 4  and H- 1 5  (8H 4.0 1  and 3.99, respectively) methyl protons to the C- 1 and 
C-4 (8c 1 63.0 and 1 04.0, respectively) carbons, respectively. C IGAR correlations 
from the H-6 (8H 7.23) aromatic proton to the C-5, C-6a, C- 1 l a  and C- 1 2a (8c 
1 82.8, 1 62.0, 1 20.2 and 1 1 0.6, respectively) carbons, confirmed the position of H-
6 as para to the hydrogen bonded alcohol at position C- 1 2  (8c 1 6 1 .0). This data 
unambiguously assigned rings A, B and C (Figure 5.9). 
Figure 5.9 : COSY (blue) and C IGAR (black arrows) correlations leading to the 
assignment of rings A, B and C (the anthraquinone core structure). 
The partial structure C- 1 1 to C-9 was constructed via COSY correlations from the 
H- l Oa,b (8H 1 .96 and 1 . 56, respectively) methylene protons to both the H- 1 1  (8H 
5 . 1 6) oxymethine proton and the H-9 (8H 1 .9 1 ) methylene protons. The partial 
structure C-9 to C- 1 6  was established via COSY correlations. The COSY 
correlations from the H-8a,b (8H 1 .75 and 1 .37) methylene protons to the H-9 (8H 
1 .9 1 )  methylenes, combined with the COSY correlations from the H-7 (8H 3.72) 
oxymethine proton to both the H-8a,b (8H 1 . 75, 1 .37) and H- 1 6  (8H 1 .29) protons 
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completed C-9 to C- 1 1 . The pyran ring D was established on the basis of the 
mass and DBE requirements. One ring assignment remained, as eleven of the 
twelve DBE had already been accounted for. Therefore, positions C- 1 1 and C-7 
were proposed to be sharing the oxygen atom. However, no CIGAR correlations 
were observed from the H-7 (8H 3.72) methine proton to the C- 1 1  (8c 76.6) 
carbon or from the H- 1 1 (8H 5.1 6) oxymethine proton to the C-7 (8c 75.9) carbon. 
Connectivity of the pyran ring, ring D, was achieved via the observed CIGAR 
correlations from both the H- l Oab and H- 1 1 (8H 1 .56, 1 .96 and 5.1 6,respecively) 
protons to the C- 1 1  and C-6a (8c 76.6 and 1 62.0, respectively) aromatic carbons 
respectively. The remaining proton at 8H 9.80 was assigned to the oxygen at C-6a 
(8c 1 62.0) on the basis of the observed hydrogen bond formation between the 
phenolic proton and the oxygen of the pyran ring, to give a pseudo 6-membered 
ring. On the basis of these findings, the structure of 5.34 was proposed (Figure 
5. 10). 
H 
H 0 H 
D 
0 
Figure 5. 10 :  The COSY (blue) and CIGAR (black arrows) correlations observed 
leading to the assignment and connectivity to the aromatic core structure of the 
pyran ring, ring D of 5.34. 
From a literature search, 1 30• 1 45 the proposed compound was identified as 6,8-0-
dimethylaverufanin ( l ,3-dihydroxy-6,8-dimethoxy-2-( 6'-meth yl-tetrah ydropyran) 
anthraquinone (5.34), Figure 5.1 1), which was first reported by Holker et al. from 
the culture broth of a mutant Aspergillus versicolor 1 93 and was later characterised 
by Aucamp and Holzapfel. 1 98 The structure was confirmed via direct comparison 
with the reported NMR data. The numbering system reported in the literature for 
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Figure 5.11: The numbering assignment reported in the literature for 6,8-0-
dimethylaverufanin (5.34). 
5. 5.2. 1 :  Stereochemistry of 5.34 
The stereochemistry was determined via NOESY experiments (Figure 5.12) . It 
was assumed, not unreasonably, that the pyran ring was in the chair 
conformation, 1 99•200 with the C- 11/C- l 1 a bond in the equatorial position. This 
positioned the H-11 proton axial on the pyran ring. In contrast, the 16-CH3 group 
could be located in either an axial or equatorial orientation. Irradiation of the H-
11 (8H 5 .16) methine proton resulted in the NOESY enhanced signal of the H-7 
(8H 3. 72) methine proton which indicated that the H-7 proton was in the axial 
position. Additional correlations were also observed to both of the H-1 Oa,b and 
H-9 (8H 1.96a, 1 56b and 1.91, respectively) protons. The converse NOESY 
correlation was observed when the H-7 (8H 3. 72) proton was irradiated, enhancing 
the H-11 (8H 5. 16) proton signal, additional enhancements of both the H-16 (8H 
1.29) methyl and the adjacent H-8a,b (8H 1.75 and 1.37, respectively) methylene 
protons were also observed. This data validated the initial hypothesis that the H-
11 (8H 5 . 16) proton was in the axial position, as no cross ring correlations would 
be observed if either proton were in the equatorial position. In order to establish 
the axial protons at C-8 and C-10, the methylene protons H- lOa and H-8a (8H 1.96 
and 1.75, respectively) were sequentially irradiated. No NOESY correlation was 
observed between these protons. No signal enhancement in this case implies that 
both of these protons are in the equatorial position, and that both H- 1 Ob and H-8b 
(8H 1.56 and 1.37, respectively) are in the axial orientation. This was confirmed 
by the sequential irradiation of both of the H- lOb and H-8b (81-1 1.56 and 1.37, 
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respectively) protons, which resulted in the NOESY signal enhancements of the 
H-8b and H- 1 Ob (8H 1 .37 and 1 .56, respectively) protons respectively. Therefore, 
the relative stereochemistry for 5.34 was proposed as 1 1  S, 7 S. Due to the lack of 
signal resolution, the H-9 axial and equatorial protons could not be assigned. 
H 
i i  i i i  iv 
Figure 5. 12: Observed NOESY correlations (red) for irradiated proton (blue). i)  
irradiation of H- 1 1 , ii) irradiation of H-7, iii) irradiation of H- l Oa and iv) 
irradiation of H-8b, for the pyran ring of 5.34. 
The experimental NMR data for 6,8-0-dimethylaverufanin (5.34) is displayed in 
Table 5.2. The arbitrary numbering assignment, shown in Figure 5.13, is 
consistent with that used in the structural elucidation and in Table 5.2. 
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Figure 5.13: The arbitrary numbering system of 5.34, used for in both structural 
elucidation and Table 5.2. 
Table 5.2: The 1 H, COSY and C IGAR NMR data for 5.34 (CDCh). 
Position COSY CIGAR 
1 63 .0 (C) 












1 0  
1 1  
I l a  
1 2  
1 2a 
OH- 1 2  
1 3  
1 65 . l (C) 
I 04.0 (CH) 7.45 ( I  H ,  d, 2 .5) 
I 37.6 (C) 
1 82 .8 (CO) 
1 32.0 (C) 
I 09.2 (CH) 7.23 ( I  H, s) 
1 62.0 (C) 
9.80 (OH, s) 
75 .9 (CH) 3 .72 ( 1 H, m) 
33 .0 (CH2) 
Sa: 1 .75 ( I  H, m) 
Sb: 1 .37 ( 1 H, m) 
23.3 (CH2) 1 . 9 1  ( I H, m) 
30. 1 (CH2) 
I Oa: l .96 ( 1 H , m) 
I Ob: 1 .56 ( 1 H, m) 
76.6 (CH) 5 . 1 6  (1 H ,  dd, 2.5, 9.0) 
1 20.2 (C) 
1 6 1 .0 
1 1 0.6 (C) 
1 3 .48 (OH, s) 
t 
1 3a 1 1 5 .S (C) 
H-2 C-5 , C-4a, C-3, C-2 
C- I 2a, C- 1 I a, C-6a, C-5 
H- 1 6, H-Sa, H-Sb C- 1 6, C-9 
H-9, H-Sb, H-7 C- 1 0, C-7 
H-9, H-Sa, H-7 C- 1 0, C-9, C-7 
H- I Oa, H - I Ob, H-Sa, H-Sb, C- 1 1 ,  C-7 
H- 1 1 ,  H- I Ob, H-9 C- 1 I , C- 1 I a, C-8 
H- 1 1 ,  H - I Oa, H-9 C- 1 1 
H - I Oa, H- I Ob C- 1 I a, C- 1 0, C-9, C-6a, 
1 4  56.8 (OMe) 4.0 1 (3H,  s) C- 1 
1 5  56.2 (OMe) 3 .97 (3H,  s) C-3 
1 6  22.3 (CH3) l . 29 (3H . d, 2.5) H-7 C-8, C-7 
§ 1
3C NMR chemical shift values (8 ppm from CDC13 at 77.0) obtained from both HSQC and 
CIGAR experiments. 1 1H MR spectra recorded at 500 MHz in CDCh (8 ppm from CHC13 at 
7 .25) followed by number of protons, multiplicity and coupling constants (J!Hz). t No 1 3C NMR 
chemical shift data obtained for this carbon. 
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5. 5. 3 :  Structural Elucidation of 5.35 
The third purified compound 5.35 (3.1 mg), was again isolated as an orange 
powder from fraction 16-705. HRESIMS identified a [M+Ht ion at m/z 
3 71.1 13 7 ( calc. 3 71.1131 ), 28 Da less than that of the previous compound 6,8-0-
dimethylaverufanin (5.34), which Jed to the molecular formula C20H 1 807, 
corresponding to 12 DBE. Analysis of the UV data confirmed that this compound 
was related to the previous compounds and possessed the anthraquinone core 
structure. Examination of the combined 1 H NMR and CIGAR data established 
that the substitution patterns of rings A, B and C were identical to that of 6,8-0-
dimethylaverufin (5.32) and 6,8-0-dimethylaverufanin (5.34). However, on 
closer inspection of the 1 H NMR spectrum (Figure 5.14), several differences were 
identified. These comprised an additional multiplet at 8H 4.17  and 2.69, each 
signal integrating for one proton, the downfield shift of the oxymethine proton 
from 8H 3.72 to 3.97 as well as the absence of a doublet methyl signal at 8H 1 .23. 
This NMR data suggested the structural differences were again located in ring D. 
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The partial structure C- 1 1  to C-8 was constructed by careful examination of the 
COSY and HSQC correlations. The H- 1 0  (8H 5.38) oxymethine proton displayed 
cross peak COSY correlations to the H-9a,b (8H 2.69 and 1 .8 1 )  methylene protons, 
while the H-8 (8H 2.08) methylene protons were coupled to both the H-9a,b (8H 
2.69 and 1 .8 1 )  methylene and H-7a,b (8H 3.97 and 4. 1 7) oxymethylene protons. 
A furan ring (ring D) was defined through the CIGAR correlation from the H-7a 
(8H 3.97) methylene proton to the C- 1 0  (8c 79.3) carbon, which satisfied the loss 
of 28 mass units (CH3-CH) observed in the mass spectrum. Connectivity of the 
furan ring to the anthraquinone core structure at C- 1 1  was established with the 
C IGAR correlations from the H- 1 0  (8H 5.38) oxymethine proton to the C-6a and 
C- 1 1 (8c 1 6 1 .9 and 1 1 8.0, respectively) aromatic carbons of ring-C (Figure 5.15). 
H 0 H 
Figure 5.15 : The observed COSY (blue) and CIGAR (black arrows) correlations 
leading to the assignment of the furan ring, ring D, and its connectivity to the 
aromatic core for compound 5.35. 
From this data, structure 5.35 was proposed. From a literature search, 1 30• 1 45 no 
direct matches were found. Repeating the literature search by replacing the 6,8-
0CH3 groups for 6,8-0H groups, identified a structural match for the compound 
bipolarin (5.36). Therefore, 5.35 was identified as being novel, and tentatively 
named 6,8-0-dimethylbipolarin (5.35) (using the numbering assigned in the 
literature, Figure 5.16). 









Figure 5.16: The numbering assignment for 5.35, which is consistent with that 
used in the literature for bipolarin (5.36). 
Bipolarin (5.36) was isolated by Aucamp and Holzapfel from the maize cultures 
of Bipolaris sorokiniana. 1 98 In 1977, the total synthesis of (±)-bipolarin was 
achieved by Castonguay and Brassard,200 however an authentic sample of 
bipolarin (5.36) was unavailable for the direct comparison of the structural data, 
although the physical and spectral properties were in excellent agreement with 
those reported for the natural product by Aucamp and Holzapfel. 1 98•200 Mayes 
and Steyn, in a later report,20 1 suggested that the structure proposed for bipolarin 
(5.36) by Aucamp and Holzapfel 1 98 was not consistent with the accepted 
biosynthetic pathway leading to sterigmatocystin (5.8), a higher metabolite. To 
unambiguiously assign the structure of bipolarin (5.36), Mayes and Steyn20 1 re­
examined the maize cultures of B. sorokiniana. After several steps of 
chromatography only the compound versiconol (5.37) was identified. No other 
compound resembling bipolarin (5.36) was isolated. Their interpretation of the 
mass spectral data reported by Aucamp and Holzapfel 1 98 for bipolarin (5.36), 
compared to that obtained experimentally for versiconol (5.37), led them to the 
reassignment of bipolarin (5.36) to versiconol (5.37).20 1 
OH 0 OH )' .. OH 0 OH J' ,. 
l' 2' OH 
, . OH 
HO OH HO OH 
0 0 
5.36 5.37 
Differentiation between these two compounds could be easily achieved by close 
inspection of the 1 H NMR spectra. The splitting pattern of the H-2' proton would 
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be diagnostic for the differentiation of these two structures. The signal for H-2' in 
bipolarin would be inherently less complex. Unfortunately, the resolution of the 
reported 1 H NMR data in bipolarin (5.36) was not sufficient enough to confirm 
that this oxymethine signal is a doublet of doublets, rather than a multiplet. 
However, the chemical shift of H-2' (8H 5.17-5.41) in bipolarin (5.36) is consistent 
with an oxymethine rather than an alkyl methine, as required in versiconol (5.37). 
In a further complication, an alternate isomeric structure for 6,8-0-
dimethylbipolarin (5.35) was proposed in the AntiBase database.1 45 This 
compound, 5.38, was structurally different, having the oxygen located between 
positions C-3' and C-5' of the furan ring (Figure 5.17). If this is the correct 
assignment, then the H-2' methine proton would be coupled to two sets of 
methylene protons and would no longer appear as a doublet of doublets. Secondly, 
no hydrogen bond could exist between the phenolic proton of the anthraquinone 
core structure and the oxygen of the furan ring. The 1 H NMR spectrum was 
obtained from the author of AntiBase following electronic communication, and, 
after careful comparison of the spectral data, the proposed structure for 6,8-0-
dimethylbipolarin (5.35) (Figure 5.16) was unambiguously assigned to be 
identical to the 1 H data obtained, supporting the hypothesis that the oxygen is 
incorrectly positioned in the database structure. A translational error may have 
occurred during the creation of the chemical structure for entry into the database. 
However, the most recent database update for this compound displays yet another 
isomeric structure (5.39) (Figure 5.17). The oxygen is still incorrectly located 
between positions C-3' and C-5' within the furan ring, however the C-8 methoxy 
is now positioned at C-1. No stereochemistry has been indicated for either 




















Figure 5.17 :  Two structures 5.38 and 5.39 proposed for 6,8-0-dimethylbipolarin 
(5.35) as indicated by the AntiBase 1 45 database using reported numbering 
annotation. 
5. 5.3 . 1 :  Stereochemistry of 5.35 
No stereochemistry has been reported for any of the bipolarin isomers isolated in 
the literature (S.35-5.39). NOESY experiments were used to determine the 
relative stereochemistry of the furan ring system (Figure 5.18). The numbering 
system used in the NOESY experiments is identical to that used during structural 
elucidation. Irradiation of the H- 1 0  (8H 5.38) methine proton resulted in NOESY 
signal enhancement of the H-9a,b (8H 2.69, 1 .8 1 ), H-8 and H-7a (8H 2.08 and 3.97, 
respectively) methylene protons, and irradiation of the H-9a (8H 2.69) methylene 
proton NOESY enhanced both the H- 1 0  and H-7a (8H 5.38 and 3.97, respectively) 
proton signals. Irradiation of the H-7a (8H 3.97) proton NOSEY enhanced both 
H-8 and H-9a (8H 2.08 and 2.69, respectively) proton signals. This data suggested 
that H-7 a, H-9a and H- 1 0  protons must be on the same side of the ring in order to 
correlate. Due to the complexity of the methylene protons at H-8 the orientation 
could not be resolved. 
��H 
0 H 
i i i  
Figure 5.18: NOESY correlations (red) for the irradiated proton (blue) observed 
for the furan ring of 5.35, i) i1Tadiation of H- 1 0, ii) irradiation of H-9a and iii) 
irradiation of H-7a The numbering system used in identical to that used in 
structural elucidation. 
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The experimental NMR data for the isolated compound 5.35 is displayed in Table 
5.4. The numbering system assigned for 5.35 is identical to that used during 
compound elucidation and used in Table 5.4 (Figure 5.19). 
1 4  H 







Figure 5.19: The structure of 5.35 with the proposed relative stereochemistry 
assigned. Structural numbering system is consistent with that used for structural 
elucidation and Table 5.3. 
Table 5.3: The 1 H, COSY, HSQC and CIGAR NMR data for 5.35 (CDC13) .  
Position 1 3c 6 § 1H 6 r  COSY CIGAR 
1 63 .0 (C) 
2 1 05 . 1 (CH) 6 .80 (1 H ,  d, 2 .5) H-4 C- 1 3a, C-4, C-3, C-1 
3 1 65 .2  (C) 
4 1 04.0 (CH) 7.47 (1 H, d, 2 .5)  H-2 C-5 , C-4a, C-3 , C-2 
4a 1 37.0 (C) 
5 1 83 .0 (CO) 
Sa 1 32.9 (C) 
6 1 09.0 (C) 7 .23 ( 1  H, s) C- 1 2a, C-6a, C-5 , C-5a 
6a 1 6 1 .9 (C) 
OH-6a 9.80 (OH, s) 
7 68.8 (CH2) 
7a: 3.97 ( 1  H, m) H-8, H-7b C-9, C-8 
7b: 4. 1 7  ( l H , m) H-8 C-9, C-8 
8 25 .7 (CH2) 2.08 (2H, m) H-9a, H-9b, H-7a, H-7b C-9, C-7 
9 33 .0 (CH2) 
9a: 2 .69 ( 1 H, m) H- 1 0, H-9b, H-8 C- 1 1 ,  C-8, C-7 
9b: 1 .8 1  ( l H, m) H- 1 0, H-9a, H-8 C- 1 1 ,  C-8, C-7 
1 0  79.3 (CH) 5 .38 (1 H ,  dd, 2 .5 ,9.0) H-9a, H-9b C- 1 2, C- 1 1 ,  C-6a 
1 1  1 1 8 .0 (C) 
1 2  1 6 1 .8 (C) 
OH- 1 2  1 3 .80 (OH, s) 
1 2a 1 1 0.0 (C) 
1 3  t (CO) 
1 3a 1 1 5 .4 (C) 
1 4  56.8 (OCH3) 4 .0 1  (3H ,  s) C- 1 
1 5  56.2 {OCH3} 3.97 (3H ,  s} C-3 
§ 1 3C NMR chemical shift values (8 ppm from CDC13 at 77 .0) obtained from both HSQC and 
CIGAR experiments. i 1H NMR spectra recorded at 500 MHz in CDC13 (8 ppm from CHCl3 at 
7 .25), followed by number of protons, multiplicity and coupling constants (J/Hz) . t No 1 3C NMR 
chemical shift data obtained for this carbon. 
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5. 5. 4: Structural Elucidation of 5.40 
The fourth compound isolated, again as an orange powder from fraction 16-708, 
was 5.40 (3.3 mg). HREIMS identified the [Mt ion at m/z 382.1037 (calc. 
382.1053) which led to the molecular formula C21 H 1 807 , 14 Da Jess than 6,8-0-
dimethylaverufin (5.32) corresponding to 13 DBE. Close examination of the 1H 
NMR spectrum (Figure 5.20) revealed that this compound had very similar 
spectroscopic characteristics to 6,8-0-dimethylaverufin (5.32). However, only one 
methyoxy signal was present (8H 3.94). The substitution of an hydroxy for a 
methyoxy group would satisfy the requirements of the mass spectrum. The 
structures of rings C, D and E were unambiguously assigned using HSQC, 
CIGAR and COSY NMR experimental correlations (Figure 5.21), and by direct 
comparison to data obtained for 6,8-0-dimethylaverufin (5.32) (see Table 5.1 ). 
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Figure 5.20: The 1 H NMR spectrum of 5.40 (CD30D). 
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Figure 5.21: The key COSY (blue) and CIGAR (black arrows) correlations 
observed for the complete assignment of rings C ,  D and E of 5.40. 
Therefore, the structural difference between 6,8-0-dimethylaverufin (5.32) and 
5.40 had been narrowed down to being on either ring A or B. The coupling 
constant for the H-4 and H-2 (8H 7.24 and 6.78, respectively, 12,4 = 2.5 Hz) 
aromatic protons extracted from the 1 H NMR spectrum, suggested that the meta 
substitution pattern previously observed, was still present. The C IGAR 
correlations from the H-4 (8H 7.24) aromatic proton to the C-2 and C-5 (8c 1 04.5 
and 1 82.7, respectively) carbons, and the H-2 (8H 6.78) aromatic proton to the C- 1 ,  
C-3, C-4 and C- 1 3a (8c 1 63.8, 1 65.6, 1 07.8 and 1 1 2.7, respectively) carbons 









Figure 5.22: The key COSY (blue) and C IGAR (black arrows) correlations 
contributing to the assignment of rings A and B of the anthraquinone core. 
However, because the H-2 (8H 6.78) proton was correlated to both the C- 1 and C-
3 (8c 1 63.8 and 1 65.6, respectively) carbons, and no C IGAR correlation was 
observed from the H-4 (8H 7.24) proton to the C-3 (8c 1 65.6) carbon, location of 
the remaining methyoxy group was impossible with the available NMR data. 
Unambiguous assignment of the methyl group's location was achieved using the 
ROESY experiment. Irradiation of the 8H 3.94 methyoxy protons resulted in a 
positive ROESY correlation (Figure 5.23) to the H-2 (8H 6. 78) aromatic proton, 
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while irradiation of the H-2 (8H 6.78) aromatic proton gave the reciprocal 
correlation to the methyoxy protons at 8H 3.94. No ROESY correlations were 
observed when the H-4 (8H 7.24) proton was irradiated ( Figure 5.23). 
Therefore, the methyl group was positioned on the oxygen at C- 1 .  This data also 
confinned the presence of only one hydroxyl group attached to ring A, and 
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Figure 5.23 : ROESY correlations (red) for irradiated protons (*). Correlations 
not observed are denoted with an 'X'. 
A literature search 1 30• 1 45 was performed on the structure proposed for 5.40. The 
structure was an exact match for the compound 8-0-methylaverufin isolated by 
Maskey et al. in 2003 from the ethyl acetate extract of a Penicillium 
chrysogenum
1 97 (Figure 5.24, with numbering assignment as reported in the 
literature). The structure was confirmed by direct comparison of the 1 H and 1 3C 
NMR data reported for 8-0-methylaverufin (5.40). 
Figure 5.24 : Numbering assigrunent for 5.40, as reported in the literature. 1 97 
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5 .  5.4. 1 :  Stereochemistry of 5.40 
No experimental optical rotation data was reported for 5.40. 1 97 The experimental 
optical rotation data ([a] 020 = -17° (c 0.20, CHCh)) obtained was within 
experimental error of that reported in the literature for 6,8-0-dimethylaverufin 
(5.32) ([a]0 = -18° (c 0.22, CHCh). 1 96 This would suggest that the 
stereochemistry at C-11 and C-7 of 5.40 (using the numbering system in Figure 
5.25) is in the same configuration as that for 5.32. The full NMR data for the 
strucuture of 5.40 is shown in Table 5.4. 
HO 
14 H OCH3 o" 'o 
1 3 I 





Figure 5.25 : The proposed structure for 5.40 annotated with the same numbering 
used during structural elucidation and in Table 5.4. 
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Table 5.4: The 1 H,  1 3C, COSY, ROESY and CIGAR NMR data for 5.40 
(CD30D). 
Position 13C 6§ 
I 1 63.8 (C) 
2 104.5 (CH) 
3 1 65.6 (C) 
4 I 07.8 (CH) 
4a t (C) 
5 1 82 .7 (CO) 
5a 1 32.8 (C) 
6 
6a 
107.9 (CH)  
1 59.4 (C) 
7 I O I .  I (C) 
8 
9 
1 0  
I I  67. l (CH) 
I l a  1 1 6.5 (C) 
1 2  1 59.7 (C) 
OH- 1 2  
1 2a I I O. I (C) 
1 3  t (CO) 
1 3a 1 1 2 .7 (C) 
6.78 ( I  H, d, 2 .5) 
7 .24 ( 1 1 - 1 , d, 2.5) 
7.05 (I H, s) 
8a: 2.02 (I H, m) 
8b: I 86 ( J H, m) 
9a: 1 .66 (I H, m) 
9b: 1 .57 (I H, m) 
I Oa: 2.06 (I H, m) 
I Ob:  1 .86 ( I H, m) 
5.38 (I H, d, 2 .5 ,  9.0) 




H-9a, H-9b, H-8b 
H-9a, H-9b, H-8a 
H-1 Oa, H-1 Ob, H-9b, H-8a, H-8b 
H-1 Oa, 1-1-1 Ob, H-9a, H-8a, H-8b 
H- 1 1 ,  H-I Ob, H-9a, H-9b 
H-1 1 ,  H-1 Oa, H-9a, H-9b, , 
H - I Oa, H- I Ob 
CIGAR 
C- I 3a, C-4, C-3, C-1 
C-5, C-2 
C-I 2a, C-1 I a, C-6a, C-5 
C-1 5, C- 1 0, C-9, C-7 
C-1 5,  C- 10, C-9, C-7 
C-1 1 ,  C-8, C-7 
C-1 1 , C-8, C-7 
C-1 1 , C-8 
C-1 1 
C-1 2,  C-1 l a, C-9 
C-1 3 
1 4  55.5 (OCH3) 3.94 (3H, s) (H-2) C-1 
1 5  26.9 (CH3) 1 .53 (3H, s) C-8, C-7 
! 13C NMR chemical shift values (8 ppm from CD30D at 49.3) obtained from both HSQC and CIGAR experiments. f ' H  
N M R  spectra recorded a t  500 M Hz i n  CD30D (8 ppm from CD30D a t  3.3) followed by number of protons, multiplicity 
and coupling constants (J/Hz). 1 No 13C NMR chemical shi ft data obtained for these carbons. 
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5. 5. 5: Structural Elucidation of 5.41 
Compound 5.41 (2.5 mg), agam a bright orange powder, was isolated from 
fraction 16-710. HRESIMS established the [M+Ht ion at m/z 370.1061 (calc. 
370.1053 ) which led to the molecular formula C20H 1 807 , corresponding to 12 
DBE. UV data confirmed the presence of the anthraquinone core structure, while 
the 1 H NMR spectrum (Figure 5.26) suggested that 5.41 was structurally related 
to the previously isolated compounds. However, a minor difference was observed. 
This was the convergence of the two O-CH3 groups to a chemical shift of 8H 3.97. 
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Figure 5.26 : The 1 H NMR spectrum of 5.41 (CD30D). 
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Ring A was easily deduced by comparison of 1 H NMR chemical shift data, COSY 
and CIGAR correlations. The H-2 and H-4 (8H 6.92 and 7.36, respectively) were 
still COSY correlated and the coupling constant (J2,4 = 2.5 Hz) extracted from the 
1 H NMR spectrum, suggested that these protons were still meta related. Carbons 
C- 1 and C-3 were located via the observed C IGAR correlations from the H-2 (8H 
6.92) proton to the C- 1 and C-2 (8c 1 62.9 and 1 04.8, respectively) carbons. The 
1 4-0CH3 and 1 5-0CH3 groups were located at C- 1 and C-3, respectively based 
on the observed C IGAR correlations from H- 1 4  and H- 1 5  (8H 3.97 and 3.97) to 
the C- 1 and C-3 (8c 1 62.9 and 1 65.6, respectively) carbons, respectively. The 
C IGAR correlations from the H-4 (8H 7.36) proton (8H 7.36) to the C-3, C-5 and 
C- 1 3a (8c 1 65.6, 1 82.3, 1 63.9) carbons led to the assignment of partial structure 
ring A (Figure 5.27). The chemical shift of C-4a was not able to be assigned with 
the available N MR data. 
Rings B and C were elucidated via CIGAR correlations from the H-6 (8H 7.09) 
proton to the C-5, C- 1 1  and C- 1 2a (8c 1 82.3, 1 2 1 .9 and 1 1 0. 1 ,  respectively) 
carbons. An hydroxyl group was tentatively positioned at C- 1 2, due to the 
presence of a hydrogen bonded phenolic proton signal at 8H 1 4. 1 2, and because of 
the chemical shift of C- 1 2  (8c 1 62.8). At this point of the structural assignment, 
1 1  of the required 1 2  DBE had been accounted for ( Figure 5.27). 
Figure 5.27 : Key C IGAR (black arrows) and COSY (blue lines) correlations 
leading to the assignment of rings A, B and C. 
A partial structure C- 1 1 to C-7 (Figure 5.28) was constructed from the COSY, I D  
and 2D TOCSY experiments. COSY cross peak correlations were observed from 
the oxymethine proton H- 1 0  (8H 5.32) to the H-9 (8H 1 .92) protons, while the H-
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8a,b (OH 1 .76 and 1 .65) methylene protons were in turn COSY correlated to both 
the H-7 and H-9 (oH 3.60, 1 .92) methylene protons. 
The position of the H- 1 0  oxymethine proton was determined by the observed 
C IGAR correlations from the H- 1 0  (oH 5.32) oxymethine proton to the C-6a, C- 1 1 , 
and C- 1 2  (oc 1 6 1 .6, 1 2 1 .9 and 1 62.8, respectively) carbons, which connected this 
fragment to the anthraq uinone core structure. The C- 1 0  to C-7 partial structure 
tenninates with a methylene unit (C-7) not a methyl, therefore, in order to satisfy 
the one remaining DBE requirement, as determined by the molecular formula, it 
was proposed that C-7 must connect back into the anthraquinone core forming a 
fourth ring. This seven-membered ring, ring D, was therefore connected through 
the oxygen located at the C-6a position into the anthraquinone core structure, as 
shown in Figure 5.28. The chemical shift of C-7 (oc 6 1 .6) also validates this 
hypothesis. 
H 0 H 
Figure 5.28: Connectivity of partial structure C- 1 1  to C-7, ring-D, with key 
COSY (blue) and CIGAR (black arrows) correlations. 
A series of 1 D TOCSY experiments (Figures 5.29 and 5.30) were utilized to 
confirm the linear sequence from H- 1 0  to H-7. The H- 1 0  (oH 5.32) oxymethine 
proton was irradiated and consecutive correlations were observed as the mixing 
time was increased from 0.005 ms to 0.08 ms. The first correlation observed at 
T l  (0.005 ms) consisted of a correlation from the H- 1 0  (oH 5.32) oxymethine 
proton to the H-9 (oH 1.92) methylene protons, followed by the H-8a,b (oH 1 . 76, 
1 .65) methylene protons. At T2 (0.08), the final correlation corresponding to the 
H-7 (oH 3.60) methylene protons was observed (Figure 5.29). 
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H-10 (oH 5.32) 
~Peak irradiated (Tl) 
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 ppm 
H-10 (oH s.32) 
~Peak irradiated (T2) 
5.5 s.o 4.S 4.0 3.S 3.0 2.s 2.0 ppm 
Figure 5.29: TOCSY correlations for irradiated proton H-10 (oH 5.32) at mixing 
times Tl (0.005 ms) and T2 (0.08 ms). 
The H-10 to H-7 sequence was further confirmed by irradiation of the H-7 (oH 
,~ 
3.60) methylene protons (Figure 5.30) with the same mixing times used in the 
previous TOCSY experiment. Correlations were observed at Tl (0.005 ms) from 
the H-7 (oH 3.60) methylene protons to both H-8a,b (oH 1.76, 1.65) and H-9 (oH 
1.92). At mixing time T2 (0.08 ms) the final correlation to the oxyrnethine at H-
10 (oH 5.32) was observed. 
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H-7 (8H 3 .60) 
� Peak irradiated (TI) 
H-8a(8H l .76) 
H-9 (S, 1 .9
\�-7 
(o, 1 .65) 
" ·� .... r,-,...._ ___ ......, _____ ._ ______ ...,._.,.........,.._.. ......... _ .. ..,.., __A_AA.,_.,_ ... ... . .. ... . .. 2.0 
H-7 (8H 3.60) 
� Peak irradiated (T2) 
� H-10 (oH 5 .32) 
5.0 ... ,.o 3 .. 3.0 , .. l.O PP• 
Figure 5.30: TOCSY correlations for irradiated proton H-7 (8H 3.60) at mixing 
times T l  (0.005 ms) and T2 (0.08 ms). 
A structure for compound 5.41 was proposed. A literature search 1 30• 1 45 for 5.41 
returned no exact matches. The novel compound was tentatively named 5,6-
dihydroxy-1,3-0-dimethoxy-2,3 ,4,5-tetrah ydro-1-oxa-cyclohepta[ b ]-anthracene 
(5.41), using the numbering system assigned for structural elucidation. 
ocH3 o-- H 'o HO 
H 13 I 
H O H 
5.41 
8 
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5. 5.5. 1 :  Stereochemistry of 5.41 
Optical rotation measurements indicated that a racem1c mixture was present 
([a]o25 = 0.00° (c 0.05 CHCl3)). 
Compound 5.41 was subjected to a NOESY l D  experiment in order to confirm 
that a racemic mixture was present. It was anticipated that irradiation of the H- 10 
(8H 5.32) proton would enhance both of the H-8a,b (8H 1.76, 1.65) methylene 
protons, indicating that C-10 (8c 68.3) exists in both the (R) and (S) 
configurations. During the NOESY experimental setup procedure it was observed 
that the 1 H NMR spectrum recorded for 5.41 was different to that obtained during 
the initial structural elucidation process. This degradation compound (5.42) on 
closer inspection revealed a second phenolic proton signal at 8H 10.25 (Figure 
5.31), similar to that observed for both 6,8-0-dimethylaverufanin (5.34) and 6,8-
0-dimethylbipolarin (5.35). The 1 H NMR spectrum of 5.42 was obtained in 
CDC13 as it was no longer soluble in CD30D, the solvent the original data was 
recorded from. 




Figure 5.31: The 1 H NMR spectrum of S.42 (CDCh). 
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The appearance of the new proton signal suggested that a structural rearrangement 
had occurred. Compound 5.42 was not fully characterised by NMR analysis. One 
possible mechanism for the conversion of 5.41 to 5.42 which accounts for the 
observed additional signal involves the opening of the seven-membered ring, 
followed by cyclisation to form a more thermodynamically stable five-membered 








H 0 H 
H O H 
5.42 
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H 0 H 
H 0 H 
Figure 5.32: The formation of the degraded compound 5.42, containing a more 
thermodynamically stable five-membered ring, via hydrolysis of 5.41 followed by 
the intramolecular loss of H20. 
Closer inspection of the 1 H NMR signals at 8 1 -1 5.34 to 5 .44 revealed a pair of 
doublet of doublets, this suggested that each signal was associated with the H-10 
proton in either the (R) or (S) configuration. This would validate the optical 
rotation data indicating that 5.41 was racemic. As before the NOESY experiment 
was used to irradiate the H-10 (8H 5.34 and 5.44) protons in an attempt to observe 
the NOESY enhanced correlations for the H-8 protons (8H 1. 76 and 1.65), 
however no NOESY correlations were observed. 
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The full experimental NMR data for 5.41 is displayed in Table 5.5. The structure 
is annotated with the arbitrary numbering system used for the structural 
elucidation (Figure 5.33). 
H 
8 
H 0 H 
Figure 5.33: The proposed structure of 5.41 with arbitrary numbering system 
used for structural elucidation and Table 5.5. 
Table 5.5 : The 1 H, 1 3C, COSY and CIGAR NMR data for 5.41 (CD30D). 
Position 13C o § 'H o t  COSY CIGAR 
1 62 .9 (C) 
2 1 04 8 (CH) 6.92 (I H, d, 2 .5)  H-4 C-1 3a, C-4, C-3 , C- 1 
3 1 65.6 (C) 
4 1 04.8 (CH) 7.36 (I H, d, 2 .5)  H-2 C-I 3a, C-5, C-3, C-2 
4a t 
5 1 82 .3 (CO) 
Sa 1 33 0 (C) 
6 I 07.7 (CH) 7.09 ( 1 H, s) C- l 2a, C-1 I ,  C-6a, C-5, C-5a 
6a 1 6 1 .6 (C) 
7 6 1 .6 (CH2) 3 .60 ( I  H, m) H-8a, H-8b C-9, C-8 
Sa: 1 .76 (I H, m) H-9, H-8b, H-7 C-9, C-7 
8 28.9 (CH2) 
Sb : 1 .65 ( I  H, m) H-9, H-8a, H-7 C-9, C-7 
9 32.5 (CH2) 1 .92 (2H, m) H- 10, H-8a, H-8b, C- 10 ,  C-8, C-7 
1 0  68.3 (CH) 5 .32 (I H, dd, 2.5, 5)  H-9 C- 1 2 , C- I I , C-9 
I I  1 2 1 .9 (C) 
1 2  1 62 8 (C) 
1 2a 1 1 0 . I  (C) 
OH- 1 2  1 4. 1 2 (0H, s) 
1 3  1 63 .9 (C) 
1 3a 1 1 4.4 (C) 
1 4  55 .7 (OCH3) 3 .97 (3H, s) C- 1 
1 5  55 .7 (OCH3) 3 .97 (3H, s) C-3 
13C NMR chemical shif1 values (8 ppm from CD300 at 49.3 ) obtained from both HSQC and CIGAR experiments. PH  
NMR spectra recorded a t  500 MHz in CD300 (8  ppm from CD300 a t  3 .30) followed by  number of  protons, multiplicity 
and coupling constants (J/Hz). t No 13C M R  chemical shif1 data obtained for this carbon. 
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5. 6: Biological Activity 
All of the purified compounds were submitted for biological activity assessment 
in the P388 (murine leukaemia) assay the results of which are shown in Table 5.6. 
Table 5.6: P388 Activity for the compounds isolated from the organic extract of 













No biological data was obtained for the degraded compound 5.42. As expected, 
compounds located in the area of activity determined by the initial microtitre plate 
assay (P388) of the crude extract were biologically active, however 5.32, eluting 
at 23 minutes, was not within this region but displayed significant activity when 
submitted as a pure compound. The novel compound 5.41 did not display any 
significant P388 activity. 
5. 7: Concluding Remarks 
The aim of this section of work was to isolate and identify the compound(s) 
responsible for the observed biological activity (P388) associated with the crude 
extract of the marine fungi Aspergillus sp. isolated from the tissue of the Antarctic 
marine sponge Kirkpatrickia varialosa (WS 76). 
Initial bioassay guided fractionation (HPLC microtitre plate collection) located 
regions of activity in the HPLC chromatogram corresponding to compounds 
displaying a variety of polarities. UV data revealed that the compounds were 
related, and displayed a chromophore consistent with that of an anthraquinone 
core. Mass and UV data did not narrow the database search profile sufficiently, as 
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more than 100 possible compounds were identified. Therefore, further 
purification was deemed necessary to unambiguously characterise the compounds 
responsible for the observed activity. 
Several steps of chromatography, including DIOL flash chromatography followed 
by semi-preparative reversed phase (C 1 8) HPLC chromatography, yielded six 
compounds. Structural elucidation of these six compounds was achieved with the 
use of 1 H, 1 3C, COSY, lD-TOCSY, NOESY, ROESY, HSQC and CIGAR NMR 
spectroscopy, high resolution ESI mass spectrometry, and subsequent 
comparisons with chemical shift data published for similar compounds. 
The two novel compounds 6-8-0-dimethylbipolarin (5.35) and 5,6-dihydroxy-1,3-
0-dimethoxy-2,3,4,5-tetrahydro-l -oxa-cyclohepta[ b ]anthracene (5.4 1 )  were 
isolated, along with the known compounds 6,8-0-dimethylaverufin (5.32), 6,8-0-
dimethylaverufanin (5.34) and 8-0-methylaverufin (5.40). 
This series of work revealed several areas in the literature that require revising. 
1) The compound 6,8-0-dimethylaverufin (5.32) was reported as a new 
metabolite isolated from the fungus Emericella foeniculicola by Maebayashi et 
al. 1 96 in 1985, however this compound was reported earlier by Holker et al.1 93 in 
1966 after having been isolated from a UV mutated fungus Aspergillus versicolor. 
2) The compound 8-0-methylaverufin (5.40) reported by Maskey et al. 1 97 as a 
new metabolite from the ethyl acetate extract of the fungus Penicillium 
chrysogenum in 2003 had also been previously isolated by Holker et al.1 93 from an 
A .  versicolor mutant in 1966. 
3) The structure of bipolarin (5.36), suggested by Aucamp and Holzapfel 1 98 in 
1970 was incorrectly reassigned by Mayes et al.201  in 1984. The reassignment 
was made on the basis that the structure of bipolarin (5.36) was not consistent 
with the currently accepted biosynthetic pathway to higher metabolites. Therefore, 
Mayes et al. 20 1 concluded that the pigment called bipolarin (5.36) was identical 
with the subsequently discovered compound versiconol (5.37) although the NMR 
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data strongly indicates that these are two distinct compounds. Bipolarin (5.36) 
was prepared synthetically in 1977 by Castonguay and Brassard.200 Although an 
authentic sample of bipolarin (5.36) was not available, they report that physical 
and spectral properties of the synthetic compound were in excellent agreement 
with those reported by Aucamp and Holzapfel 1 98 for the original natural product. 
4) Alternative isomeric structures have been reported in the AntiBase database 
for 6,8-0-dimethylbipolarin (5.35), where the oxygen is located between the C-3' 
and C-5' of the furan ring (5.38) (using the reported structural numbering 
assignment). Analysis of the original 1 H NMR spectrum of 6,8-0-
dimethylbipolarin (5.35), supplied by the author, supported the hypothesis that the 
oxygen is incorrectly positioned in the database structure. Nevertheless, the most 
up to date database still has the oxygen positioned between C-3' and C-5 ' within 
the furan ring, although the methoxy previously postioned at C-8 is positioned at 
C-1 (5.39). No stereochemistry was reported for either compound 5.38 or 5.39. 
Partial stereochemical assignments were determined for 6,8-0-
dimethylaverufanin (5.34) and 6,8-0-dimethylbipolarin (5.35) via comparison of 
optical rotations with reported data along with l D  NOESY experiments. 
All purified compounds were assessed in-house for cytotoxic activity in the P388 
assay. The compound 5.41 did not display any biological activity (ICso > 12.5 
µg/mL). This result was expected as this compound was identified as being 
outside the area of activity indicated by the initial microtitre plate assay (P388). 
Suprisingly, 5.32, was cytotoxic (IC50 7.5 µg/mL) when submitted for assay 
despite being located outside the areas of activity on the microtitre plate assay. 
Anthraquinones represent an important group of anti-cancer drugs that display a 
wide spectrum of activity and have great potential in the field of cancer 
chemotherapy.202 These compounds undergo addition and substitution reactions, 
with direct activity on cellular nucleophiles such as thiols. Their primary mode of 
action is the damage of cellular DNA. Many of these compounds, such as 
doxorubicin ( 1 . 1 6), exert their activities through a number of mechanism such as 
redox cycling (resulting in generation of reactive oxygen species), direct 
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intercalation into DNA and inhibition of the enzyme topoisomerase II.202 
Doxorubicin (1.16) has shown a wide range of activity in solid human tumours, 
such as the breast, lung, ovary, head and bladder, and is currently the most 
effective single agent against soft-tissue sarcomas in adults.202 This preclinical 
position is likely to be challenged, however, when the first marine anti-cancer 
drug ecteinascidin 743 (Yondelis™ 1.67), developed by PharmaMar, is licensed, 
most likely in 2006. Yondelis™ (1.67) is also very effective against soft-tissue 
scarcomas. Clearly anthraquinones represent an important class of therapeutic 
agents and warrant further investigation. 
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5. 8: Summary of Isolation 
Aspergillus sp (WS 76) 
EtOAc ExtracllOn (228.8 mg) 




1 'r1 M1°"1 r MeOH/H,O 
Fraction # I 2 3* 4 5* 6 7 8* 9 10*  I I  1 2  1 3  14 1 5  1 6  1 7  
Mass (mg) 2.2 0.4 78.6 1 3.9 1 5.6 26.6 6.3 5.2 4.7 5.4 6.2 6.5 4. 1 0.9 10.3 34.5 20.2 
I I 
Semi-preparative (C 1 8) 
Chromatography 
65"o Acetonitrile in water _J 
I 
Semi-preparative (C18) 
I S.3S (3. 1  mg) J.l�/�f,'.
�
�P;Xer 
5.32 (4.4 mg) 5.40 (3.3mg) 5.34 (3 .4 mg) 
5.4 1 (2.5 mg) 
1 87 
Scheme 5.1: Chromatographic purification summary for the Antarctic marine 
sponge-derived (Kirkpatrickia varialosa) fungus Aspergillus sp. *Fraction 
contains biologically active compounds of interest. 
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CHAPTER 6 
ISOLATION OF COMPOUNDS FROM THE 
ANTARCTIC MARINE SPONGE-DERIVED 
FUNGUS Ulocladium sp . (WS 132) 
6. 1 :  General Introduction 
The fungal genus Ulocladium is widely distributed throughout nature, most 
commonly being isolated from soil and decaying herbaceous material. 
Ulocladium has at least seven species described, two of which are associated with 
causing disease in both healthy and immunocompromised patients. 203 The most 
common clinical manifestations associated with Ulocladium sp. are subcutaneous 
· fi · d · d" 203 204 m ect10n an respiratory 1sease. 
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Literature relating to biologically active compounds isolated from Ulocladium spp. 
is limited, with only a handful of biologically active compounds having been 
reported to date. 
The tyrosine kinase (TK, p56 Jck) inhibitor ulocladol (6. 1 ), along with the related 
compound botrallin (6.2), were isolated from the fungus Ulocladium botrytis 
derived from the marine sponge Callyspongia vagina/is collected in the Caribbean, 
by Holler et al. 205 Since p56Jck is necessary for T-cell activation, inhibition by 
compounds like ulocladol (6. 1 )  could prove useful for treating autoimmune 
diseases. 1 0 Botrallin (6.2), has also been reported previously from the fungus 
Botrytis allii by Kameda et al.206 However, it was only tentatively identified from 
the extracts of Ulocladium botrytis by 1 H NMR spectroscopy and ESI mass 









Ulocladol A (6.3) and ulocladol B (6.4), novel terpenoid compounds, were 
isolated from the culture filtrate of Ulocladium chartarum.207 Both of these 
compounds are structurally related to the host-specific phytotoxins of Alternaria 
citri, a morphologically related genus. 







Alternaria infectoria, a filamentous fungal isolate, was chemical ly investigated by 
Larsen et al. as this species was recognised as the most common fungus infecting 
barley.208 Infection of cereals and feedstuffs is of increasing concern as these 
fungal species are capable of producing a broad range of secondary metabolites 
that have an impact on human health. The compound infectopyrone ( 6.5) was 
isolated and characterised from the isolate of Alternaria infectoria. During this 
investigation, HPLC screening of Ulocladium isolates showed that Ulocladium 
consortiale could also produce infectopyrone (6.5) .208 However, no cytotoxic 





The Ulocladium sp. specimen (WS 132) isolated from an Antarctic marine sponge 
was targeted for further investigation due to the lack of literature relating to 
biologically active compounds isolated from the Ulocladium genus. This hinted 
strongly at the possibility of discovering new chemistry. 
Work in this chapter focused on the isolation and structural elucidation of the 
biologically active compounds present in the extract. As a result, six compounds 
were isolated via bioassay guided fractionation (HPLC microtitre plate P388 assay) 
of the crude extract. These were comprised of three previously reported 
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compounds trypacidin (6.6),209•2 1 0  sulochrin-2'-0-methyl ether (6.7)2 ' 8 and 
pseurotin A (6.16),2 1 1 -2 1 6  along with three previously unreported compounds: 
asterric acid-3'-0-methyl ether (6.9), methyl asterrate-3'-0-methyl ether (6.13); 
and the methyl asterrate-4-0-acetyl-3'-0-methyl ether (6.15). 
6.2 :  Introduction 
The fungus Ulocladium sp. (WS 1 32) was derived from the Antarctic marine 
sponge Mycale acerata, collected at McMurdo Sound, Ross Island, Antarctica, at 
a depth of 25-30 m by SCUBA. The sponge tissue was sliced into cubes (5 mm), 
and placed onto fungal-specific media and incubated at 26 °C until cultures 
appeared. The EtOAc extract of the small-scale culture displayed anti-tumour 
activity (IC50 6 µg/mL). The isolate was re-cultured on brown rice (500 g) to 
obtain enough material for extraction and structural elucidation of the compound(s) 
responsible for the observed activity. 
6. 3 :  Extraction of the Antarctic Marine Sponge­
derived Fungus Ulocladium sp. (WS 132) 
The solid culture rice medium (500 g) of WS 1 32 was extracted with various 
combinations of the solvents EtOAc, DCM and MeOH. The extract was filtered 
through a bed of celite after homogenization. The solid material was then re­
suspended and extracted a further two times with the same solvent combinations. 
The solvent was removed under vacuum to yield a deep green extract ( 1 .54 g). 
The organic extract was subjected to further analysis via HPLC microtitre plate 
assay (P388). The region of activity corresponded to the compounds eluting 
between 1 1 .5 and 1 4.8 minutes (Figure 6.1). Four major compounds were 
contained within this region of activity, consisting of approximately half of the 
mass detected in the entire organic extract of WS 1 32 (Evaporative Light 
Scattering Detection (ELSD)). UV spectra (Figure 6.2) were obtained for 
compounds within the region of activity via HPLC PDA (CH3CN/H20, 0.05 TF A). 
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The chromophores of the major components eluting between 14 and 15 minutes 
were similar, with A.max at both 215 and 285 nm, while the compound at 14.76 
minutes displayed an extended chromophore with an additional maximum at 432 
nm. This data suggested that these compounds were structurally related and 
possessed aromaticity. The compound eluting at 12.96 minutes seemed umelated, 
with a A.max at 205 . Analysis of these compounds by LCMS of the crude extract 
resulted in ion mass peaks ranging from 320 to 450 mass units. Over 11 ,000 
compound matches were found in the AntiMarin database, searching on the mass 
parameters. Addition of the UV data narrowed the list of possible structures to 67, 
which still encompased a wide variety of structural classes. At this point of the 
isolation, no further structural information was available to supplement the search 
parameters and restrict the number of possible compound candidates. It was 
unlikely that an unambiguous identification of these compounds could be 
achieved, therefore it was determined that further purification of the compounds 
was necessary. 
mA~U~--------------------------
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Figure 6.1: HPLC trace of crude organic extract of WS 132 (blue). The region 
of biological activity indicated between 11.5 and 14.8 minutes (black) as 
determined by microtitre plate analysis (P388). 
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Figure 6.2: UV profiles of the major compounds observed in the region of 
biological activity (11.5 to 14.8 minutes), as determined by microtitre plate 
analysis (P388). 
6. 4: Chromatographic Isolation of Bioactives 
6.4.1: Reversed Phase (C18) Flash Chromatography of the 
Organic Extract of the Antarctic Marine Sponge-
derived Fungus Aspergillus sp. (WS 132) 
The organic extract (1.54 g) was dissolved in a minimum volume of solvent and 
loaded onto a reversed phase (C 18) flash chromatography column. The column 
was equilibrated to 90 % H20/10 % MeOH, and eluted using a steep stepped 
solvent gradient consisting of varying mixtures of H20 , MeOH and DCM. The 
column was washed clean of any remaining material with MeOH and DCM (0.1 
% TFA). All twelve fractions collected were analysed on a reversed phase (C1 s) 
HPLC column to locate the fractions that contained the peaks responsible for the 
observed activity, as identified by the initial microtitre plate assay analysis. 
Fractions wjm23- l 007 and wjm23-1008 were recognised to contain the 
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compounds of biological interest. Due to their complexity, these two fractions 
required further chromatographic purification. 
6. 4. 2: Reversed Phase (C18) Semi-preparative HPLC 
Chromatography of Fractions wjm2 3- 1 00 7 and 
wjm23- 1 008 
Fractions wjm23-1007 and wjm23-1008 were combined (wjm23- 1 007-8), based 
upon the HPLC analysis, and dissolved in a minimum volume of MeOH. During 
storage at 4 °C, crystalline material formed in the methanolic solution. This 
fraction was filtered, and the crystals (wjm23- l 007-8.xtl) were collected and 
analysed by 1 H, 1 3C and 2D NMR spectroscopy and mass spectrometry. 
Structural elucidation of the purified compound (6.6) (corresponding to peak 
number 2) is described in Section 6.5.1. 
Fraction wjm23-1007-8, the supernatant, was further purified by reversed phase 
(C 1 8) semi-preparative HPLC chromatography using a gradient solvent system 
ranging from 30 % CH3CN/H20 to 55 % CH3CN/H20 (0.05 % TF A) over 25 
minutes. The gradient solvent system had been developed on the analytical HPLC 
for maximum resolution of the eluting compounds. Seven fractions were 
collected as peaks eluted (Figure 6.3), however, both peaks one and seven were 
outside the region of activity as determined by HPLC microtitre plate analysis. 
The purity of the collected compounds was confirmed by re-injection onto the 
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Figure 6.3: HPLC trace of combined fractions wjm23- l 007 and wjm23- l 008 
after elution gradient development. The seven fractions of interest are indicated. 
Insufficient material from the first fraction was collected to allow for structural 
elucidation. Only peaks numbered two to seven were subsequently examined by 
1 H, 1 3C and 2D NMR spectroscopy and ESI mass spectrometry. Structural 
elucidation of these purified compounds is discussed in Section 6.5 . 
6. 5: Structural Elucidation o
f 
Compounds Isolated 
from the Antarctic Marine Sponge-derived 
Fungus Ulocladium sp. (WS 132) 
6. 5. 1 :  Structural Elucidation of 6. 6 
The first compound, (6.6), which had crystallised from MeOH (co1Tesponding to 
peak number two), was separated from the filtrate of the combination of fractions 
wjm23- 1 007 and wjm23- 1 008 as white needles (6.0 mg). HRESI mass 
spectrometry identified a [M+Ht ion at m/z 345.0987 (calc. 345.0974) which Jed 
to the molecular fo1mula C 1 8H 1 707, possessing 1 1  DBEs. The 1 3C NMR ( Figure 
6.4) combined with the HSQC identified 1 8  well defined carbon signals 
corresponding to three carbonyl carbons (8c 1 90.5 ,  1 85 .7 and 1 69.5), one s/ 
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quaternary carbon (8c 84.0), six s/ quaternary carbons (8c 174.2, 163.4, 158.2, 
152.2, 138.0 and 108.0), four s/ methine carbons (8c 137.2, 105.5, 105.3 and 
103.9), three methoxy carbons (8c 56.6, 55.9 and 52.7) and one methyl carbon (8c 
23.3), satisfying the carbon requirements of the molecular formula. The presence 
of three methoxy groups (8H 3.94, 3.68 and 3.66) and one methyl (8H 2.44) group 
was confirmed by the presence of four singlet signals visible in the 1 H NMR 
spectrum (Figure 6.5). The remaining proton signals were located in the 
olefinic/aromatic region (8H 7.01, 6.55, 6.37 and 5.77) .  These 16 protons satisfied 
the proton requirements of the molecular formula, leaving just one oxygen atom 
to assign. 
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Figure 6.4 : The 1 3C NMR spectrum of compound 6.6 (CDC13) . 
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Figure 6.5 : The 1 H NMR spectrum of compound 6.6 (CDCh). 
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Connectivity of the carbons from C-3 to C-5 was achieved by close inspection of 
both the 1 H NMR and COSY spectra. A COSY cross peak correlation was 
observed from the H-3 (8H 7.0 1 )  proton to the H-5 (8H 5.77) proton, combined 
with the small coupling constant extracted from the 1 H NMR spectrum (J3,5 = 1 .5 
Hz), initially suggested that these protons (H-3 and H-5) might be meta to one 
another on an aromatic ring system. However CIGAR correlations from both of 
the H-3 and H-5 (8H 7.0 1 and 5 .77, respectively) protons to the C-4 (8c 1 85.7) 
carbonyl carbon indicated that the suspected ring system was not aromatic. The 
chemical shift of C-4 (8c 1 85 .  7) suggested the presence of a ketone functionality 
at this position. Therefore H-3 and H-5 were assigned as olefinic not aromatic, a 
to the ketone moiety at C-4. The methoxy group (8H 3.68) was assigned at 
position C-2 on the basis of the observed CIGAR correlations from both the H-3 
(8H 7.0 1 )  olefinic proton and the H-9 (8H 3.68) methyl protons to the C-2 (8c 
1 63 .4) carbon, and also confirmed by the observed NOE signal enhancement of 
the H-9 (8H 3.68) methyl protons following irradiation of the H-3 (8H 7.0 1 )  
olefinic proton. The partial structure for 6.6, ring A was proposed on the basis of 
this N MR data ( Figure 6.6). 
Figure 6.6 : Partial structure of 6.6, ring A, showing key COSY (blue), C IGAR 
(black) and NOESY (red) experimental correlations. 
The remaining atoms of ring A were assigned utilising the CIGAR experiment. 
Carbons C- 1 ,  C-6 and C-7 were assigned by the observed CIGAR co1Telations 
from the H-5 (8H 5.77) methine proton to the C-7 carbonyl and C- 1 quaternary 
carbons (8c 1 69.5 and 84.0, respectively), together with a weak correlation to the 
C-6 (8c 1 3  8.0) carbon. The methyl ester consisting of the C-7 carbonyl and C-8 
methyl carbons (8c 1 69.5 and 56.6, respectively) was positioned on the C-6 
carbon, based on a NOESY correlation between the H-8 (8H 3.66) methyl protons 
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and the H-5 (8H 5. 77) olefinic proton, combined with the CIGAR correlations 
from the H-8 methyl protons (8H 3.66) to the C-7 (8c 169.5 ) carbonyl carbon. The 
C-1 carbon position was confirmed via the CIGAR correlation from the H-3 (8H 
7.01) protons to the C-1 (8c 84.0) carbon. The HSQC spectrum confirmed that 
the C-1 carbon was quaternary, while the 1 3C chemical shift suggested that this 
b · 191 h d car on was a sp1ro centre. T e complete ring, A, was therefore proposed for 
6.6 (Figure 6.7). 
0 
Figure 6.7: Ring A proposed for 6.6, with key COSY (blue), CIGAR (black) and 
NOESY (red) experimental correlations. 
The assignment of ring C was achieved by careful examination of the NOESY 
and CIGAR spectra. Carbons C-1' and C-5 '  were assigned using the observed 
CIGAR correlations from the H-3' (8H 6.37) proton to the C-1' and C-5 '  carbons 
(8c 108.0 and 8c 105.5, respectively), while the CIGAR correlation from the H-5 ' 
(8H 6.55) proton to the C-1' and C-3' (8c 108.0 and 105.3 respectively) carbons 
confirmed the assignment of the C-1' and C-3' positions. Irradiation of the H-3' 
(8H 6.37) aromatic proton resulted in two NOESY enhanced signals corresponding 
to both of the H-7' and H-8' (8H 3.94 and 2.44, respectively) methyl protons, 
placing the H-3' proton between these two functionalities, while the H-8' methyl 
group was positioned between both H-3' and H-5' based upon the NOESY 
enhanced signals observed after irradiation of the H-8' (8H 2.44) protons, which 
resulted in the signal enhancement of both the H-3' and H-5 '  (8H 6.37 and 6.55, 
respectively) aromatic protons. The H-8' (8H 2.44) aromatic methyl protons were 
tentatively positioned at C-4' (8c 152.2), based upon the CIGAR correlation from 
the H-8' (8H 2.44) methyl protons to the C-4' (8c 152.2) aromatic carbon. The H-7' 
(8H 3.94) methyoxy group was positioned at C-2' (8c 158.2) based upon the 
previously observed NOESY correlation from the H-7' (8H 3.94) protons to the H-
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3' (8H 6.37) proton combined with the additional CIGAR correlation from the H-7' 
(8H 3.94) proton to the C-2' (8c 158.2) aromatic carbon. The remaining aromatic 
carbon (8c 174.2) was detennined by a 2JcH CIGAR correlation from the H-5' (8H 
6.55) proton to the C-6' (8c 174.2) sp2 carbon. From this data the substitution 
pattern for the aromatic ring, ring C was proposed for 6.6 ( Figure 6.8). 
Figure 6.8: Proposed partial structure, ring C of 6.6, with key CIGAR (black) 
and NOESY (red) experimental correlations. 
However, because ring C does not possess any symmetry (i.e. the functional 
groups on C-1' and C-6' are not equivalent, by the requirements of the molecular 
formula and the carbon chemical shifts), there are two possible aromatic ring 
substitution patterns ( Figure 6.9). 
The experimental C IGAR data confirmed that both the H-5 '  and H-3' (8H 6.55 and 
6.37, respectively) aromatic protons are 3JcH correlated to the C-1' (8c 108.0) 
carbon, while the H-5' (8H 6.55) proton is 2JCH correlated to the C-6' (8c 174.2) 
carbon. The proposed substitution pattern for ring C was therefore validated as 
shown in Figure 6.9. 
Figure 6.9: The partial structure, ring C of 6.6, with key C IGAR correlations in 
black used to assign the substitution pattern. 
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The atoms left to assign, as determined by the molecular formula, consisted of one 
oxygen and one carbon (8c 190.5) atom. The 1 3C chemical shift of this carbon 
suggested that it was part of a carbonyl group. Its assignment was achieved 
through the very weak CIGAR correlation observed from the H-3' (8H 6.37) 
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Figure 6.10: The 4JCH CIGAR correlation observed from aromatic proton H-3' 
(81-1 6.37) to the C-10 (8c 190.5) carbonyl carbon (CDCh). 
As no further atoms were left to assign (as determined by the HRESI derived 
molecular formula), ring B was tentatively assigned as a furanone. The proposed 
connectivity of the spiro center at C-1 (8c 84.0) to ring A was through both the C-
6' oxygen and the C- 1 0  (8c 190.5) carbonyl carbon to the C-1 (8c 84.0) quaternary 
carbon. The structure as shown in Figure 6.11, was proposed for compound 6.6 
which also satisfied the remaining DBE requirement. 
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Figure 6.11: The very weak CIGAR correlation observed from the H-3' (6.37) 
aromatic proton to the C- 10 (8c 190.5) carbonyl carbon, completing the 
assignment of the proposed structure for 6.6. 
A literature search 1 30' 1 4 5  on the proposed structure for compound 6.6 revealed that 
a compound with an identical structure, trypacidin, had been isolated as a new 
antibiotic from the fungal culture of an Aspergillus fumigatus collected from a 
sample of Chinese soil in 1963.2 1 0 Trypacidin (6.6) had been identified by the use 
of various physical and spectroscopic experiments including melting point, UV 
and IR spectroscopy, elemental analysis and mass spectrometry combined with 
salting-out paper chromatographic techniques. The 1 H NMR data of trypacidin 
(6.6) was presented several years later by Balan et al.,209 where their NMR 
assignments were supported by previous studies of similar compounds, 
griseofulvin derivatives. 2 1 7  
The literature numbering system for trypacidin (6.6) used in the structural 
elucidation, is shown in Figure 6.12, while the experimental 1 H, 1 3C, COSY, 
NOESY and CIGAR NMR data are shown in Table 6.1. 
0 
Figure 6.12: Numbering system of trypacidin (6.6) used in Table 6.1. 
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Table 6.1: The 1 H, 1 3C, COSY, NOESY and CIGAR NMR data for compound 
trypacidin (6.6) (CDC13). 
Position 
1 84.0 (C) 
2 1 63 .4 (C) 
COSY 
(NOESY) 
3 1 37 .2 (CH) 7.01 ( l H, d, 1 .5) H-5 (H-9) 
4 1 85 .7  (CO) 
5 1 03 .9  (CH) 5 .77 ( l H, d, 1 .5 )  H-3 (H-8) 
6 1 38 .0 (C) 
7 1 69.5 (CO) 
8 56 .6 (OCH3) 3 .66 (3H, s) 
9 52 .7 (OCH3) 3 .68 (3H, s) 
1 0  1 90.5 (CO) 
l '  1 08 .0 (C) 
2' 1 58 .2  (C) 
3' 1 05 .3  (CH) 
4' 1 52 .2 (C) 
5' 1 05 .5  (CH) 
6' l 74.2(C) 
6 .37 ( l H, s) 






C-5, C-4, C-2, C-1 
C-7, C-6 (w), C-4, C-3, C- 1 
C-7 
C-2 
C- I O(vw), C-8', C-5', C-2', C- 1 '  
C-8', C-6', C-3', C- 1 '  
7 '  55 .9 (OCH3) 3 .94 (3H, s )  (H-3') C-2' 
8' 23.2 (CH3) 2 .44 (3H, s) (H-5', H-3') C-5', C-4', C-3' 
§ 1 3C NMR spectra recorded at 1 25 MHz in CDC13 . 13C NMR chemical shifts 8 ppm from CDC13 
(77 .0). r 1H NMR spectra recorded at 500 MHz. 1H chemical shift values 8 ppm from CHCl3 
(7 .25) followed by number of protons, multiplicity and coupling constant (J/Hz) . 
6. 5. 2: Structural elucidation of 6. 7 
The second compound (6.7) was isolated as a pale yellow powder (5 .4 mg). 
HRESI mass spectrometry identified a [M+Ht ion at m/z 347. 1 0 13 (calc. 
347 . 1 131), which led to the molecular formula C 1 8H 1 807 , and corresponded to 10 
DBE, 2 Da greater than that for trypacidin (6.6). Both the 1 H and 1 3C NMR 
spectra were also reminiscent of trypacidin (6.6), suggesting that these compounds 
might be structurally related. The 1 H NMR spectrum (Figure 6.13) revealed the 
presence of one methyl group associated with an aromatic ring (8H 2.42) and three 
methoxy groups (8H 3.64, 3.6 1 and 3.33), however the most significant difference 
was the downfield shift of the H-5 (8H 5.77) methine proton in trypacidin (6.6) to 
8H 6.95 in compound 6.7. The 1 3C NMR spectrum (Figure 6.14) confirmed the 
presence of three methoxy groups (8c 56.0, 55.6 and 52. 1), two carbonyl carbons 
(8c 199.9 and 166.7), four sp2 methines (8c 1 10.3, 107.8, 103.3 and 103. 1 )  and 
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eight sp2 quaternary carbons (8c 163.7, 161.0, 1 57.6, 156.9, 148.0, 1 28.2, 1 26.8 
and 110. 7). However, the absence of the s/ C-1 (8c 84.0) spiro carbon and the 
conjugated C-4 (8c 185. 7) dienone carbonyl carbon strongly suggested that this 
cyclic system was aromatic. 
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Ring A was constructed by careful comparison of the NMR spectra ( 1 H, 1 3C and 
CIGAR) for 6.7 with that obtained for trypacidin (6.6). Connectivity from C-3 to 
C-5 was established via the coupling constant extracted from the I H NMR 
spectrum between the H-3 and H-5 (8H 6.58 and 6.95, respectively, J3,5= 1 .5 Hz ) 
aromatic protons, suggesting a meta configuration, while CIGAR correlations 
from the H-3 and H-5 (8H 6.58 and 6.95, respectively) aromatic protons to the C-4 
(8c 1 57.6) carbon implied that carbon C-4 was between both of these protons. 
The 1 3C chemical shift of C-4 also suggested that this carbon was no longer part 
of a carbonyl but was still substituted with an oxygen (hydroxyl group). As 
before, the methoxycarbonyl group was positioned at C-6 (8c 1 28.2) on the basis 
of the 3JcH CIGAR correlations from both the H-5 methine and H-8 methoxy 
protons (8H 6.95 and 3.6 1 ,  respectively) to the C-7 (8c 1 66.7) carbonyl carbon. 
The H-9 (8H 3.64) methyl protons associated with the methoxy group were 
positioned at C-2 (8c 1 56.9) on the basis of the CIGAR correlations from both the 
H-3 (8H 6.58) aromatic proton and the H-9 (8H 3.64) methoxy protons to the C-2 
(8c 1 56.9) aromatic carbon. NOESY correlations were used to confirm the 
proposed substitution pattern for ring A. Irradiation of the H-3 (8H 6.58) aromatic 
proton enhanced the H-9 (8H 3.64) methyl proton signal, while the irradiation of 
the H-5 (8H 6.95) aromatic proton enhanced the H-8 (8H 3.6 1 )  methyl proton 
signal. Carbon C- 1 was assigned by CIGAR correlations from the H-3 and H-5 
(8H 6.58 and 6.95, respectively) aromatic protons to the C- 1 (8c 1 26.8) carbon. 
The proposed partial structure for 6.6, ring A, is shown in Figure 6. 1 5 . 
Figure 6. 1 5 :  Proposed structure for ring A of 6.7, indicating key CIGAR (black), 
COSY (blue) and NOESY (red) correlations. 
The remaining portion of the structure ( Figure 6. 1 6) was constructed using the I H 
and 1 3C NMR chemical shift data comparison with trypacidin (6.6), combined 
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with experimental NOESY data. The substitution pattern of the suspected 
aromatic ring for carbons C-2' to C-5' was determined by irradiation of the H-3 '  
(cSH 6.03) methine proton to give NOE enhanced signals for both the H-7' and H-8' 
(cSH 3.94 and 2.42, respectively) methyl protons, confirming H-3 ' was still located 
between these two methyl groups. Irradiation of the H-5' (cSH 6.39) aromatic 
proton resulted in only one NOE enhanced signal, that of the H-8' (cSH 2.42) 
methyl protons, placing the H-5 ' proton adjacent to the H-8' methyl group as 
indicated by red arrows in Figure 6. 1 6 . 
The CIGAR correlation from the H-7' (cSH 3.94) methyoxy protons to the C-2' (cSc 
1 6 1 .0) carbon located the 7'-methoxy group on position C-2', and the correlation 
from the H-8' (cSH 2.42) methyl protons to the C-4' (8c 1 48.0) carbon, located the 
methyl group on C-4', while the 3 JCH correlations to the C-3 '  and C-5' (8c 1 03. 1 
and 1 1 0.3) carbons confirmed that the 8'-methyl group was between H-3 ' and H-5', 
as previously determined by the NOESY data. The 3JCH correlations from both H-
3' and H-5' (8H 6.03 and 6.39, respectively) protons to the C- 1 '  (8c 1 1 0.7) carbon, 
combined with the 2JCH CIGAR correlation from the H-5' (8H 6.39) proton to the 
C-6' (8c 1 63. 7) carbon completed the assignment and substitution pattern of the 
proposed partial structure ring C, for 6.7 ( Figure 6. 1 6) . The 1 3C chemical shift of 
C-6' ( 1 63.7) suggested that this position was substituted with an oxygen (hydroxyl 
group), similar to that of the previously isolated compound trypacidin (6.6). 
Figure 6. 1 6 :  Proposed structure ring C ,  for 6.7 with key C IGAR (black) and 
NOESY (red) con-elations. 
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One carbonyl carbon and one proton were left to assign , as required by the 1 3C 
and 1 H NMR spectra, and one DBE by the molecular formula. Careful 
examination of the CIGAR spectrum revealed a very weak correlation from the H-
3' (8H 6.03) aromatic proton to the C-10 (8c 199.9) carbonyl carbon. The 
chemical shift comparison of the C- 1 and C-1' carbons assigned for both 
trypacidin (6.6) and 6.7 confirmed that a carbonyl was bridging rings C and A at 
these positions; this assignment accounted for the remaining DBE. The remaining 
proton was assigned on the oxygen at the C-6' position. A working structure for 




Figure 6.17: Final structure proposed for 6.7, showing the very weak CIGAR 
(black) correlation from the H-3' (8H 6.03) proton, to the C-10 (8c 199.9) carbonyl 
carbon, connecting ring A to ring C. 
A literature search 1 30' 1 45 was performed on the proposed structure for 6. 7. The 
isolated compound (6.7) was found to be sulochrin-2'-0-methyl ether, previously 
isolated from the fungal culture of Aspergillus terreus var. aureus by Inamori et 
/ 21 8 a .  The experimental NMR data was also compared to that reported in the 
literature for sulochrin (6.8), the 2'-0-demethyl metabolite, as no NMR data was 
reported with 6.8.2 1 9'220 The chemical shift data was found to match closely with 
those reported for 6.8, excluding the C-2' position. 
H 
HO 
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The arbitrarily assigned numbering for sulochrin-2'-0-methyl ether (6.7) is shown 
in Figure 6.18 while the full experimental 1 H, 1 3C, COSY, NOESY and CIGAR 
NMR data for sulochrin-2'-0-methyl ether (6.7) are shown in Table 6.2. 
9 7' 
OCH3 0 OCH3 
: 1 � 
10 
/? 6 
HO HO 5'  CH3 8' 
c 1  
o,;:, 'ocH 
8 3 
Figure 6.18 : Numbering system assigned for sulochrin-2'-0-methyl ether (6.7). 
as used in Table 6.2. 
Table 6.2: The 1 H, 1 3C, COSY, NOESY and CIGAR NMR data for sulochrin-2'-
0-methyl ether (6.7) (CDCIJ) .  
Position. IJC () §  
1 26 .8  (C) 
2 1 56.9 (C) 
3 1 03 .3  (CH) 
4 1 57.6 (C) 
5 1 07 .8 (CH) 
6 1 28 .2 (C) 
7 1 66 .7 (CO) 
8 52 . 1 (OCH3) 
9 56.0 (OCH3) 
1 0  1 99.9 (CO) 
I '  1 1 0.7 (C) 
2' 1 6 1 .0 (C) 
3 '  1 03 . 1 (CH) 
4' 1 48.0 (C) 
'H o r  
6 .58 ( I H, d, 1 . 5 )  
6 .95 ( I H, d ,  1 .5 )  
3 .6 1  (3H,  s )  
3 . 64 (3H,  s )  
6 .03 ( I H, s )  
COSY CIGAR (NOESY) 
H-5 (H-9) C-5, C-4, C-2, C- 1 
H-3 (H-8) C-7, C-6, C-4, C-3, C- 1 
(H-5) C-8', C-2' 
(H-3) C-2 
(H-8', H-7') C-1 O(vw), C-8', C-5', C-4', C-2', 
C- 1 ' 
5 '  1 1 0.3 (CH) 6.39 ( I H, s)  (H-8') C-8',C-6', C-4', C-3', C- 1 '  
6' 1 63 .7(C) 
7' 55 .6  (OCH3) 3 .94 (3H, s) (H-3') C-2' 
8' 22.3 (CH3) 2 .42 (3H, s) (H-5', H-3') C-5', C-4', C-3' 
§ 1
3C NMR spectra recorded at 1 25 MHz in CDCl3 . 1 3C chemical shifts 8 ppm from CDCl3 (77.0). 
1 1H NMR spectra recorded at 500 MHz. 1H chemical shift values 8 ppm from CHCl3 (7.25) 
followed by number of protons, multiplicity and coupling constant (J/Hz). 
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6. 5 .  3 :  Structural elucidation of 6. 9 
The third compound (6.9) was also isolated as a pale yellow powder (6. 7 mg). 
The HRESI mass spectrometry identified the [M+Nat ion at m/z 385.0879 (calc 
385.0899), 16 Da greater than that of sulochrin-2'-0-methyl ether (6.7), which led 
to a molecular formula of C 1 8H 1 808, corresponding to 10 DBE. Both the 
1H and 
1 3C NMR spectra were reminiscent of the data obtained for sulochrin-2'-0-methyl 
ether (6.7), suggesting that these compounds were structurally related. The 1 H 
NMR spectrum (Figure 6.19) revealed the presence of one methyl group 
associated with an aromatic ring (8H 2.20), three methoxy groups (8H 3.86, 3.76 
and 3.73) and four aromatic methine protons (8H 6.86, 6.78, 6.53 and 5.89). 
Although the signals observed in the 1 3C NMR spectrum (Figure 6.20) were weak, 
two carbonyl carbons were tentatively assigned at 8c 166.4 and 168.3, while the 
absence of a third carbonyl in the 8c 200 region suggested that this compound was 
no longer a diphenylketone. 
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Figure 6.19: The 1 H NMR spectrum of compound 6.9 (CD30D). 
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Figure 6.20: The 1 3C NMR spectrum of compound 6.9 (CD30D). 
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As before, ring A was readily deduced by direct comparison of the NMR data 
(HSQC, C IGAR) with that obtained for the two previously isolated compounds 
6.6 and 6.7. The H-3 and H-5 (8H 6.86 and 6.78, respectively, J3,5 = 1 . 5 Hz) 
aromatic protons were still COSY correlated, confirming the connectivity from 
the C-3 to C-5 carbons. Carbon C-4 was determined by the C IGAR correlations 
from both the H-3 and H-5 (8H 6.86 and 6.78, respectively) aromatic protons to 
the C-4 (8c 1 55.4) aromatic carbon. The 1 3C chemical shift of C-4 suggested that 
this position was again phenolic. The carboxylic acid ester group was located at 
the C-6 (8c 1 25.6) carbon (CIGAR correlations from both the H-5 and H-8 (8H 
6.78 and 3 .73 ,  respectively) protons to the C-7 (8c 1 66.4) carbonyl carbon). The 
location of the 9-methoxy group at C-2 (8c 1 54.0) was confirmed via the C IGAR 
correlations from both the H-3 (8H 6.86) aromatic proton and the H-9 (8H 3. 76) 
methyl protons to the C-2 (8c 1 54.0) aromatic carbon. Carbon C- 1 was located by 
3 JCH C IGAR coupling from both of the H-3 and H-5 (8H 6.86 and 6.78, 
respectively) aromatic protons to the C- 1 (8c 1 34. 7) quaternary carbon. This data 
established that ring A (Figure 6.2 1 )  was identical to that of sulochrin-2'-0-
methyl ether (6.7), previously isolated and identified in Section 6.5.2. This data 
inferred that the difference in the structure was associated with the arrangement of 
the remaining atoms. 
HO 
Figure 6.2 1 :  The key COSY (blue) and C IGAR (black) correlations for the 
proposed paitial structure, ring A of 6.9. 
Ring C was also constructed by careful interpretation of the 1 H and C IGAR NMR 
data. The CIGAR correlations from the H-9' (8H 2.20) methyl protons to the C-4', 
C-5 '  and C-6' (8c 1 04.5, 1 4 1 .4 and 1 06. 1 ,  respectively) aromatic carbons 
confinned that the H-9' methyl group was still located between both methine 
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protons at the C-5' (8c 1 4 1 .4) position. This was further established via NOESY 
correlations from the irradiated H-9' (8H 2.20) methyl protons to the signals 
corresponding to the H-4' and H-6' (8H 6.53 and 5.89, respectively) aromatic 
protons. The orientation of H-4' and H-6' was determined via sequential 
irradiation of protons utilising the NOESY experiment. Irradiation of the H-8' (8H 
3.86) methoxy protons resulted in the single NOE enhancement corresponding to 
the H-4' (8H 6.53) aromatic proton signal, positioning the H-8' methoxy group 
adjacent to H -4' (8H 6.53) on the C-3' (8c 1 57.3) carbon. This was confirmed by 
the CIGAR correlation observed from the H-8' (8H 3.86) methyl protons to the C-
3' (8c 1 5 7.3) carbon. Irradiation of the H-4' (8H 6.53) proton in a NOESY 
experiment enhanced both the H-8' and H-9' (8H 3.86 and 2.20, respectively) 
methyl protons positioning the 9'-methyl group on C-5' (8c 1 4 1 .4). Finally, the H-
9' (8H 2.20) methyl protons were irradiated, giving NOE enhancement of both the 
H-4' and H-6' (8H 6 .53 and 5.89, respectively) aromatic protons, positioning H-6' 
adjacent to the 9'-methyl group. The C-4' and C-6' carbon assignments were 
confirmed by the C IGAR correlations observed from the H-9' (8H 2.20) methyl 
protons to C-4' and C-6' (8c 1 04.5 and 1 06. 1 ,  respectively) carbons. The C-2' 
position was located by the observed 3 JCH CIGAR correlations from both the H-4' 
and H-6' (8H 6.53 and 5.89, respectively) aromatic protons to the C-2' (8c 1 1 0.0) 
carbon. Carbon C- 1 '  was assigned using the 2JCH CIGAR correlations from the H-
6' (8H 5.89) proton to the C- 1 '  ( 1 56.3) carbon. The partial structure, ring C, for 6.9 
was proposed as shown in Figure 6.22 .  
7' ' 
Figure 6.22 :  The key CIGAR (black) and NOESY (red) correlations for the 
proposed structure, ring C, of 6.9. 
An ether bridge connecting ring A to C was inferred from the 1 3C chemical shift 
data for both carbons C- 1 and C- 1 '  (8c 1 34.7 and 1 56.3 respectively) in 6.9. I f a 
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carbonyl was involved in bridging the two rings then the chemical shift for both 
C-1 and C-1' carbons would be closer to those observed for sulochrin-2'-0-
methyl ether (6.7) (8c 126.8 and 110.7, respectively). Additionally, no ketone 
carbonyl resonance was observed in the 8c 180-200 region of the 1 3C NMR 
spectrum. 
In order to complete the structure, it was necessary to ascertain the substituent at 
C-2'. There were very weak CIGAR correlations from both the H-4' and H-6' (8H 
6.53 and 5.89, respectively) aromatic protons to the C-7' (8c 168.3) carbonyl 
carbon, possibly associated with a carboxylic acid group. This was in keeping 
with the remaining atoms left to assign from the molecular formula. The working 
structure proposed for 6.9 is shown in Figure 6.23. The arbitrary numbering 
system shown is subsequently used for the NMR data shown in Table 6.3. 
H 
HO H 
Figure 6.23: Proposed structure of 6.9, with arbitrary numbering system as used 
for NMR data displayed in Table 6.3. 
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Table 6.3: The 1 H, 1 3C, COSY, NOESY and CIGAR NMR data for asterric acid-
3'-0-methyl ether (6.9) (CD30D). 
Position. 1 3c o § 
1 1 34.7 (C) 
2 1 54.0 (C) 
3 1 04.5 (CH) 
4 1 55 .4 (C) 
5 1 07.6 (CH) 
6 1 25 .6 (C) 
7 1 66.4 (CO) 
8 5 1 .3 (OCH3) 
9 55 . 1 (OCH3) 
1 '  1 56.3 (C) 
2' 1 1 0.0 (C) 
3' 1 57.3 (C) 
4' 1 04.5 (CH) 
5' 1 4 1 .4 (C) 
1
H o '  
6.86 ( l H, d, 1 .5) 
6.78 ( l H, d, 1 .5 )  
3 .73 (3H,  s )  
3 .76 (3H,  s )  
6 .53 ( l H, s )  
COSY CIGAR (NOESY) 
H-5 C-7, C-6, C-4, C-3, C-1 
H-3 C-7, C-6, C-4, C-3 , C- 1 
C-7 
C-2 
(H-9', H-8') C-9', C-7'(vw), C-6', C-3', 
C-2' 
6' 1 06. 1 (CH) 5 .89 ( l H, s) (H-9') C-9', C-7'(vw), C-2', C- 1 '  
7' 1 68 .3 (CO) 
8' 55 .0 (OCH3) 3 .86 (3H, s) (H-4') C-3 ' 
9' 20.6 (CH3) 2 .20 (3H, s) (H-6', H-4') C-6', C-5', C-4' 
§ 1 3C NMR spectra recorded at 1 25 MHz in CD30D, chemical shift values o ppm from CD30D at 
49.3 .  1 1H NMR spectra recorded at 500 MHz in CD30D (o ppm from CD30D at 3 .3 )  followed by 
number of protons, multiplicity and coupling constant (J!Hz). 
A literature search 1 30• 1 45 on the proposed structure for 6.9 returned no exact 
structural matches. A wider search profile was performed by replacing the 3'-0-
methoxy group with 3'-0H, resulting in the identification of asterric acid (6.10). 
H OH 
HO H 
Asterric acid (6.10) was isolated from the culture medium of a new strain of 
fungus, Aspergillus terrus Thom., by Hassell et al.221 Structural elucidation of 
this compound was achieved via chemical degradation experiments, where the 
evidence led to a likely structure based on their extensive knowledge of related 
compounds. No NMR data was reported in this paper. Asterric acid (6.10) was 
CHAPTER6 Ulocladium sp. 219 
later isolated by Hargreaves et al.,219 from the mycelium extract of the fungus 
Aspergillus sp. recovered from leaf litter collected from Perth, Western Australia. 
The NMR data for 6.9 was compared to that reported in this subsequent isolation 
of asterric acid (6.10). The 13C and 1H NMR chemical shifts for the mutual atoms 
(excluding C-3 ') were in good agreement. Compound 6.9 was therefore 
tentatively assigned as the novel 3'-0-methyl ether derivative of asterric acid (6.9). 
It is interesting to note that although the NMR chemical shift assignments have 
been reported correctly, the structure of asterric acid (6.10) has been incorrectly 
drawn in the literature by both Hargreaves219 (6.11) and Adeboya222 (6.12). 
Hargraves was mistaken as to which carboxylic acid had been methylated, as no 
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6.5.4: Structural elucidation of 6.13 
The compound (6.13) was also isolated as a pale yellow powder (4.9 mg). HRESI 
mass spectrometry identified a [M+Nat ion at m/z 399.1027 (calc. 399.1057) 
which led to the molecular formula C19H200 8, corresponding to 10 DBE. 
Analysis of the 1H NMR spectrum (Figure 6.24) revealed that this compound was 
structurally related to the previously isolated compound asterric acid-3'-0-methyl 
ether (6.9). Initial interpretation of the NMR data (Figure 6.24 and Figure 6.25) 
identified the presence of four aromatic proton signals at 88 6.84, 6.77 6.52 and 
5.88 (8c 107.5, 8c 104.4, 104.8 and 106.2, respectively), one aromatic methyl 
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group at 8H 2.22 (8c 20.4), and four methoxy groups at 8H 3.88, 3.84, 3 .76 and 
3.72 (8c 51.3, 55.2, 55.3 and 51.4, respectively). The data differed from that 
observed for asterric acid-3'-0-methyl ether (6.9) by the addition of a methoxy 
signal at 8H 3.72 (8c 51.4). 



























Figure 6.24: The 1 H NMR spectrum of compound 6.1 3  (CD30D). 
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Figure 6.25 : The 1 3C NMR spectrum of compound 6.13 (CD30D). 
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As before, ring A was readily deduced by CIGAR correlations and chemical shift 
comparison with asterric acid-3'-0-methyl ether (6.9). The H-3 (8H 6.77) 
aromatic proton displayed COSY cross peak correlations to the H-5 (8H 6.84) 
proton, and CIGAR correlations to the C- 1 ,  C-2 and C-4 (8c 1 34.7, 1 53.9 and 
1 55.3, respectively) carbons. The H-5 (8H 6.84) proton was CIGAR correlated to 
the C- 1 ,  C-4, C-6 and C-7 (8c 1 34.7, 1 55.3, 1 26. 1 and 1 67.6, respectively) 
carbons. This combined data completed the connectivity from C- 1 to C-7. 
Carbon C-4 was assigned as being substituted with an hydroxyl group, based on 
the chemical shift comparison with the C-4 (8c 1 55.4) carbon of asterric acid-3'-
0-methyl ether (6.9). The first of the four methoxy groups was located at C-7, 
based on the C IGAR correlations observed from both of the H-5 aromatic and H-8 
methyl (8H 6.84 and 3.76, respectively) protons to the C-7 (8c 1 67.6) carbonyl 
carbon. The second methoxy group was positioned at C-2 on the basis of the 
C IGAR correlations observed from both the H-3 aromatic and H-9 methyl (8H 
6.77 and 3.72, respectively) protons to the C-2 (8c 1 53.9) aromatic carbon. The 
proposed partial structure, ring A, for 6. 13,  is shown in Figure 6.26. This data 
suggested that the structural differences between 6. 13  and asterric acid-3'-0-
methyl-ether (6.9) were associated with the remaining atoms. 
Figure 6.26: The key COSY (blue) and CIGAR (black) correlations used to 
construct the partial structure, ring A, of 6. 13 .  
Ring C was also assembled by careful comparison of both the 1 H NMR and 
C IGAR data. The connectivity of carbons C- 1 '  to C-6' was established with 
C IGAR correlations from the H-4' (8H 6.52) aromatic proton to the C-2', C-3', C-5' 
and C-6' (8c 1 09.9, 1 56.6, 1 4 1 .5 and 1 06.2 respectively) carbons, combined with 
the CIGAR correlations from the H-6' (8H 5.88) proton to the C- 1 ', C-2', C-4' and 
C-5' (8c 1 5 7.4, 1 09.9, 1 04.8 and 1 4 1 .5,  respectively) carbons. The aromatic 
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methyl group was still positioned at C-5', based on the CIGAR correlation from 
the H-9' (8H 2.22) methyl protons to the C-5' (8c 1 4 1 .5) carbon. The H-9' (8H 2.22) 
methyl protons were NOE enhanced when the H-4' and H-6' (8H 6.52 and 5.88, 
respectively) protons were sequentially irradiated suggesting that the H-9' methyl 
group was positioned between the H-4' and H-6' protons on C-5 '. This was 
validated by the CIGAR correlations observed from the H-9' (8H 2.22) protons to 
both the C-4' and C-6' (8c 1 04.8 and 1 06.2, respectively) carbons. An additional 
NOESY enhanced signal corresponding to the resonance at 8H 3.84 was observed 
when H-4' (8H 6.52) was irradiated, this combined with the CIGAR correlation 
from the H-8 (8H 3.84) methyl protons to the C-3' (8c 1 56.6) carbon, confirmed 
that a methoxy group (8'-methoxy) was still located at the C-3' carbon. However, 
irradiation of the H-8' (8H 3.84) methoxy protons, resulted in NOE enhanced 
signals associated with both the H-4' (8H 6.52) aromatic proton and the remaining 
unassigned methoxy protons (H- 1 O', 8H 3.88). The observed CIGAR correlation 
from the H- 1 0' (8H 3.88) methoxy protons to the C-7' (8c 1 66.5) carbonyl carbon 
suggested that the acid group previously positioned at C-2 '  in asterric acid-3'-0-
methyl ether (6.9), was now methylated. The 1 3C chemical shift data for C-2' in 
both asterric acid-3'-0-methyl ether (6.9) and 6. 1 3  were within 0. 1 ppm of each 
other, validating the C-2' assignment. Therefore, the partial structure ring C, was 
proposed for 6. 13 ( Figure 6.27). 
Figure 6.27:  The partial structure, ring C, of 6. 13, with key C IGAR (black) and 
NOESY (red) correlations. 
In order to complete the structure, it was necessary to ascertain the substituent at 
both C- 1 and C- 1 '. One oxygen atom was left to assign as determined by the 
molecular formula. By direct comparison of the 1 3C chemical shift data for both 
of the C- 1 and C- 1 '  carbons with those of asterric acid-3'-0-methyl ether (6.9), the 
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oxygen was assigned as an ether bridge linking ring A to C. This also satisfied 
the requirements of the DBE. The completed working structure for 6.13 is 
proposed in Figure 6.28. 
OCH3 
OCH3 
H 0 OCH3 
HO H H 
H CH3 
0 OCH3 
Figure 6.28 :  Proposed structure for isolated compound 6.13. 
A literature search 1 30• 1 45 on the proposed structure for 6.13 gave no exact 
structural matches. A wider search profile was again performed by replacing the 
3'-methoxy group with 3'-0H. This resulted in the identification of methyl 
asterrate (6.14), a compound previously reported from the fungus Oospora 
sulphure ochrace by Natori et al.223 Methyl asterrate (6.14) was subsequently 
isolated by Hargreaves et al. from the EtOAc extract of an Aspergillus sp. 
fungus.2 1 9  As the spectral data previously reported by Natori did not 
unambiguously define the substitution pattern of the phenyl rings, Hargreaves 
undertook single-crystal X-ray diffraction studies to confirm the structure.2 19  
OCH3 
OCH3 
H 0 OH 




The isolated compound 6.13 was tentatively named methyl asterrate-3'-0-methyl 
ether. The arbitrary numbering system used for the NMR data (Table 6.5) is 
shown in Figure 6.29. 









0 OCH3 9' 
Figure 6.29: Numbering system assigned to methyl asterrate-3'-0-methyl ether 
(6.13) used in Table 6.4. 
Table 6.4: The 1 H, 1 3C, COSY, NOESY and CIGAR NMR data for methyl 
asterrate-3'-0-methyl ether (6.13) (CD30D). 
Position 
1 34 .7 (C) 
2 1 53 .9 (C) 
3 1 04.4 (CH) 
4 1 55 .3 (C) 
5 1 07 .5 (CH) 
6 1 26. l (C) 
7 1 67 .6 (CO) 
8 55 .3  (OCH3) 
9 5 1 .4 (0CH3) 
l '  1 57.4 (C) 
2' 1 09.9 (C) 
3' 1 56 .6 (C) 
4' 1 04 .8 (CH) 
5' 1 4 1 . S (C) 
6' 1 06.2 (CH) 
7' 1 66.5 (CO) 
6.77 ( I H, d, 1 .5) 
6 . 84 ( IH, d, 1 .5 )  
3 .76 (3H,  s )  
3 . 72 (3H,  s )  
6 .52 ( I H, s) 








C-5, C-4, C-2, C- 1 
C-7, C-6, C-4, C-3, C-1  
C-7 
C-2 
C-9', C-6', C-5', C-3' C-2' 
C-9', C-5', C-4' C-2', C- 1 '  
8 '  55 .2  (CH3) 3 . 84 (3H, s) (H- 1 0', H-4') C-3' 
9' 20.7 (CH3) 2.22 (3H, s) (H-6', H-4') C-6', C-5', C-4' 
1 0' 5 1 .3 (OCH3) 3 . 88  (3H, s) (H-8') C-7' 
§ 1 3C NMR spectra recorded at 1 25 MHz in CD30D, chemical shift values 8 ppm from CD30D at 
49.3 .  1 1 H NMR spectra recorded at 500 MHz in CD30D (8 ppm from CD30D at 3 .3 )  followed by 
number of protons, multiplicity and coupling constant (J/Hz). 
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6. 5. 5: Structural elucidation of 6. 15 
The compound (6. 1 5) was isolated as a pale yellow oil (3.7 mg). HRESI mass 
spectrometry identified a [M+Nat ion at m/z 441 .1164 (calc. 441.1162) which led 
to the molecular formula C2 1 H2209, corresponding to 11 DBE and 42 Da more 
than methyl asterrate-3'-0-methyl ether (6.13). The 1 H NMR spectrum (Figure 
6.30) revealed that this compound was again structurally related to the previously 
isolated compounds. Initial interpretation of the 1 H NMR data identified the 
presence of an additional singlet signal at 8H 2.35 that integrated for three protons. 
This was paired with a carbon signal at 8c 22.0 in the HSQC spectrum, allowing 
for the tentative assignment of an acetyl group. The remaining spectral features 
were identical with those reported for methyl asterrate-3'-0-methyl ether (6.13) 
(see Table 6.6). 
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7 
J 
Figure 6.30: The 1 H NMR spectrum of compound 6. 1 5  (CDC13) .  
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As with the previously isolated compounds, ring C was easily deduced by C IGAR 
correlations and chemical shift comparisons with methyl asterrate-3'-0-methyl 
ether (6. 13 ) .  The substitution pattern of the aromatic ring was confirmed with 
NOESY experiments. These consisted of irradiation of the H-9' (8c 2.22) methyl 
protons which NOE enhanced the signals corresponding to both the H-4' and H-6' 
(8H 5.94 and 6.42, respectively) aromatic protons, while irradiation of the H-8' (8H 
3.86) methoxy methyl protons resulted in the NOESY enhancement of both the H-
4' and H-10' (8H 5.95 and 3.94) protons. This NMR data suggested that ring C 
was identical to that of methyl asterrate-3'-0-methyl ether (6. 13 )  and this partial 
structure for 6. 1 5  is proposed in Figure 6.3 1 .  
Figure 6.3 1 :  The proposed partial structure, ring C, for 6. 1 5  with important 
NOESY (red) correlations. 
The data suggested that the additional signal observed in the NMR data must be 
associated with ring A. The H-3 (8H 7.24) aromatic proton displayed COSY cross 
peak correlations to H-5 (8H 6.94, J3,5 = 1.5 Hz) and C IGAR correlations to the C­
l ,  C-2 and C-4 (8c 1 40.7, 1 54.0 and 147.8, respectively) carbons, confirming 
connectivity from C-1 to C-5. 
The C-2 carbon methoxy substitution was confirmed by C IGAR correlations from 
both the H-3 (8H 7.24) aromatic and H-9 (8H 3.80) methoxy protons to the C-2 (8c 
154.0) carbon, while the C-6 substitution was confirmed with the 3 JCH C IGAR 
co1Telations observed from both the H-5 and H-8 (8H 6.94 and 3.76, respectively) 
protons to the C-7 carbonyl carbon at 8c 165.2. 
In order to complete the structure, the substituents at C-1, C-1' and C-4 had to be 
ascertained. Direct comparison of the 1 3C NMR chemical shift data with methyl 
asterrate-3'-0-methyl ether (6. 1 3) suggested that the ether linkage connecting 
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rings A and C through C- 1 to C- 1 '  was still present. This left assigrunent of the 
substituent at C-4. There was a upfield chemical shift associated with C-4 (8c 
1 47.8) in 6. 1 5  compared to that for methyl asterrate-3'-0-methyl ether (6. 13 )  C-4 
(8c 1 55.3) carbon. This suggested that the acetyl group associated with the H- 1 0  
(8H 2.35) methyl signal was attached at the C-4 position. This was confirmed by 
the CIGAR experiment as a correlation from the H- 1 0  (8H 2.35) methyl protons to 
the C- 1 1 (8c 1 69 .2) carbonyl carbon was observed. Therefore the structure for the 
isolated compound 6. 1 5  was proposed as the acetyl derivative of 6. 1 3  (Figure 
6.32) .  
H 7 , CH3 
0 (5H3 
Figure 6.32 : The proposed structure of 6. 1 5, with key COSY (blue lines) and 
CIGAR (black arrows) correlations. 
A literature search, 1 30• 1 4 5  was performed on the proposed structure for the isolated 
compound 6. 1 5  which resulted in no exact matches. Therefore, this compound 
was tentatively named as the novel 4-0-acetyl-3'-0-methyl ether derivative of 
methyl asterrate (6. 1 5) .  



















Figure 6.33: Numbering system assigned for methyl asterrate-4-0-acetyl-3'-0-
methyl ether (6.15) as used in Table 6.5. 
Table 6.5 : The NMR data for methyl asterrate-4-0-acetyl-3 '-0-methyl ether 
(6.15) (CDCh). 
Position 1 3C o § I H  O i COSY CIGAR {NOESY) 1 40.7 (C) 2 1 54 .0 (C) 3 1 1 5 .6  (CH) 7 .24 ( 1 H, d, 1 .5 )  H-5 C-5, C-4, C-2, C- 1 4 1 47 .8 (C) 5 1 1 0.8 (CH) 6.94 ( I H, d, 1 . 5 )  H-3 C-7, C-6, C-4, C-3, C-1 6 * 7 1 65 .2  (CO) 8 52 .4 (OCH3) 9 56.5 (OCH3 ) 1 0  22.0 (CH3) 1 1  1 69.2 (CO) 1 '  1 57 .5  (C) 2' 1 1 0.8 (C) 3 '  1 57.3 (C) 4' 1 06.5 (CH) 5 '  1 4 1 . 5 (C) 6' 1 05 .4 (CH) 7' 1 66.9 (CO) 
3 .76 (3H, s) 3 .80 (3H, s) 2 .35 (3H, s) 
5 .94 ( I H, s) 
6.42 ( I H, s) 
(H-9', H-8') 
(H-9') 
C-7 C-2 C- 1 1  
C-9', C-6', C-5', C-3', C-2' 
C-9', C-5', C-4', C-2', C l '  
8' 55 .9  (CH3) 3 .86 (3H, s) (H- 1 0', H-4') C-3 ' 9' 22.0 (CH3) 2.22 (3H, s) (H-6', H-4') C-6', C-5', C-4' 1 0' 52 .3 (OCH3) 3 .94 (3H, s) C-7' 
§ 1 3C NMR spectra recorded at 1 25 MHz in CDCl3 . 1 3C chemical shifts 8 ppm from CDC13 (77 .0). 1 1H NMR spectra recorded at 500 MHz. 1H chemical shift values 8 ppm from CHC13 (7.25) followed by number of protons, multiplicity and coupling constant (J/Hz). * No 1 3C NMR chemical shift data recorded for this carbon. 
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6. 5. 6: Structural elucidation of 6. 16 
The final compound 6.16 was isolated as a white powder (2.9 mg). HRESI mass 
spectrometry identified a [M+Nat ion at m/z 454.1476 (calc. 454.1478) which led 
to the molecular formula C22H25N08, corresponding to 11 DBE. The 1 H NMR 
spectrum (Figure 6.34) revealed that this compound was structurally unrelated to 
the previously isolated compounds. Initial interpretation of the 1 H and HSQC 
NMR data revealed the presence of proton signals associated with an aromatic 
ring 8H 8.38, 7.68 and 7.54 (8c 131.7, 134.8 and 129.5,  respectively). These 
signals were a doublet, a triplet and a triplet, respectively, representing a pattern 
consistent with a mono-substituted aromatic ring system, two olefinic methine 
protons at 8H 5 .65 and 5.51 (8c 137.3 and 128.7, respectively), three methyl 
signals, one of which was a triplet at 8H 1.01 (8c 14.5), the second, a vinyl at 8H 
1.79 (8c 5.8), and the third, a singlet methoxy group at 8H 3.37 (8c 52.5); three 
oxymethines at 8H 4.71, 4.58 and 4.53 (8c 69.6, 76.2 and 72.9, respectively) and a 
multiplet methylene signal at 8H 2.13-2.24 (8c 22.2). The 1 3C NMR data (Figure 
6.35) confirmed the presence of additional functionalities. These consisted of 
three carbonyl carbons (two at 8c 199.3 and 197.0, and a third was reminiscent of 
an amide carbonyl carbon at 8c 169.1 ), two sp2 quaternary carbons at 8c 188.8 and 
135.2, and two sp3 quaternary carbons at 8H 93.9 and 93.6. 
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Figure 6.35 : The 1 3C NMR spectrum of compound 6.16 (CD30D). 
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The COSY, HSQC and CIGAR NMR experimental data were employed to assign 
connectivity and deduce the structure of 6. 1 6 . 
The starting point was the methylene protons at OH 2. 1 3-2.24 (H-2), which 
displayed COSY cross coITelations to both the H- 1 (OH 1 .0 1 )  methyl and the H-3 
(OH 5.65) olefinic protons. This was reinforced by the observed CIGAR 
coITelations from the H- 1 (OH 1 .0 1 )  methyl protons to both C-2 and C-3 (oc 22.2 
and 1 37.3, respectively). CIGAR coITelations from the H-4 (oH 5.5 1 )  olefinic 
proton to C-3, C-5 and C-6 (oc 1 37.3, 69.6 and 72.9, respectively), established the 
sequence C-3 to C-6, which was confirmed with the sequential COSY correlations 
from H-3 (oH 5.65) to H-4, H-5 and H-6 (oH 5.5 1 ,  4.7 1  and 4.53, respectively) 
(Figure 6.36) .  
Figure 6.36:  The partial structure, C- 1 to C-6 of 6. 1 6, with key COSY 
correlations shown in blue. 
The strong C IGAR coITelation observed from the H-5 (OH 4.7 1 )  oxymethine 
proton to a quaternary carbon at Oc 1 88.8 positioned this carbon adjacent to C-6 
(C-7), but the chemical shift of this carbon was at first puzzling. The dilemma 
was solved with the assignment of C-8 and C-9. These were deduced via CIGAR 
correlations from the H-6 (OH 4.53) oxymethine proton to the clearly olefinic C-8 
(oc 1 1 4.4) carbon, while the OH 1 . 79 protons from a methyl group located at the 
C-8 position (by C IGAR coITelations from the C-20 methyl protons at OH 1 .  79 to 
the C-8 (oc 1 1 4.4) carbon) were coITelated to both C-7 and C-9 (oc 1 88.8 and 
1 99.3, respectively). The very low field carbon C-7 (oH 1 88.8) was considered in 
keeping with an oxygenated s/ carbon at the /3 position of an a,/3-unsaturated 
carbonyl system ( Figure 6.37) .  
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Figure 6.37: The assignment of C-1 to C-9, including the methyl group at C-20, 
with key CIGAR correlations (black). 
The sequence of carbons C-9 to C-13 and C-22 was defined via CIGAR 
correlations from the H-11 (8H 4.58) oxymethine proton (see Figure 6.38). This 
included correlations to three carbonyl carbons, two at 8c 199.3 and 197.0 (C-9 
and C-13, respectively) while the third, consistent with that of an amide carbonyl, 
was at 8c 169.l (C-22), as well as to two sp3 quaternary carbons at 8c 93 .6 and 
93.9 (C-10 and C-1 2, respectively) . The methyl protons associated with a 
methoxy group at 8H 3.37 were positioned at C-12 by the CIGAR correlation from 
the H-21 (8H 3.37) methyl protons to the C-12 (8c 93 .9) carbon (Figure 6.38). 
OH 0 
Figure 6.38: The assignment of patiial structure C-1 to C-13 of 6.16, including 
the C-21 methoxy and C-22 amide carbonyl groups. The key CIGAR correlations 
are shown in black. 
The aromatic ring, incorporating carbons C-14 to C-19, was established via 
observed CIGAR and COSY correlations, and also from coupling constants 
extracted from 1H NMR data. This unit was then joined to the sequence as the 
3
JCH CIGAR correlations were observed from both the H-19 and H-15 (8H 8.38) 
aromatic protons to the C-13 (8c 197.0) carbonyl carbon. The aromatic carbon C-
14 was located by the CIGAR correlation from both aromatic protons H-16 and 
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H- 1 8  (8H 7.54) to the C- 1 4  (8c 1 35.2) carbon. The partial structure for 6. 1 6  was 
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Figure 6.39 : The proposed partial structure for 6. 1 6, with key COSY (blue) and 
CIGAR (back) correlations. An arbitrary numbering system has been assigned to 
the structure to aid structural elucidation. 
This left positions 7a, I Oa and 1 2a to assign. The partial structure requires nine 
degrees of unsaturation, however, the molecular formula requires 1 1  degrees of 
unsaturation, however one proton is left to assign. Therefore, the 7a and 1 Oa 
oxygens were postulated to be the same, thus forming a five-membered furanone 
ring system. This assignment was confirmed after close examination of the 
CIGAR data. A very weak correlation was observed from the H-6 (8H 4.53) 
oxymethine proton to the C- 1 0  (8c 93.6) sp3 carbon. This 4JcH correlation could 
only exist if a five-membered ring was present, linking C-7 to C- 1 0  and 
accounting for the 1 0111 degree of unsaturation. 
Carbon C- 1 2  had to be quaternary, as defined by both the 1 3C and HSQC NMR 
data. As no further carbon atoms were left to assign, position 1 2a was connected 
to N- 1 ,  forming a lactam ring. This accounted for the final proton assignment and 
the 1 1 111 degree of saturation. All atoms were now assigned and the complete 
structure for 6. 1 6  was proposed ( Figure 6.40). 







0 OH o 
Figure 6.40: The proposed structure of 6 . 1 6. This arbitrary numbering 
assignment is used in Table 6.6. 








1 4 .5 (Cl-b) 
22.2 (CH2) 
1 37.3 (CH) 
1 28.7 (CH) 
69 6 (CH) 
72.9 (CH) 
7 1 88.8 (C) 
8 1 1 44 (C) 
9 1 99.3 (CO) 
1 0  93.6 (C) 
1 1  76.2 (CH) 
1 2 93.9 (C) 
1 3 1 97.0 (CO) 
1 4  1 35.2 (C) 
1 5 
1 6  
1 7  





1 31 .7 (CH) 
1 29.5 (CH) 
1 34 .8(CH) 
1 29.5 (CH) 
1 31 .7 (CH) 
5.8 (CH,) 
52.5 (OCH3) 
1 69 . 1  (CO) 
1 .0 1 (3H, t, 7 .5) 
2 . 1 3-2 .24 (2H, m) 
5 .65 ( 1 H, d, t, 7.0, 1 0.5) 
5 .5 1  ( 1 H, t, 10 .5 ) 
4 .7 1 ( 1 H, t, 8.5) 
4.53 ( 1 H, d, 6.5) 
4 .58 ( 1 H, s) 
8.38 ( 1  H, d, 7 .5) 
7.54 ( 1  H, t, 7 .5) 
7.68 ( 1 H, t, 8 .0) 
7 .54 (1  H, t, 7 .5) 
8 .38 (1  H, d, 7.5) 
1 .79 (3H, s) 
3.37 (3H, s) 
COSY 
H-2 
H- 1 ,  H-3 
H-4, H-2 





C-4, C-3, C- 1 
C-5 , C-4, C-2, C- 1  
C-6, C-5, C-3, C-2 
C-7, C-6, C-4, C-3 
C- lO(vw), C-8, C-7, C-5 , C-4 
C-22, C- 1 3, C- 1 2 ,  C- 10, C-9 
H- 1 6 C- 1 9, C- 17 , C- 1 3 
H- 1 7,  H- 1 5  C- 1 8, C- 1 4, 
H- 1 8, H- 1 6 C- 1 9, C-1 5 
H- 1 9, H- 1 7 C- 1 9, C- 1 6  
H- 1 8 C- 1 7 , C- 1 5 , C- 1 3 
C-9, C-8, C-7 
C- 1 2  
§ 1 3C NMR spectra recorded at 1 25 MHz i n  CD30D. 1 3C chemical shifts 8 ppm from CD30D 
(49.3) .  1 1H NMR spectra recorded at 500 MHz. 1H chemical shift values 8 ppm from CH30D 
(3 .3 )  followed by number of protons, multiplicity and coupling constants (J/Hz). 
A literature search 1 30• 1 45 on the structure proposed for 6. 1 6  identified this 
compound as pseurotin A, shown in Figure 6.4 1 numbering assignment consistent 
with that reported in the literature. Pseurotin A (6. 1 6), an antimicrobial secondary 
metabolite was isolated from the culture filtrates of Pseudeurotium ovalis STOLK 
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by Bloch et at? ' The structure was determined from spectral data, chemical 
transformations and by X-ray analysis of the dibromo derivative.2 1 2  
OH 0 15  
H3C 1 3  1 2  1 1  1 0  
1 4  1 9  
OH 
1 7  1� 
H3C 3 1
20 
16  0 23 � 21 
22 
Figure 6.4 1 : Numbering assignment and relative stereochemistry for the reported 
compound pseurotin A (6. 1 7) .2 1 1 -2 1 3 
However, direct comparison of the reported 1 3C NMR data2 1 3  with that obtained 
from the Ulocladium sp. (WS 132) metabolite disclosed inconsistencies in 
assignments for carbons at C-2 and C-6. Reported data places C-2 at 8c 167.3 and 
C-6 at 8c 187.7 in the 1 3C NMR spectrum, while C-2 and C-6 are assigned as 8c 
188.8 and 169.1, respectively, for the isolated compound. Although the 1 3C NMR 
spectra were obtained in different solvents, CDCh for the reported compound and 
CD30D for the isolated compound, carbons C-2 and C-6 were unambiguously 
assigned by CIGAR correlations from the H-11 and H-10 (8H 4.71 and 4.53, 
respectively) oxymethine protons to the C-2 (8c 188.8) quaternary carbon, while 
the C-6 carbon was assigned from an important CIGAR correlation from the H-9 
(8H 4.58) oxymethine proton to the C-6 (8c 169.1) carbonyl carbon. On this basis, 
the literature assignments for C-2 and C-6 should be reversed. 
The double bond stereochemistry for C-3/C-4 was established from the relative 
magnitude of the coupling constant between H-3 and H-4 protons. The coupling 
constant (J3,4 = 10.5 Hz) was consistent with a (Z) configuration.224 The relative 
stereochemistry of pseurotin A (6. 1 6) was determined to be the same as that 
reported for pserotin A (6. 1 7) on the basis that the chemical shift data, coupling 
constants (Table 6.4) and optical rotation data ([a]020 = -7° (c 0.5 MeOH)) 
closley matched that reported in the literature. 2 1 1 '2 1 3  The absolute stereochemistry 
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of pseurotin A (6.17) was determined in the literature by X-ray crystal structure 
analysis of the 12,13-dibromopseurotin A derivative.2 1 2  
Table 6.7: Comparison of the 1 H NMR chemical shift data for the isolated 
pseurotin A (6.16) (CD30D) and those reported for Pseurotin A (6.17) (CDCh).2 1 4  
Isolated pseurotin A (6.16) Reported pseurotin A (6.17) 
Position 1 3C o § 
2 1 88.8 (C) 
3 1 1 4.4 (C) 
4 1 99.3 (CO) 
5 93 6 (C) 
6 1 69.1 (CO) 
8 93.9 (C) 
9 76.2 (CH) 
1 0  72.9 (CH) 
1 1  69.6 (CH) 
1 2  1 28 .7 (CH)  
1 3  1 37.3 (CH) 
1 4  22.2 (CH2) 
1 5  1 4 .5 (CH1) 
1 6  5.8 (CH1) 
1 7  1 97.0 (CO) 
1 8  1 35.2 (C) 
1 9  1 3 1 .7 (CH) 
20 1 29.5 (CH) 
21 1 34.8(CH) 
22 1 29.5 (CH) 
4.58 ( 1 1-1, s) 
4.53 (I 1-1 ,  d, 6.5) 
4.71 (I 1- 1, dd, 6.5, 8.5) 
5.51 (I H,  dd, 8.5, I 0.5) 
5.65 (I 1-1, dt, 7.5, 1 1 .0) 
2 . 1 3-2.24 (2H, m) 
1 .01  (31 1 ,  t, 7 .5) 
1 .79 (31-1 ,  s) 
8 .38 ( I  1 -1 ,  d, 7 .5) 
7.54 ( I  1-1 ,  t, 7 .5) 
7 .68 (1 1- 1 ,  t ,  7.5) 
1 66.6 (C) T 
1 1 1 .6 (C) 
1 96.7 (CO) 
92.4 (C) 
1 86.8 (CO) T 




1 28.4 (CH)  
1 34.0 (CH) 
20.6 (CH2) 
14 . 1 (CH1) 
5.6 (Cl-Ii) 
1 96.4 (CO) 
1 33.6 (C) 
1 30 2 (CH) 
1 28.4 (CH) 
1 33.6 (CH) 
4.4 1 ( 1 H, s) 
4.56 ( !  H, d, 3.8) 
4.71 ( 1 1- 1 ,  dd, 3.8, 8.8) 
5 .31 ( 1 1-1 , m) 
5.62 (I H, dt, 1 1 .3, 14.9)* 
2.1 (2 1 -1, m) 
0.90 (3H, t, 7.0) 
1 .65 (3H, s) 
8.22 (! H, d, 7.2) 
7.43 (! H ,  t, 7 .5) 
7.57 ( !  H, t, 7 .3) 
7.54 ( I H, t, 7 .5) 1 28.4 (CH) 7.43 (! H ,  t, 5.0)* 
23 1 31 .7 (CH) 8.38 ( I H, d, 7 .5) 1 30.2 (CH) 8.2-8.4 (! H ,  m) 
24 52.5 (OCH3) 3.37 (3H, s) 5 1 . 7  (OCH3) 3.26 (3H, s) 
§ 1
3C NMR spectra recorded at 1 25 MHz in CD30D. 1 3C chemical shifts 8 ppm from CD30D 
(49.3) .  1 1H NMR spectra recorded at 500 MHz. 1H chemical shift values 8 Pfim from CH30D 
(3 .3)  followed by number of protons, multiplicity and coupling constant (J/Hz). 1 3C NMR spectra 
recorded at 1 00 MHz in CDC13 . 1 3C chemical shifts 8 ppm from CDC13 (77.0). t 1H NMR spectra 
recorded at 500 MHz. 1H chemical shift values 8 ppm from CHC13 (7 .25) followed by number of 
protons, multiplicity and coupling constants (J/Hz). *Coupling constants reported for these protons 
do not match with those calculated from the 1H NMR spectrum supplied in the online supporting 
information.2 15 rThese literature assignments should be revised on the basis of the CIGAR 
correlations observed in the assignment of structure 6. 1 6. 
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6. 6: Biological Activity 
All isolated compounds were subjected to the in-house anti-tumour assay system 
to assess their biological activity (P388), the results of which are shown in Table 
6.8. 
Table 6.8 : The P388 activity for the compounds isolated from the organic extract 
of WS132. 
COMPOUND ACTIVITY ( IC50 µ mL 
6.6 1 .0 
6.7 > 1 2 .5 
6.9 >12 .5 
6.13 1 1 .4 
6. 1 5  1 .9 
6. 1 6  8 .0 
6. 7: Concluding Remarks 
In this section the aim was to isolate and identify the compounds responsible for 
the biological activity (P388) observed in the crude extract of the fungal isolate 
Ulocladium sp. (WS 132) isolated from the Antarctic marine sponge Mycale 
acerata. 
Six compounds were isolated as a direct result of bioassay-guided fractionation 
(HPLC microtitre plate P388 assay) of the crude extract. These included the three 
previously reported compounds trypacidin (6.6),209•2 1 0  sulochrin-2'-0-methyl 
ether (6.7)2 ' 9•220 and pseurotin A (6.16),2 1 1 -2 1 6 along with the previously 
unreported compounds asterric acid-3'-0-methyl ether (6.9), methyl asterrate-3'-
0-methyl ether (6.13) and methyl asterrate-4-0-acetyl-3'-0-methyl ether (6.15). 
All the purified compounds were isolated by successive chromatographic steps. 
The initial reversed phase (C 1 8) flash column chromatography was followed by 
semi-preparative reversed phase (C 1 8) HPLC. Purity was assessed by analytical 
HPLC. Location of the biologically active 'peaks' of interest was maintained 
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throughout the purification process with the help of analytical reversed phase 
HPLC analysis. 
Structural elucidation of all of the isolated compounds was achieved with the help 
of lD and 2D NMR spectroscopic experiments, combined with high resolution 
mass spectrometry. The structural data obtained was directly compared to that 
reported in the literature. However, during the comparison of 1 3C NMR chemical 
shift data published for pseurotin A (6.15) the assignment of carbons C-2 and C-6 
were noted to be inconsistent with the experimental data obtained. The 
assignment made in the current work was consistent with data obtained 
independently by Ms Sonia van der Sar for the same compound isolated from the 
culture broth of a Penicillium sp. fungal isolate collected from a beach in 
Vancouver, Canada.225 The chemical shift data from the NMR experiments 
unambiguously assigned these carbons. 
Each of the purified compounds was submitted for biological activity assessment 
in-house. The compounds 6.6, 6.13 6.15 and 6.16 (IC50 of 1.0, 11.4, 1.9 and 8.0 
µg/mL, respectively) were identified as being responsible for the biological 
activity located in the initial microtitre plate (P388) assay. 
This body of work represents an expans10n of the literature relating to the 
compounds isolated from the fungus Ulocladium sp. It also includes necessary 
corrections for structural data presented in previous publications. 
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6. 8: Summary of Isolation 
Ulocladium sp. (WS 132) 
I . 
EtOAc Extract10n (1.54 g) 
I 
Reverse Phase (C 18) Chromatography 
9:1 MeOH/H20 I MeOH DCM 
I I I I I I I I I I I I 
Fraction# 1 2 3 4 5 6 7* 8* 9 10 11 12 
Mass (mg)250 9.5 3.6 0.7 14.2 23 .9 32.2 43.6 25 .3 115.1421.l 679.0 
F·1 .I 1 trat1on 
6.6 (6.0mg) 
Semi-preparative (C 18) 
Chromatography 
(3~: SS~ A<0;;"'l ;, ·;~ o; 2S ;;'"'~) 
Fraction # 1 2 3 4 5 6 7 
Mass (mg) 0.9 6.0 5.4 2.9 4.9 3.7 6.7 




Scheme 6.1: Chromatographic purification summary of compounds isolated from 
the Antarctic marine sponge-derived fungus Ulocladium sp. *Fraction contains 
biologically active peak(s) of interest 
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CHAPTER 7 
EXPERIMENTAL 
7. 1 :  General Met hods 
7. 1 . 1 :  Nuclear Magnetic Resonance 
The 1 H, lDTOCSY, 2DTOCSY, COSY ROESY, NOESY, HSQC, and CIGAR 
NMR spectra were recorded on a Varian INOV A 500 NMR at 23 °C, operating at 
500 MHz. The INOV A was equipped with a variable temperature and indirect 
broadband PFG (pulsed field gradient) 5 mm probe. The 1 3C NMR spectra were 
recorded on a Varian UNITY 300 NMR spectrometer, at 23 °C, operating at 75 
MHz. The UNITY was equipped with a variable temperature direct broadband 5 
mm probe. Chemical shifts are expressed in parts per million (ppm) on the 8 scale, 
and were referenced to the appropriate solvent peaks: CDCh (0.1 µL pyridine) 
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referenced to CHCh at 8H 7.25 (1 H) and CHCl3 at 8c 77.0 ( 1 3C), CD30D 
referenced to CH30D at 8H 3.3 (1 H) and CH30D at 8c 49.3 ( 1 3C) and DMSO-d6 
referenced to CD3(CHD2)SO at 81 1  2.60 (1 H) and (CD3)2SO at 8c 39.6 ( 1 3C). 
7. 1 . 2: Mass Spectrometry 
7. 1 . 2. 1 :  Electron Impact Mass Spectrometry 
High Resolution Electron Impact Mass Spectra (HREIMS) were also obtained on 
a Kratos MS80RF A Mass Spectrometer, operating with a 4 kV accelerating 
potential, 70 eV, and a 250 °C source temperature. 
7. 1 .2 .2:  Electrospray Ionisation Mass Spectrometry 
High Resolution Electrospray Ionisation Mass Spectra (HRESIMS) were obtained 
from a Micromass LCT spectrometer, with a probe voltage of 3200 V and 
temperature of 150 °C. The nebuliser gas flow of 160 L/hr and desolvation gas 
flow of 520 L/hr, the source temperature was set at 80 °C. The carrier solvent was 
50 CH3CN/H20 at 20 µL/minutes (for direct injection mode). A 10 µL injection 
of sample was made from a 10 µg/mL solution. 
Positive ESI mass spectra were recorded after addition of one of the following, 
formic acid, sodium iodide or caesium iodide to the sample prior to analysis. 
While negative ESI mass spectra were recorded after the addition of diethylamine 
to the sample. 
7. 1 .2. 3 :  Liquid Chromatography Electrospray Mass Spectrometry 
Liquid Chromatography Mass Spectrometry (LCESIMS) samples were analysed 
with a Waters 2790 high pressure liquid chromatography (HPLC) system 
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equipped with a Waters photodiode array detector (PDA) coupled in parallel to a 
Micromass LCT mass spectrometer, as described above. 
7. 1 . 3 : Chromatography 
7. 1 . 3. 1 :  Flash Column Chromatography 
All column chromatography was performed in glass columns or sintered glass 
funnels. Solvents used were of commercial grade distilled once in glass 
distillation apparatus, except for MeOH which was distilled twice. 'Flash' 
columns were run using positive N2 (oxygen-free) pressure, while size exclusion 
columns were run at atmospheric pressure under gravity. 
Reversed phase flash chromatography (RP) utilised Bakerbond (40 µm) octadecyl 
(C 1 8) packing. Samples were either dissolved in a minimum volume of solvent 
and loaded directly onto the column, or alternatively, adsorbed onto a plug of 
fresh C 1 8  using a minimum volume of solvent which was removed under vacuum 
prior to the C 1 8  plug being loaded onto the column. The standard elution profile 
consisted of column equilibration to 100 % H20, and then fractions were eluted 
with increasing concentrations of MeOH in steps of 10 % per fraction. Any 
material remaining on the column was washed off using combinations of MeOH 
and DCM (with TF A). 
Size exclusion chromatography was carried out on Sephadex LH20 (Pharmacia 
Biotech AB) solid phase. Samples fractionated with Sephadex LH20 were 
dissolved in a minimal volume of solvent. Fractions were collected by automatic 
fraction collector LKB Bromma 2212 Helirac, based upon solvent volume. 
Normal phase flash chromatography was performed on DIOL ( 40 µm APD) solid 
phase. Samples were either dissolved in a minimum volume of solvent and 
loaded directly onto the column, or alternatively, adsorbed onto a plug of fresh 
DIOL using a minimum volume of solvent which was removed w1der vacuum 
prior to the DIOL plug being loaded onto the column. The standard elution 
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profile consisted of colunm equilibration to 100 % Pet. ether, then fractions were 
eluted with increasing concentrations of DCM through to 100 % EtOAc in steps 
of 10 % per fraction. Any material remaining on the colunm was washed off 
using combinations ofEtOAc, MeOH and water. 
7. 1 . 3 .2 :  High Pressure Liquid Chromatography 
Analytical High Pressure Liquid Chromatography (HPLC) was performed using a 
Shimadzu LC-l OAD VP liquid chromatograph, with an SPD-Ml OA VP 
photodiode array detector. For reversed phase HPLC, a Phenomenex Prodigy 
C18 5-0DS (5µ, 250 x 4.6 mm) colunm was used with a flow rate of 1 mL/minute. 
The mobile phase solvents consisted of variable concentrations of CH3CN (HPLC 
grade) and H20 (Milli-Q). Some projects required the use of 0.05 % TFA in the 
H20. 
All samples were filtered through 0.45 µm PTFE membrane filters before 
injection. 
The standard gradient method comprised of the following solvent elution gradient; 
2 minutes 10 % CH3CN/H20, a linear gradient to 75 % CH3CN/H20 over 12 
minutes, 75 % CH3CN/H20 isocratic for 10 minutes, a linear gradient to 100 % 
CH3CN/H20 over 2 minutes, 100 % CH3CN/H20 isocratic for 4 minutes then 
returned to 10 % CH3CN/H20 over 2 minutes, and finally re-equilibrated over an 
eight minute period. 
Semi-preparative HPLC was performed on a Shimadzu LC-4A instrument 
equipped with a Hewlett Packard 3390A integrator. Reversed-phase HPLC 
chromatography was performed on Phenomenex Luna 5µ C 18(2) (5µ, 250 x 10 
mm)) column using a 5 mL/minute flow rate and variable concentrations of 
MeOH, CH3CN (HPLC grade) and H20 (milli-Q) with 0.05 % TFA added as 
required, as the mobile phase solvents. 
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7. 1 . 4: Optical Rotation 
Rotation values were obtained on a Perkin Elmer 341 polarimeter at 20 °C at a 
wavelength of 589 nm. The optical rotations were then calculated using the 
following equation: 
[ a ]20 = _!!__ D LC 
Where L is the cell path length (dm) and C is the concentration (g/mL). 
7. 1 . 5: Media and Incubation Conditions 
7. 1 . 5. 1 : Fungal Isolation from Substrate 
Sponge tissue was sliced into 5 mm cubes and placed onto the fungal-specific 
media which included oatmeal Emersons and Sabouraud agar. Media was 
incubated at 26 °C until cultures grew. 
7. 1 . 5. 2: Difeo™ Oatmeal Agar 
Oatmeal agar is intended for the cultivating fungi, particularly for macrospore 
formation. Oatmeal is a source of nitrogen, carbon, protein and nutrients. Agar is 
the solidifying agent. 
Approximate formula per litre consists of oatmeal (60.0 g) and agar (12.5 g). 
Preparation of media was in accordance with the accompanying manufacturers 
directions. 
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7. 1 . 5.3 :  Difeo™ Emerson Agar 
Emerson agar is used for culturing Allomyces and other fungi. The yeast provides 
a source of trace elements, vitamins and amino acids while the soluble starch 
provides starch for the hydrolysis, detoxification of metabolite byproducts and 
acts as a carbon source. Dipotassium phosphate is a buffer. Magnessium sulphate 
is a source of divalent cations and sulphate. Agar is the solidifying agent. 
The agar (approximate per L) is made up of the following constituents :  yeast 
extract 4.0 g, soluble starch 1 5.0 g, dipotassium phosphate 1 .0 g, magnesium 
sulphate 0.5 g and agar 20.0 g. 
Preparation of media was in accordance with the accompanying manufacturers 
directions. 
7. 1 . 5. 4: Sabouraud Dextrose Agar in Seawater 
Used for the cultivation isolation and identification of pathogenic fungi. This 
medium contains glucose and is especially suitable for dermatophytes. Its 
composition is 1 / 1 0  strength Dextrose agar (3.9 g Dextrose, 0.3 g Yeast, 9.0 g 
agar) in fresh filtered seawater (Cape Armitage, Antarctica, autoclaved). 
Preparation of media was in accordance with the accompanying manufacturers 
directions. 
7. 1 . 5. 5: Yi Sabouraud Dextrose Yeast (SDY) Broth Medium 
The Y2 SDY medium has been adapted by Nie Cummings, School of Biogical 
Sciences, University of Canterbury, as a general purpose medium used in the 
cultivation and isolation of fungi that grow more favourably in a liquid medium. 
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The medium consists of dextrose (10 g), polypeptone (5 g, BBL), yeast extract (1 
g), distilled water (1 L). 
Water ( 1  L) was boiled for 2 minutes, the ingredients were added and stired until 
dissolved. The medium solution was autoclaved at 121 cc for 20 minutes. 
Medium was inoculated with spore suspension (10 mL) and incubated at 26cc for 
three weeks, or until visual inspection confirms that fungal growth is in the Jog 
phase. 
7. 1 . 5. 6: Brown Rice Medium 
The solid brown rice medium is an all purpose medium used for the cultivation 
and isolation of a variety of fungi. The Brown rice medium (Brown rice, 175 g; 
distilled water, 325 mL; K2HP04, 0.25 g; yeast extract, 0.5 g) was prepared in 
square 2 L Nalgene® bottles. The mixture was then boiled in the microwave for 
2-3 minutes, followed by sterilisation in the autoclave for 20 minutes at 121 cc. 
Medium was inoculated with 10 mL of spore suspension which was spread across 
the entire rice surface. Fungal samples were then incubated at 26 cc for three 
weeks. Visual inspection was used to determine when the growth cycle was at the 
Jog phase. 
7. 1 . 6: Biological Assays 
7. 1 . 6. 1 :  The Anti-tumour assay 
The anti-tumour assay225 is the most sensitive assay for cytotoxicity. It consists of 
a 2-fold dilution series of the sample of interest incubated for 72 hours with P388 
(murine leukaemia) cells. The concentration of sample required to reduce the 
P388 cell growth by 50 % (compared to control cells) is determined using the 
absorbance values obtained when the yellow MTT tetrazolium is reduced by 
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healthy cells to produce the purple coloured MTT formazan. The result 1s 
expressed as the IC50 (ng/mL). 
Tetrazolium salt MTT Formazan 
Figure 7.1: Conversion of yellow MTT tetrazolium to purple MTT formazan by 
healthy P388 cells. 
7. 1 . 6.2 :  Microtitre Plate Collection/ P388 Assay 
In order to identify the compounds responsible for the activity observed in the 
chemical pre-screening process, a small aliquot of the biologically active extract 
(250 µg) was subjected to analytical reversed phase (C18) HPLC chromatography 
and fractionated into a 96 well plate ('Master plate', 250 µL/well); flow rate was 1 
mL/minute. Due to the inherent sensitivity of the polystyrene plates to high 
concentrations of acetonitrile (>75 %), the compounds that eluted from 25-30 and 
31-35 minutes were collected in two vials, dried down and re-suspended in 250 
µL of MeOH and added to wells 88 and 89 respectively. Eluant from the 'master 
plate' was transferred into dilution plates ('Daughter plates', 50 and 5 µL) and 
dried under vacuum in a centrifugal evaporator and submitted for P388 anti­
tumour assay. Wells that possessed activity (Cl O-D l 1, coloured yellow) are 
related directly to the HPLC chromatogram (time in minutes), thus, activity can be 
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Figure 7.2: A 50 µL dilution microtitre daughter plate submitted for the P388 
biological assay. Activity has been located in wells C 10 to E 11, represented by 
the yellow wells. 
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7. 2: Work Described in CHAPTER 2 
7. 2. 1 :  Extraction of New Zealand Marine Sponge 
Rhabderemia stel letta (OJMNP0729) 
253 
Initial investigation of the sponge O 1 MNP0729 began by assessing of a portion of 
the crude extract in the P388 anti-tumour assay. 
The frozen sponge sample (330 g) was thawed in MeOH (500 mL) and 
homogenised for three minutes. Before filtering through celite under vacuum, the 
residue was re-suspended and re-extracted a further three times using MeOH (3 x 
300 mL), MeOH/DCM (1: 1, 300 mL) and finally with DCM (300 mL). All 
filtrates were combined and the solvent was removed under vacuum. The crude 
extract was partitioned between EtOAc and H20 (1:1, 500 mL). The organic and 
aqueous solvents were separated, collected and the solvent was removed from 
each fraction under vacuum to yield a thick yellow/brown and a thick brown gum 
respectively. Both fractions were analysed for biological activity using the P388 
assay. Only the organic fraction (1.11 g) was cytotoxic (IC50 < 975 ng/mL). The 
aqueous layer (2.45 g) contained no significant cytotoxic activity (IC50 > 12500 
ng/mL). Analysis of the organic extract by reversed phase (C 1 8) HPLC revealed a 
variety of polar and non-polar components. 
7.2. 2: Reversed Phase (C18) Chromatography of the Organic 
Extract of the New Zealand Marine Sponge 
Rhabderemia stelletta (OJMNP0729) 
The EtOAc soluble fraction extract (1.11 g) was dissolved in a minimum volume 
of MeOH/DCM, adsorbed onto a plug of fresh C 1 8  (2 g), and loaded onto a 
reversed phase flash chromatography column (30 mm x 300 mm) which had been 
packed with Bakerbond (C 1 8, 40 µm; 50 g) and equilibrated to 100 % H20. The 
column was eluted using a stepped solvent gradient of 100 % H20 to 100 % 
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MeOH, increasing the MeOH concentration 10 % every fraction (25 mL). The 
column was finally eluted with combinations of DCM/MeOH (25 mL), increasing 
the DCM concentrations 20 % every fraction. The remaining material was 
washed from the column with MeOH/DCM (1:1, 0.1 % TFA, lOOmL). Seventeen 
fractions were collected. All fractions were analysed for biological activity using 
the P388 assay. The biological activity was localised in fraction wjm 1 2-312 
which eluted with 4:1 DCM/MeOH (IC50 2001 ng/mL, 79.4 mg). Fraction 
wjm12-312 was analysed by analytical reversed phase HPLC (C 1 8, no TFA) using 
microtitre plate collection P388 assay. The P388 activity indicated the peaks 
eluting between 27-32 minutes, were responsible for the observed activity. 
7. 2. 3 :  Normal Phase (DIOL) Chromatography of Fraction 
wjm 12-312  
Fraction wjm 1 2-312 (79.4 mg) was dissolved in a minimum volume of pet. ether 
and applied directly onto a normal phase (DIOL) flash chromatography column 
(15 mm x 150 mm, 15 g) equilibrated to 100 % pet. ether. The column was eluted 
with a stepped solvent gradient consisting of 100 % Pet. ether to 100 % DCM in 
50 % steps, then 100 % DCM to 100 % EtOAc, increasing the EtOAc 
concentration 20 % every 7 mL collected. The column was finally eluted with 
combinations of 1:1 EtOAc/MeOH, 100 % MeOH (14 mL) and 9:1 MeOH/H20. 
A total of 12 fractions were collected. Odd numbered fractions were analysed for 
cytotoxic activity (P388). Fractions wjm12-701 to wjm12-703 (23.9 mg) were 
analysed by reversed phase (C 1 8) HPLC using the standard gradient method (see 
Section 7.1.3). Due to fraction complexity, further purification was deemed 
necessary in order to elucidate the biologically active compound(s). 
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7. 2. 4: Reversed Phase (C18) Semi-preparative HPLC 
Chromatography of Fractions wjml  2- 701 
to wjml  2- 703 
255 
Fractions wjml2-701 to wjm1 2-703 (30 mg) were combined in a minimum 
volume of MeOH and subjected to further purification by reversed phase (C 1 8) 
semi-preparative HPLC chromatography (Phenomenex Luna, 5µm C18, 250 x 
10mm) using the conditions developed on the analytical HPLC column and scaled 
up by an appropriate factor (Flow rate 5 mL/minute, 91.5 % MeOH and 8.5 % 
H20, A =  230 nm). Four fractions were collected as peaks eluted, and all fractions 
were analysed by 1 H NMR. The fractions that contained sufficient mass were 
subjected to the full suite of 2D NMR spectroscopic experiments and ESI mass 
spectrometry, leading to the elucidation of compounds 2.23 (6.5 mg), 2.24 ( 4.1 
mg), 2.25 (2.8 mg) and 2.26 (2.5 mg) were elucidated. Purity was confim1ed by 
re-injection on to the analytical reversed phase HPLC column. In order to obtain 
enough material for further structural elucidation (following degradation of 
compounds), the remaining portion of the frozen sponge material was processed. 
7.2. 5: Extraction and Chromatography of Remaining 
Sponge Material 
The remainder of the frozen sponge sample (153 g) was exhaustively extracted 
using combinations of MeOH and DCM ( 4 x 500 mL) to yield 1.8 g of organic 
extract. The organic extract was partitioned between H20 and EtOAc. The 
EtOAc fraction ( 450 mg) was re-dissolved in a minimum volume of EtOAc and 
adsorbed onto C 1 8 (10 g). The solvent was removed under high vacuum and the 
adsorbed fraction loaded onto the top of a reversed phase (C 1 8) flash column (30 
mm x 300 mm, 60 g) that was equilibrated to 100 % H20. The aqueous fraction 
from the partitioning was partially dried under vacuum and used as the first 
fraction of the column. The column was then eluted using a stepped solvent 
gradient from 1 00 % H20 to 1 00 % MeOH, increasing the MeOH concentration 
10 % every 30 mL, then 100 % MeOH to 100% DCM in 20 % steps from 
fractions 12 to 1 7. The column was finally eluted with 1 :1 DCM/MeOH (0.05 % 
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TFA, 100 mL) followed by 100 % MeOH (0.05 % TFA, 100 mL). All fractions 
were examined for biological activity in the P388 assay. The activity was 
concentrated in fraction wjml2-151 l (IC50 = 5649 ng/mL, 30 mg). 
7.2. 6: Gel-permeation (LH-20) Chromatography of Fraction 
wjm l 2- 15 1 1 
Fraction wjml2- 1 51 l (30 mg) was subjected to further purification via LH-20 
gel-permeation chromatography (40 g, 15 mm x 400 mm). The fraction was 
dissolved in a minimum volume of MeOH and applied directly to the top of the 
column. The column was eluted with 100 % MeOH. Nine fractions were 
collected (30 mL), and all fractions were analysed for biological activity. All nine 
fractions were found to be inactive. Analysis by re-injection on the analytical 
reversed phase (C 1 8) column confirmed the loss of activity as no peaks associated 
with the initial activity were detected. Further work on these fractions was 
abandoned at this point. 
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7. 3 :  Work Described in CHAPTER 3 
7. 3. 1 :  Extraction of Unidentified Antarctic Marine 
Sponge 02 WMOJ-33 
257 
The frozen specimen 02WM01-33 (133 g) was thawed and extracted with 
combinations of MeOH and DCM (1:1, 500 mL). The extract was filtered 
through a bed of celite after homogenization and the solid material was re­
suspended and extracted a further two times with MeOH and DCM ( 1  :1, 250 mL). 
The solvent was removed under vacuum to yield a yellow extract (1.09 g). A 
small sample of this organic extract (250 µg) was analysed by reversed phase C 1 8  
HPLC microtitre plate analysis (P388 assay). Wells A4-A9 were identified to 
contain the biological activity (P388) as observed in the crude extract. This area 
of activity corresponded to the compounds eluting between 2.8 to 4.2 minutes in 
the HPLC chromatogram. 
7. 3 .2 :  Reversed Phase (c,s) Flash Chromatography 
of the Organic Extract of02 WMOJ-33 
The organic extract (1.1 g) was dissolved in  a minimum volume of solvent 
(MeOH/DCM) and adsorbed onto a plug of fresh C 1 8  (1 g) solid phase. The 
solvent was removed under vacuum and the C 1 8  plug was loaded onto a reversed 
phase C 1 8 flash chromatography column (30mm x 300 mm, 60 g), equilibrated to 
100 % H20. Fractions were collected using the following solvent elution gradient 
system; 100 % H20 to 100 % MeOH in steps of 10 % MeOH every 20 mL;, the 
remaining material was eluted from the column as fraction 12 (MeOH/DCM, 1 :  1 ). 
Odd numbered fractions were analysed by reversed phase (C 1 8) HPLC to identify 
the fractions that contained the compounds responsible for the activity as located 
by rnicrotitre plate analysis (2.8 and 4.2 minutes). As a result fraction wjm20-203 
was chosen for further purification. 
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7. 3. 3 :  Reversed Phase (C18) Semi-preparative 
HPLC Chromatography of Fraction wjm20-203 
Fraction wjm20-203 (32 mg) was further purified by reversed phase (C 1 8) semi­
preparative HPLC chromatography (Phenomenex Luna, 5µm C l  8, 250 x 10mm) 
using a gradient solvent system of: 2minutes 5 % CH3CN/H20, 20 minutes 36 % 
CH3CN/H20, after the column was equilibrated back to 5 % CH3CN/H20 over 3 
minutes; H20 contained 0.05 % TF A (Flow rate 5 mL/minute, 11. = 230 nm). Four 
fractions were collected as peaks eluted. Purity was confirmed by re-injection 
through the reversed phase (C1 8) analytical HPLC. Fractions wjm20-203.2 (14 
mg) and wjm20-203.4 (5.0 mg) were analysed by 1 H and 1 3C NMR, and deemed 
to contain enough material for further 2D NMR experiments. HSQC and CIGAR 
NMR spectra were used to identify compounds 3.13 (14.0 mg) and 3.15 (5.0 mg). 
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7. 4: Work Described in CHAPTER 4 
7. 4. 1 :  Extraction of Antarctic Marine Sponge 
Suberites sp. (02 WMOJ-46) 
259 
The frozen specimen 02WM01-46 (62 g) was thawed in a combination of 
MeOH/DCM (1: 1, 500 mL). After substantial homogenisation (5 min) the extract 
was filtered through a bed of celite then the solid material was re-suspended and 
extracted twice with MeOH/DCM (1 :1, 250 mL). The solvent was removed under 
reduced pressure to yield a green extract (248 mg). A small sample (250 µg) of 
the EtOAc soluble fraction of the organic extract was analysed by analytical 
reversed phase (C 1 8) HPLC chromatography microtitre plate analysis (see Section 
7.1.6.2). The biological activity was attributed to the compound eluting at 7.8 
minutes. 
7. 4. 2: Reversed Phase (C18) Vacuum Chromatography 
of the Organic Extract 
The organic extract of 02WM01-46 (248 mg) was dissolved in a mm1mum 
volume of MeOH/DCM (3:1) and loaded onto a plug of fresh C1 s solid phase (1.0 
g). The solvent was removed under vacuum and the C 1 8 plug was loaded onto a 
reversed phase (C 1 8) vacuum chromatography column (50 mm x 20 mm, 35 g) 
equilibrated to 100 % H20. The column was eluted with a solvent system 
consisting of 100 % H20 to 100 % MeOH in steps of 10 % MeOH every 20 mL. 
The remaining material was eluted from the column as fraction 12 (MeOH/DCM, 
1 :  1 ). Even numbered fractions were analysed by reversed phase (C 1 8) HPLC 
chromatography, to identify the fractions that contained the compounds 
responsible for the activity indicated by the P388 assay (microtitre plate). Based 
upon this analysis fractions wjm9-3204 to wjm9-3206 were combined for further 
purification. 
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7. 4. 3:  Reversed Phase (C18) Semi-preparative 
Chromatography of Combined Fractions 
wjm9-3204 to wjm9-3206 
260 
HPLC 
Fraction combination (wjm9-3204 to wjm9-3206) wjm9-3401 ( 1 2.4 mg) was 
subjected to further purification by reversed phase (C 1 8) semi-preparative HPLC 
chromatography (Phenomenex Luna, 5µ.m C l8, 250 x 10mm) using a gradient 
solvent system of: 2 minutes 100 % H20, 15 minutes 36 % CH3CN/H20, after 
which the column was equilibrated back to 100 % H20 over 3 minutes (Flow rate 
5 mL/minute, A. =  254 nm). Four fractions were collected as peaks eluted. Purity 
was confirmed by re-injection onto a reversed phase (C 1 8) analytical HPLC 
column. Fraction wjm9-340 1 .3 (4.5 mg) was analysed by 1 H and 1 3C NMR, and 
deemed to contain enough material for further 2D NMR experiments. HSQC, 
CIGAR, Long range COSY and I D  NOSEY NMR spectra were used to elucidate 
compound 4.8 (4.5 mg). 
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7. 5: Work Described in CHAPTER 5 
7. 5. 1 :  Extraction of Antarctic Marine Sponge-derived 
Fungus Aspergi l lus sp. (WS 76) 
261  
The entire fungal culture WS 76 (500 mL) was homogenised for 5 minutes, 
ensuring complete maceration of the mycelial mat. This material was filtered 
through a bed of celite, re-suspended m EtOAc and repeatedly 
homogenised/extracted with 3 x 500 mL of EtOAc until no further colour was 
removed from culture. The organic extract was partitioned between EtOAc and 
H20 (1: 1, 500mL). The EtOAc soluble fraction (228.8 mg) was analysed by 
analytical reversed phase (C 1 8) HPLC chromatography (standard 10 % gradient, 
see Experimental, Section 7.1 .3). Due to the modest level of P388 activity 
observed in the crude extract (IC50 19750 ng/mL), 100 and 50 µL 'daughter plates' 
were submitted for P388 assay. Two areas of activity were identified, which 
corresponded to compounds eluting from 12.5 to 16.5 and 25 to 30 minutes of the 
HPLC chromatogram. 
7. 5.2: Normal Phase (DIOL) Chromatography of Organic 
Extract of Antarctic Marine Sponge-derived Fungus 
Aspergi llus sp. (WS 76) 
The EtOAc soluble fraction (228.8 mg) was dissolved in minimum volume of 
EtOAc and MeOH and adsorbed onto a solid plug of fresh DIOL (500 mg). The 
DIOL plug was loaded onto a DIOL flash chromatography column (15 mm x 150 
mm, 15 g) equilibrated with 100 % pet. ether and was eluted with the following 
solvent gradient : 100 % pet. ether to 100 % DCM in 50 % steps, and then from 
100 % DCM to 100 % EtOAc, increasing the EtOAc concentration 10 % every 5 
mL collected for the next seven fractions. The column was finally eluted with 
combinations of 1:1 EtOAc/MeOH, 100 % MeOH (14 mL) and two fractions of 
9: 1 MeOH/H20. Seventeen fractions were collected. All fractions were analysed 
by reversed phase (C 1 8) analytical HPLC to locate the fractions that contained the 
active compounds as determined by microtitre plate analysis. Fractions wjml6-
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703 (79 mg), wjm16-705 (15.6 mg), wjm16-708 (5.2 mg) and wjm16-710 (5.4 mg) 
were selected for further purification on this basis. 
7. 5. 3 :  Reversed Phase (C18) Semi preparative 
HPLC Chromatography of Fraction wjm l  6- 703 
Fraction wjm 16-703 (78.6 mg) was subjected to further purification by reversed 
phase (C 1 8) semi-preparative HPLC chromatography (Phenomenex Luna, 5µm 
C18, 250 x 10mm) using a solvent system developed on the analytical HPLC and 
scaled by an appropriate factor (Flow rate 5 mL/min, 65 % CH3CN and 25 % H20, 
'A. =  330 nm). Two fractions were collected as peaks eluted, wjm16-703.1 and 
wjm16-703.2. Purity was confirmed by re-injection on to the analytical reversed 
phase HPLC using the standard 10 % gradient. Both fractions were analysed by 
1 H NMR and contained sufficient mass suitable for COSY, HSQC and CIGAR 
2D NMR spectroscopic experiments. Molecular mass was confim1ed by ESI 
mass spectrometry; this led to the identification of compounds 5.32 ( 4.4 mg) and 
5.34 (3.4 mg). 
7. 5. 4: Reversed Phase (C18) Semi-preparative 
HPLC Chromatography of Fraction wjm l 6- 705 
Fraction wjml6-705 (15.6 mg) was subjected to further purification by reversed 
phase (C18) semi-preparative HPLC chromatography (Phenomenex Luna, 5µ,m 
C18, 250 x 10mm) using an isocratic solvent system developed on the analytical 
HPLC and scaled by an appropriate factor (Flow rate 5 mL/minute, 65 % CH3CN 
and 35 % H20, 'A. = 300 nm). Four fractions were collected as peaks eluted, 
wjm16-705.1 to wjm16-705.4. The purity of each fraction was confirmed by re­
analysing via analytical reversed phase (C 1 8) HPLC using the standard 10 % 
gradient. All four fractions were analysed by 1 H NMR, to identify the fractions 
suitable for 2D NMR analysis. Fractions wjm16-705.2 (3.1 mg) and wjm16-
705.3 (1.7 mg) were subsequently analysed by 2D NMR spectroscopy and mass 
spectrometry, where the compounds 5.35 (3.1 mg) were elucidated. 
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7. 5. 5: Reversed Phase (C18) Semi-preparative 
HPLC Chromatography of Fraction wjm l  6- 708 
Fraction wjm16-708 (5.2 mg) contained predominantly one compound as 
indicated by reversed phase (C 1 8) analytical HPLC analysis. Purification of this 
fraction was achieved by reversed phase (C 1 8) semi-preparative HPLC 
chromatography (Phenomenex Luna, 5µm C18, 250 x 10mm) using an isocratic 
solvent system (Flow rate 5 mL/minute, 70 % CH3CN and 30 % H20, 'A = 300 
nm). Two fractions were collected, however only fraction wjm 16-708.1 (major 
peak of interest) contained enough material for further elucidation. Fraction 
purity was confim1ed by re-injection onto an analytical reversed phase (C 1 8) 
HPLC column using the standard 10 % gradient. Compound 5.40 (3.3 mg) was 
structurally elucidated using 1 D and 2D NMR spectroscopy and mass 
spectrometry. 
7. 5. 6: Reversed Phase (C18) Semi-preparative 
HPLC Chromatography of Fraction wjm l  6- 71 0 
Fraction wjm16-710 (2.5 mg) contained predominantly one compound by 
reversed phase analytical HPLC analysis. This fraction was subjected to further 
purification by reversed phase (C 1 8) semi-preparative HPLC chromatography 
(Phenomenex Luna, 5µm C18, 250 x 10mm) using an isocratic solvent system 
(Flow rate 5 mL/min, 70 % CH3CN and 30 % H20, 'A =  300 nm). One fraction 
was collected as the major peak eluted affording fraction wjm16-710. 1. Purity 
was confim1ed by analytical reversed phase (C 1 8) HPLC chromatography column 
using the standard 10 % gradient. The novel anthraquinone 5.41 (2.5 mg) was 
identified on the basis of HREI mass spectrometry, I D  and 2D NMR 
spectroscopy. 
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7. 6: Work Described in CHAPTER 6 
7. 6. 1 :  Extraction of Antarctic Marine 
Sponge-derived Fungus Ulocladium sp. (WS 132) 
264 
The solid rice culture (500 g) of WS 1 32 was extracted with solvent combinations 
consisting of EtOAc/DCM/MeOH (3:2:1, 500 mL). The extract was filtered 
through a bed of celite after homogenization; the solid material was re-suspended 
and extracted a further two times with the same solvent combinations. The 
solvent was removed under vacuum to yield a deep green extract (1.54 g). 
7. 6. 2: Reversed Phase (C18) Chromatography of the 
Organic Extract of the Marine Sponge-derived Fungus 
Ulocladium sp (WS 76) 
A small portion of the organic extract was analysed by analytical reversed phase 
(C 1 8) HPLC chromatography. Fractions were collected in a microtitre plate (96 
well) . Dilution plates (100 and 50 µL) were submitted for biological activity 
assay (P388). The activity corresponded to the compounds eluting from 11.5 to 
14.8 minutes. 
The organic extract (1.54 g) was dissolved in a minimum volume of solvent 
(H20/MeOH, 9:1) and loaded onto a reversed phase (C 1 8) flash chromatography 
column (30 mm x 300 mm, 100 g). The column was equilibrated to the solvent 
mixture 90 % H20/10 % MeOH. Fractions were collected using the following 
solvent elution gradient : 90 % H20 to 100% MeOH in steps of 10 % MeOH every 
20 mL, the remaining material was eluted from the column as the final fraction, 
fraction 1 2  (MeOH/DCM, 1:1). All fractions were analysed by reversed phase 
(C 1 8) HPLC to locate the fractions that contained the peaks responsible for the 
observed activity. Fractions 23-1007 and 23-1008 were subsequently identified 
for further purification (IC50 6 µg/mL). 
CHAPTER 7 EXPERIMENTAL 265 
7. 6. 3 :  Reversed Phase (c,B) Semi-preparative 
HPLC Chromatography of Fraction wjm23-1 007 
and wjm23-1 008 
Fractions 23-1007 (32.2 mg) and 23-1008 (43.6 mg) were combined in a 
minimum volume of MeOH. During storage at 4 °C, crystals dropped out of 
solution, so the fraction was filtered and the crystals (fraction 23-1007.xtl) were 
collected and analysed by l D  and 2D NMR spectroscopy and mass spectrometry. 
The purified compound trypacidin (6.6, 6.0 mg) was identified. 
Fraction wjm23-1007-8, the supernatant, was further purified by reversed phase 
(C1 8) semi-preparative HPLC chromatography (Phenomenex Luna, 5µ, C18, 250 x 
10mm) using a gradient solvent system of: 2 min 30 % CH3CN/H20, 25min 55 % 
CH3CN/H20, the column was equilibrated back to 30 % CH3CN/H20 over 5 
minutes; the H20 portion contained 0.05 % TF A (Flow rate 5 mL/min, 'A =  210 
nm). Seven fractions were collected as peaks eluted. Purity was confirmed by re­
injection on the reversed phase (C1 8) analytical HPLC column. Fractions wjm23-
1007.1 (0.9 mg) wjm23-1007.2 (6.0 mg), wjm23-1007.3 (5.4 mg), wjm23-1007.4 
(6.7 mg), wjm23- 1007.5 (4.9 mg), wjm23-1007.6 (3.7 mg) and wjm23-1007.7 
(3.9 mg) were analysed by 1 H NMR, however, only fractions three to seven were 
deemed to contain enough mass suitable for 2D NMR experiments. 1 H, 1 3C and 
2D NMR spectroscopy combined with ESI mass spectrometry were used to 
identify the purified compounds sulochrin-2'-0-methyl ether (6.7, 5.4 mg), 
asterric acid-3'-0-methyl ether (6.9, 6.7), methyl asterate-3'-0-methyl ether (6.13, 
4.9 mg), methyl asterrate-4-0-3'-0-methyl ether (6.15, 3. 7 mg) and pseurotin A 
(6.16, 2.9 mg). 
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